

**VARIATIONS IN STROKE INCIDENCE IN FOUR US COMMUNITIES:
THE CARDIOVASCULAR HEALTH STUDY (CHS)**

By

Aiman El-Saed

M.B.B.Ch., Mansoura University, 1993

MSc, Occupational Health and Industrial Medicine, Mansoura University, 1998

Submitted to the Graduate Faculty of

Department of Epidemiology

Graduate School of Public Health in partial fulfillment

of the requirements for the degree of

Doctor of Philosophy

University of Pittsburgh

2004

UNIVERSITY OF PITTSBURGH
Graduate School of Public Health

This dissertation was presented

By

Aiman El-Saed

It was defended on

December 1, 2004

and approved by

Committee Chairperson/ Advisor:

Dr Lewis Kuller, MD, DrPH

Professor of Epidemiology

Department of Epidemiology

GSPH, University of Pittsburgh

Committee member:

Dr Anne Newman, MD, MPH

Associate Professor of Medicine and Epidemiology

Department of Epidemiology

GSPH, University of Pittsburgh

Committee member:

Dr Oscar Lopez, MD

Associate professor of Neurology

Neurology Department

UPMC, University of Pittsburgh

Committee member:

Dr Joseph P. Costantino, DrPH

Professor of Biostatistics

Department of Biostatistics

GSPH, University of Pittsburgh

Committee member:

Dr Kathleen McTigue, MD

Assistant Professor of General Medicine and Epidemiology

Department of Internal Medicine

UPMC, University of Pittsburgh

**VARIATIONS IN STROKE INCIDENCE IN FOUR US COMMUNITIES:
THE CARDIOVASCULAR HEALTH STUDY (CHS)**

Aiman El-Saed, PhD

University of Pittsburgh, 2004

BACKGROUND: Although stroke rates are much higher in old age, recent data on geographic variation in stroke incidence in older American populations were rare. Moreover, geographic variation in stroke incidence and mortality remain unexplained in United States.

OBJECTIVES: To compare stroke incidence rates and stroke risk factors and their control in four US communities

METHODS: Participants in the Cardiovascular Health Study (CHS) who had no history of stroke at baseline (n=5639) were followed for 10 years for the development of stroke events. Site specific stroke incidence and mortality rates were calculated. Possible risk factors at baseline and their control across the visits were compared among the four CHS sites.

RESULTS: Age and sex standardized total stroke incidence rates per 1000 person-years were 9.6 (CI 7.7, 11.5) in Allegheny, 19.2 (CI 15.6, 22.8) in Forsyth, 20.7 (CI 16.9, 24.5) in Sacramento, and 19.8 (CI 16.1, 23.5) in Washington Counties. Although Allegheny County had the lowest stroke incidence among the 4 sites, risk factor distributions at baseline were similar. After adjustment for age, hypertension, diabetes, education, BMI, LDL cholesterol and previous coronary heart disease, transient ischemic attack (TIA), and atrial fibrillation (AF), there was modest reduction of the excess hazard in the other 3 sites compared to Allegheny County (HR=1.52, CI 1.17, 1.98 compared to 1.74 CI 1.42, 2.14). Moreover, between baseline and year

9, control of hypertension, diabetes, lipids, smoking, AF, and TIA were similar across sites. White matter grade (WMG) ≥ 3 on the baseline brain MRI was less common in Allegheny County than the other 3 sites (25.8% and 36.3% respectively, $p < 0.001$) and accounted for 25% of the excess hazard in the other 3 sites compared to Allegheny County (HR=1.65, CI 1.20-2.26 compared to 1.87 CI 1.36-2.55)

CONCLUSION: Site-differences in stroke risk factors at baseline and their subsequent control only partially explain site-differences in stroke incidence.

PUBLIC HEALTH SIGNIFICANCE: White matter grade may be a marker of integrated exposure and control of stroke risk factors and its progression could be used as a marker of the efficacy of different stroke prevention strategies on a community level.

TABLE OF CONTENTS

1. INTRODUCTION	1
1.1. Stroke morbidity statistics:	1
1.2. Stroke mortality statistics:.....	2
1.3. Stroke disability:	2
1.4. Stroke incidence studies versus mortality data	3
1.5. Comparability of stroke incidence studies.....	4
1.6. International geographic variation in stroke incidence.....	4
1.7. Stroke Belt and its contributing factors	5
1.8. Stroke risk factors prevalence and regional variation in stroke incidence.....	6
1.9. Control of stroke risk factors and stroke risk.....	7
1.10. The Cardiovascular Health Study (CHS).....	8
1.11. Research Hypothesis.....	8
1.12. References.....	10
2. FIRST ARTICLE: Variations in stroke incidence and mortality in four US communities: The Cardiovascular Health Study (CHS).....	14
2.1. ABSTRACT.....	14
2.2. INTRODUCTION	16
2.3. METHODS	18
2.3.1. Study population:	18
2.3.2. Outcome assessment:	18
2.3.3. Statistical analysis:.....	19
2.4. RESULTS	22
2.4.1. Demographics:	22
2.4.2. Crude incidence rates:.....	22
2.4.3. Age standardized incidence rates:.....	22
2.4.4. Age specific incidence rates:	23
2.4.5. Stroke type-specific incidence:	23
2.4.6. Mortality and case fatality:	24
2.4.7. Cumulative incidence and mortality:	24
2.5. DISCUSSION.....	32
2.5.1. Overall total stroke Incidence:	32
2.5.2. Site specific total stroke incidence:.....	34

2.5.3.	Type-specific stroke incidence:	35
2.5.4.	Stroke mortality and case fatality:	36
2.5.5.	Conclusions:.....	36
2.6.	REFERENCES	38
3.	SECOND ARTICLE: Variations in stroke risk factors at baseline relative to variations in stroke incidence among four US communities: The Cardiovascular Health Study (CHS)	42
3.1.	ABSTRACT.....	42
3.2.	BACKGROUND	44
3.3.	METHODS	46
3.3.1.	Study population:	46
3.3.2.	Risk factors and outcome assessments:	46
3.3.3.	Statistical analysis:.....	47
3.4.	RESULTS	50
3.4.1.	Socio-demographics:.....	50
3.4.2.	Hypertension:	50
3.4.3.	Diabetes:	51
3.4.4.	Blood cholesterol:	51
3.4.5.	Smoking and alcohol drinking:.....	51
3.4.6.	Medical and family History:	52
3.4.7.	Sub-clinical cardiovascular disease and MRI findings:.....	52
3.4.8.	Stroke Hazards:.....	52
3.5.	DISCUSSION	60
3.5.1.	Prevalence of potential risk factors at baseline:.....	60
3.5.2.	Multiple risk factors at baseline and site-differences in stroke risk:	60
3.5.3.	White matter grade at baseline and site-differences in stroke risk:	61
3.5.4.	Medication use and sub-clinical cardiovascular disease:.....	62
3.5.5.	Alternative explanation of site-differences in stroke risk:	62
3.5.6.	Conclusions:.....	63
3.6.	REFERENCES	64
4.	THIRD ARTICLE: Control of stroke risk factors across visits relative to variations in stroke incidence among four US communities: The Cardiovascular Health Study (CHS).....	68
4.1.	ABSTRACT.....	68
4.2.	BACKGROUND	70

4.3.	METHODS	72
4.3.1.	Study population:	72
4.3.2.	Risk factors and outcome assessments:	72
4.3.3.	Statistical analysis:	73
4.4.	RESULTS	75
4.4.1.	Demographics and stroke hazard:	75
4.4.2.	Blood pressure and hypertension:	75
4.4.3.	Blood glucose and diabetes:	76
4.4.4.	Blood cholesterol:	76
4.4.5.	Smoking and alcohol drinking:	77
4.4.6.	Medical history:	77
4.4.7.	Carotid stenosis:	77
4.4.8.	Brain MRI findings:	77
4.5.	DISCUSSION	85
4.5.1.	Blood pressure and hypertension:	85
4.5.2.	Blood glucose and diabetes:	85
4.5.3.	LDL cholesterol:	86
4.5.4.	Alcohol drinking and cigarette smoking:	86
4.5.5.	Carotid stenosis:	86
4.5.6.	History of transient ischemic attack and atrial fibrillation:	87
4.5.7.	Brain MRI white matter grade (WMG):	87
4.5.8.	Conclusion:	88
4.6.	REFERENCES	90
5.	GENERAL DISCUSSION	93
5.1.	Studying stroke incidence in CHS population:	93
5.2.	Overall total stroke Incidence:	94
5.3.	Site specific total stroke incidence:	97
5.4.	Type-specific stroke incidence:	98
5.5.	Stroke mortality and case fatality:	98
5.6.	Prevalence of potential risk factors at baseline:	99
5.7.	Multiple risk factors at baseline and site-differences in stroke risk:	100
5.8.	Medication use and sub-clinical disease at baseline:	101
5.9.	Blood pressure and hypertension control across visits:	102
5.10.	Blood glucose and diabetes control across visits:	102
5.11.	LDL cholesterol control across visits:	103
5.12.	Alcohol drinking and cigarette smoking control across visits:	103
5.13.	Carotid stenosis across visits:	103
5.14.	History of transient ischemic attack and atrial fibrillation across visits:	104
5.15.	Brain MRI white matter grade and stroke risk:	104
5.16.	Alternative explanation of site-differences in stroke	105
5.17.	REFERENCES	107

6.	APPLICATION TO PUBLIC HEALTH.....	113
6.1.	Epidemiological studies and stroke prevention:	113
6.2.	Stroke risk in older population:.....	114
6.3.	Reducing stroke risk:	114
6.4.	White matter grade and stroke prediction:.....	114
6.5.	References.....	116
7.	SUMMARY	117
7.1.	First article:	117
7.2.	Second article:.....	117
7.3.	Third article:.....	118
	APPENDIX A: US census 2000 standard population	120
	APPENDIX B: Cumulative stroke incidence and mortality tables	121
	APPENDIX C: Incident CHS end points.....	123
	BIBLIOGRAPHY	124

LIST OF TABLES

Table 1: CHS participants at baseline by cohort and demographic characteristics by site.....	25
Table 2: Incident total stroke events, stroke follow up period (person-years), and crude rates of CHS participants at baseline by cohort and demographic characteristics by site.....	26
Table 3: Age standardized total stroke incidence rates and 95% confidence intervals per 1000 person-years of CHS participants by cohort, gender, and race by site	27
Table 4: CHS participants by cohort and demographic characteristics by site.....	54
Table 5: Prevalence of potential stroke risk factors at baseline among CHS participants by sites	55
Table 6: Control of potential stroke risk factors at baseline among CHS participants by sites....	57
Table 7: Sub-clinical cardiovascular disease and multiple risk factors at baseline among CHS participants by sites.....	58
Table 8: Total stroke incidence hazard reduction for the other three CHS sites compared to Allegheny County	59
Table 9: Demographic characteristics of CHS participants at baseline, year 5, and year 9 by site	80
Table 10: Hypertension control in CHS participants at baseline, year 5, and year 9 by site.....	81
Table 11: Diabetes and blood lipids control in CHS participants at baseline, year 5, and year 9 by site	82
Table 12: Control of other potential stroke risk factors in CHS participants at baseline, year 5, and year 9 by site	83
Table 13: Cumulative total stroke incidence and SE per 1000 persons for all CHS participants*	121

Table 14: Cumulative total stroke mortality and SE per 1000 persons for all CHS participants 122

Table 15: Adjusted* hazard ratio of CHS cardiovascular end points in the three CHS sites combined compared to Allegheny County 123

LIST OF FIGURES

Figure 1: Age specific total stroke incidence rates per 1000 person-years of CHS participants by site.....	28
Figure 2: Proportionate frequency of incident stroke types of stroke type of CHS participants by site.....	29
Figure 3: Age and sex standardized stroke type-specific incidence rates per 1000 person-years of CHS participants by site.....	29
Figure 4 Age and sex standardized stroke mortality rates and 95% confidence intervals per 1000 person-years of CHS participants by site.....	30
Figure 5: Stroke type-specific one-month case fatality of CHS participants by site	30
Figure 6: Adjusted* cumulative total stroke incidence (above) and mortality (below) per 1000 CHS participants over follow up years by site.....	31
Figure 7: Total stroke adjusted* hazard ratio at different CHS visits in the three CHS sites separately (above) and combined (below) compared to Allegheny County.....	79
Figure 8: Total stroke hazard ratio at first MRI in the three CHS sites combined compared to Allegheny County	84

*This work is dedicated to my wonderful wife **Reda**,
my beautiful daughter **Lena**, and lovely son **Ahmad***

1. INTRODUCTION

1.1. Stroke morbidity statistics:

From the early 1970s to early 1990s, the estimated number of non-institutionalized stroke survivors among Americans 25-74 years of age, increased from 1.5 million to 2.4 million, probably due to population growth, population aging, and substantial improvement of survival after stroke during the 1970s and 1980s.¹ In 2002, the number of non-institutionalized American adults 18 years or more who ever had a stroke was 4.83 million with 2.4% prevalence rate (48.9% for males and 51.1% for females).² Stroke incidence, on the other hand, declined during the 1970s in several population-based studies and did not decline or even increased during the 1980s or 1990s in these populations.³⁻⁵

Based on recently published stroke incidence epidemiologic studies as “Greater Cincinnati/Northern Kentucky Stroke Study” and “Atherosclerosis Risk in Communities Study” American Heart Association reported that, each year about 700,000 people experience a new or recurrent stroke. About 500,000 of these are first attacks, and 200,000 are recurrent attacks.⁶ On average, every 45 seconds someone in the United States has a stroke. The age-adjusted stroke incidence rates per 100,000 for first-ever strokes were estimated from population-based studies to be 167 for white males, 138 for white females, 323 for black males and 260 for black females.⁶

1.2. Stroke mortality statistics:

A substantial decline in stroke mortality in United States since the 1950s has been reported in several population-based studies, the decline showed an acceleration in the 1970s.⁷⁻¹¹ However, national data and data from selected communities have suggested that the rate of decline in stroke mortality rates slowed down during the latter half of the 1980s.^{3, 7, 11, 12} Stroke continues as the third leading cause of death among the US population in 2001, after heart diseases and cancer. Stroke accounted for more than 1 of every 15 deaths in the United States in 2001 (about 164,000 or 6.8% of total 2,416,000 deaths).¹¹ World-wide, it is even worse; stroke was the second among the 30 leading causes of global mortality in 1990 with 4.38 million deaths, almost 3 million in developing countries.¹³ On average, every 3 minutes someone dies of a stroke in United States. The 2001 overall death rate for stroke for all Americans of all ages per 100,000 was 57.9. Death rates were 56.5 for white males and 85.4 for black males, and 54.5 for white females and 73.7 for black females.⁶

1.3. Stroke disability:

Stroke is a leading cause of serious, long-term disability in the United States. In 1999 more than 1,100,000 American adults reported some form of disability resulting from stroke.^{11, 14} Stroke imposes a substantial economic burden on individuals and society. In 2004, the estimated total cost of stroke was 53.6 \$ billion, of which 33.0 \$ billion direct cost (hospital stay, nursing homes, physicians/other professionals, drugs/other medical durables, and home health care) and 20.6 \$ billion, indirect cost (loss of productivity due to morbidity and/or mortality).⁶ After converted to 1999 dollars, the mean lifetime cost of ischemic stroke in the United States is estimated at \$140,048.¹⁵

1.4. Stroke incidence studies versus mortality data

The majority of stroke studies in United States and worldwide are mortality hospital-based studies which may lead to problems in comparing geographic stroke rates on a national or international scale. Mortality data are limited by inaccuracy of death certificate stroke diagnosis with reported false positive range between 21% and 35%,¹⁶⁻¹⁸ variability of stroke subtypes reporting in death certificates with over-reporting of cerebral hemorrhage and under-reporting of cerebral embolus,¹⁶ limited reliability to distinguish between ischemic stroke versus primary intra-cerebral hemorrhage,¹³ and the absence of information on mild or nonfatal strokes (e.g. lacunar stroke) excluding the significant proportion of stroke patients who survive.¹⁹ Accuracy can also be compromised by variations in how stroke is recorded and coded, especially if it appears in part two of the death certificate, in different countries or in different times in the same country.¹³

Community-based stroke incidence studies can overcome at least some of the above mortality data limitations. To be comparable, studies of stroke incidence must use the same definitions, methods, and mode of data presentation. These studies allow more valid geographic comparisons of stroke rates; may yield data that can be used to follow stroke trends with time. Also they can be utilized in stroke follow-up in terms of case fatality, recurrence, and disability; in conducting case-control studies of various incident stroke risk factors; in assessment of stroke services; and in assisting in healthcare planning within communities.²⁰ However, community-based studies require considerable resources and rigorous methods, and it is difficult to be sure that all the cases have been found and accurately diagnosed. Also, sample sizes have nowhere been all that large, which makes comparisons of incidence by time and place imprecise.²¹

1.5. Comparability of stroke incidence studies

As stroke incidence geographic or secular comparisons are only meaningful if they are based on studies that use similar definitions, methods, and data presentation, Sudlow and Warlow²⁰ reviewed and refined the original criteria proposed by Malmgren and colleagues²² to consider stroke incidence studies comparable with each other. Most recently, these criteria were further updated by Feigin and colleagues.²³ It seems that ideal study does not exist in reality or at least very challenging.²⁰ However, to make sense of geographic and secular comparisons, it should be recognized that the studies that come close to the ideal are the most likely to provide reliable and comparable results.²⁰ The main criteria described by researchers were:^{20, 22, 23} (1) Using a standard stroke definitions based on WHO clinical definition of stroke. (2) Using standardized definitions for classifying stroke (pathological types and first ever versus recurrent) (3) Using several overlapping sources of information to ensure complete case ascertainment with at least 80% verification of stroke type using CT or MRI (4) Using a prospective design that pursue stroke cases as they occur "hot pursuit". (5) Using a well defined and stable population of appropriately large size (6) Assessing the completeness of case ascertainment by performing either a cross-sectional survey or the capture-recapture technique. (7) Using a standard data presentation for men and women separately and with rates calculated for mid-decade 10-year age bands (e.g. 45 to 54, 55 to 64 years).

1.6. International geographic variation in stroke incidence

Despite the fact there are many stroke incidence studies worldwide, the number of comparable studies on a worldwide scale remains limited, being largely confined to developed, westernized countries. In a recent review article, Feigin and colleagues²³ used the same criteria described before²⁰ in reviewing worldwide population-based stroke studies conducted at 1990 or later and

with no upper age limit, 15 population-based stroke incidence studies that met their eligibility criteria were identified and included in the analysis. Age-standardised incidence of total stroke per 1000 person-years for people of all age ranges included in the fifteen stroke incidence studies ranged from 1.3 to 4.1. The highest rates were reported in Oyabe, Japan 4.1 (3.8–4.4),²⁴ Arcadia, Greece 3.4 (3.1–3.7),²⁵ and Frederiksberg, Denmark 3.1 (2.7–3.4).²⁶ On the other hand, the lowest rates were reported in South London, UK 1.3 (1.2–1.4),²⁷ Erlangen, Germany 1.3 (1.2–1.4),^{28,29} and Auckland, New Zealand 1.4 (1.3–1.5).³⁰

WHO MONICA investigators published a report³¹ that compares stroke incidence, case fatality, and mortality rates, during the first years of the study, among 18 populations in 10 mainly European countries (Germany, Italy, Denmark, Sweden, Finland, Lithuania, Yugoslavia, Poland, Russia, China). There was a three-fold differential among men with the highest stroke attack rate reported in Finland 359 (328-392), Russia 344 (300-393), and Lithuania 286 (256-319), and the lowest stroke attack rate in Italy 121 (112-130), Sweden 128 (114-143), and Germany 136 (117-157). In women, a five-fold differential with the highest stroke attack rate reported in Russian 294 (260-332) and Finland 194 (172-217), and the lowest stroke attack rate in Germany 58 (51-67) and Italy 63 (57-70).

1.7. Stroke Belt and its contributing factors

Excess stroke mortality in the Southeastern region of the United States was first documented in 1965 and has existed at least since 1940. Although there is no "official" definition for the boundaries of the stroke belt, definitions of the "stroke belt" frequently include the entire Southeastern region of the United States excluding the state of Florida (ie, North Carolina, South Carolina, Georgia, Tennessee, Arkansas, Mississippi, Alabama, and Louisiana). Depending on the specific geographic boundaries used (which vary between reports) and the time period of the

analysis, the stroke belt has a stroke mortality that is 1.3-1.5 times the risk in the remainder of the nation.³²

Despite the persistence of the stroke belt over the past six decades and the dramatic magnitude of the excess stroke mortality, the contributing cause or causes remains a mystery.³² Many studies tried to explain the causes of this geographical difference in stroke mortality. A number of reports showed higher prevalence of hypertension, lower anti-hypertensive drug efficacy, and poor hypertension control in the Southeastern region of the United States.³³⁻³⁷ Higher stroke incidence rates were also reported.³⁸ Elevated blood glucose levels,³⁷ lower educational achievements,³⁹ and lower socioeconomic status⁴⁰ were reported in studies from stroke belt states. A graded risk of stroke mortality by birthplace was reported, with the highest among individuals born in South Carolina, intermediate in those born in the Southeast other than South Carolina, and lowest for those born outside the Southeast.⁴¹ Dietary and environmental factors such as high salt intake, low potassium and calcium intake and soft water consumption have been hypothesized as important factors.³⁴

1.8. Stroke risk factors prevalence and regional variation in stroke incidence

According to NHANES I data,³⁸ age adjusted stroke risk in white men aged 45-74 years was significantly higher in the Southeast than the Northeast or the West. After adjustment of baseline risk factors that included age, sex for blacks, smoking status, history of diabetes, history of heart disease, education, systolic blood pressure, alcohol use, and physical activity; the risk still lower in Northeast but not the West compared to Southeast. The same data showed that the prevalence of current smoking and abstinence from alcohol were higher in the Southeast than other regions of the United States, but the highest rates of diabetes prevalence were in the Northeast in women and Midwest in men. In the Three-area epidemiological study,³⁷ only blood pressure in white

men and black women and glucose intolerance in both races mirrored a gradient observed for stroke mortality in 3 areas in the United States; Savannah, Georgia (high stroke rates), Hagerstown, Maryland (intermediate stroke rates) and Pueblo, Colorado (low stroke rates). No consistent pattern was found correlating stroke mortality with other cerebrovascular risk factors, including the prevalence of transient ischemic attacks, angina, cigarette smoking, cholesterol levels, or height and weight.

1.9. Control of stroke risk factors and stroke risk

There is strong evidence from epidemiological studies and clinical trials that control of modifiable traditional stroke risk factors specially hypertension, diabetes, blood lipids, smoking, atrial fibrillation, and carotid stenosis were associated with subsequent reduced risk of stroke.⁴² Data from randomized controlled trials in older population indicated that a 10 mm Hg reduction in systolic BP was associated with a reduction in risk of stroke of approximately one third.⁴³ Tight control of hypertension in diabetics significantly reduces stroke incidence.⁴⁴ Angiotensin-converting-enzyme (ACE) was reported to reduce the risk of stroke in high-risk diabetic patients by one third.⁴⁵

The double stroke risk associated with current smoking was shown to disappear about 5 years after cessation.⁴⁶ Several meta-analysis of large randomized trials suggests that statins reduce the incidence of stroke by about 20-25% in patients with and without coronary heart disease.⁴⁷⁻⁴⁹ Carotid endarterectomy was repeatedly reported as a highly effective stroke preventive measure among patients with severe carotid stenosis and recent transient ischemic attack.^{50, 51} Warfarin and to a less extent aspirin were reported in clinical trials to be highly effective in reducing stroke in atrial fibrillation patients.⁵²

1.10. The Cardiovascular Health Study (CHS)

The Cardiovascular Health Study (CHS) is a population-based, longitudinal study of coronary heart disease and stroke in adults aged 65 years and older. Participants of the CHS were recruited from a random sample of Health Care Financing Administration (HCFA) Medicare eligibility lists in four US communities: Forsyth County, NC; Sacramento County, CA; Washington County, MD; and Allegheny County, PA. 5888 men and women 65 years of age or older at study entry, were recruited in 2 waves. A total of 5,201 participants were recruited in 1989 to 1990 in the first wave (original cohort) and additional 687 black participants were recruited in 1992 to 1993 in the second wave (new cohort). The main study outcomes were myocardial infarction, angina pectoris, congestive heart failure, peripheral vascular disease, stroke, transient ischemic attack, and all-cause mortality. Extensive historical, physical and laboratory evaluations were performed at baseline examination for each cohort to identify the presence and severity of the cardiovascular risk factors. Ascertainment of new stroke events was carried out by questionnaire at the annual visits and interim telephone contacts, from notification of events by participants, and reviewing Medicare hospitalization data.

1.11. Research Hypothesis

First: Stroke incidence rates (crude and adjusted for age, gender, race, and follow up years) were lower in Allegheny County site compared to the other three CHS sites (Forsyth County, Sacramento County, and Washington County). This hypothesis will be tested in the first article.

Second: Those differences in stroke incidence rates were related to the variations in the prevalence of potential stroke risk factors at baseline (hypertension, diabetes, smoking, atrial fibrillation, transient ischemic attacks, carotid stenosis, MRI findings, educational levels...etc)

between Allegheny County and the other three CHS sites (Forsyth County, Sacramento County, and Washington County). This hypothesis will be tested in the second article.

Third: Control of potentially modifiable stroke risk factors (hypertension, diabetes, smoking, atrial fibrillation, transient ischemic attacks, and carotid stenosis...etc) across visits (baseline, year 5, and year9) was better in Allegheny County compared to the other three CHS sites (Forsyth County, Sacramento County, and Washington County). This hypothesis will be tested in the third article.

1.12. References

1. Muntner P, Garrett E, Klag MJ, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. *Stroke*. 2002;33:1209-1213
2. Lethbridge-ÇejkuM, SchillerJS, BernadellL. Summary health statistics for U.S. Adults: National health interview survey, 2002. National Center for Health Statistics. *Vital health stat* 10(222). 2004.
3. Broderick JP, Phillips SJ, Whisnant JP, O'Fallon WM, Bergstralh EJ. Incidence rates of stroke in the eighties: The end of the decline in stroke? *Stroke*. 1989;20:577-582
4. Broderick JP. Stroke trends in Rochester, Minnesota, during 1945 to 1984. *Ann Epidemiol*. 1993;3:476-479
5. Wolf PA, D'Agostino RB, O'Neal MA, Sytkowski P, Kase CS, Belanger AJ, Kannel WB. Secular trends in stroke incidence and mortality. The Framingham study. *Stroke*. 1992;23:1551-1555
6. American Heart Association. Heart disease and stroke statistics — 2004 update. 2004
7. McGovern PG, Burke GL, Sprafka JM, Xue S, Folsom AR, Blackburn H. Trends in mortality, morbidity, and risk factor levels for stroke from 1960 through 1990. The Minnesota Heart Survey. *JAMA*. 1992;268:753-759
8. Howard G. Decline in stroke mortality in North Carolina. Description, predictions, and a possible underlying cause. *Ann Epidemiol*. 1993;3:488-492
9. Whisnant JP. The decline of stroke. *Stroke*. 1984;15:160-168
10. Soltero I, Liu K, Cooper R, Stamler J, Garside D. Trends in mortality from cerebrovascular diseases in the United States, 1960 to 1975. *Stroke*. 1978;9:549-558
11. National Center for Health Statistics. Health, United States, 2003 with chartbook on trends in the health of Americans. 2003
12. Cooper R, Sempos C, Hsieh SC, Kovar MG. Slowdown in the decline of stroke mortality in the United States, 1978-1986. *Stroke*. 1990;21:1274-1279
13. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global burden of disease study. *Lancet*. 1997;349:1269-1276
14. CDC. Prevalence of disabilities and associated health conditions among adults, United States, 1999. *MMWR*. 2001;50:120-125

15. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. *Stroke*. 1996;27:1459-1466
16. Corwin LE, Wolf PA, Kannel WB, McNamara PM. Accuracy of death certification of stroke: The Framingham study. *Stroke*. 1982;13:818-821
17. Hasuo Y, Ueda K, Kiyohara Y, Wada J, Kawano H, Kato I, Yanai T, Fujii I, Omae T, Fujishima M. Accuracy of diagnosis on death certificates for underlying causes of death in a long-term autopsy-based population study in Hisayama, Japan; with special reference to cardiovascular diseases. *J Clin Epidemiol*. 1989;42:577-584
18. Reggio A, Failla G, Patti F. Reliability of death certificates in the study of stroke mortality. A retrospective study in a Sicilian municipality. *Ital J Neurol Sci*. 1995;16:567-570
19. Bonita R, Broad JB, Anderson NE, Beaglehole R. Approaches to the problems of measuring the incidence of stroke: The Auckland stroke study, 1991-1992. *International Journal of Epidemiology*. 1995;24:535-542
20. Sudlow CL, Warlow CP. Comparing stroke incidence worldwide: What makes studies comparable? *Stroke*. 1996;27:550-558
21. Warlow CP. Epidemiology of stroke. *Lancet*. 1998;352 Suppl 3:SIII1-4
22. Malmgren R, Warlow C, Bamford J, Sandercock P. Geographical and secular trends in stroke incidence. *Lancet*. 1987;2:1196-1200
23. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: A review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. *Lancet Neurol*. 2003;2:43-53
24. Morikawa Y, Nakagawa H, Naruse Y, Nishijo M, Miura K, Tabata M, Hirokawa W, Kagamimori S, Honda M, Yoshita K, Hayashi K. Trends in stroke incidence and acute case fatality in a Japanese rural area : The Oyabe study. *Stroke*. 2000;31:1583-1587
25. Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamatelopoulos S. Stroke incidence and case fatality in southern Greece: The Arcadia Stroke Registry. *Stroke*. 1999;30:363-370
26. Jorgensen HS, Plesner A-M, Hubbe P, Larsen K. Marked increase of stroke incidence in men between 1972 and 1990 in Fredericksburg, Denmark. *Stroke*. 1992;23:1701-1704
27. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CDA. Ethnic differences in incidence of stroke: Prospective study with stroke register. *British Medical Journal*. 1999;318:967-971

28. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann K-G, von Stockert TR. A prospective community-based study of stroke in Germany-the Erlangen stroke project (ESPRO): Incidence and case fatality at 1, 3, and 12 months. *Stroke*. 1998;29:2501-2506
29. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: Incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study. *Stroke*. 2001;32:2735-2740
30. Bonita R, Broad JB, Beaglehole R. Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981-91. *The Lancet*. 1993;342:1470-1473
31. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas A-M, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. *Stroke*. 1995;26:361-367
32. Howard G. Why do we have a stroke belt in the southeastern United States? A review of unlikely and uninvestigated potential causes. *American Journal of the Medical Sciences*. 1999;317:160-167
33. Lackland DT, Egan BM. The dominant role of systolic hypertension as a vascular risk factor: Evidence from the southeastern United States. *Am J Med Sci*. 1999;318:365-368
34. Perry HM, Roccella EJ. Conference report on stroke mortality in the southeastern United States. *Hypertension*. 1998;31:1206-1215
35. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs cooperative study group on antihypertensive agents. *Arch Intern Med*. 2000;160:825-831
36. Lackland DT, Moore MA. Hypertension-related mortality and morbidity in the southeast. *South Med J*. 1997;90:191-198
37. Stolley PD, Kuller LH, Nefzger MD, Tonascia S, Lilienfeld AM, Miller GD, Diamond EL. Three-area epidemiological study of geographic differences in stroke mortality. II. Results. *Stroke*. 1977;8:551-557
38. Gillum RF, Ingram DD. Relation between residence in the southeast region of the United States and stroke incidence. The NHANES I epidemiologic follow-up study. *Am J Epidemiol*. 1996;144:665-673
39. Heyman A, Karp HR, Heyden S, Bartel A, Cassel JC, Tyroler HA, Hames CG. Cerebrovascular disease in the biracial population of Evans County, Georgia. *Arch Intern Med*. 1971;128:949-955

40. Howard G, Anderson R, Johnson NJ, Sorlie P, Russell G, Howard VJ. Evaluation of social status as a contributing factor to the stroke belt region of the United States. *Stroke*. 1997;28:936-940
41. Lackland DT, Egan BM, Jones PJ. Impact of nativity and race on "stroke belt" mortality. *Hypertension*. 1999;34:57-62
42. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: A statement for healthcare professionals from the stroke council of the American Heart Association. *Stroke*. 2001;32:280-299
43. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: An overview of published reviews. *Stroke*. 2004;35:776-785
44. Tuomilehto J, Rastenyte D. Diabetes and glucose intolerance as risk factors for stroke. *J Cardiovasc Risk*. 1999;6:241-249
45. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. *Diabetes Metab Res Rev*. 2002;18 Suppl 3:S82-85
46. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham study. *JAMA*. 1988;259:1025-1029
47. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials. *Am J Med*. 2004;117:596-606
48. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. *Br J Clin Pharmacol*. 2004;57:640-651
49. Vrečer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. *Int J Clin Pharmacol Ther*. 2003;41:567-577
50. Dodick DW, Meissner I, Meyer FB, Cloft HJ. Evaluation and management of asymptomatic carotid artery stenosis. *Mayo Clin Proc*. 2004;79:937-944
51. Brott TG, Brown RD, Jr., Meyer FB, Miller DA, Cloft HJ, Sullivan TM, Dodick DW, Meissner I. Carotid revascularization for prevention of stroke: Carotid endarterectomy and carotid artery stenting. Evaluation and management of asymptomatic carotid artery stenosis. *Mayo Clin Proc*. 2004;79:1197-1208
52. Matchar DB, McCrory DC, Barnett HJM, Feussner JR. Medical treatment for stroke prevention. *Ann Intern Med*. 1994;121:41-53

2. FIRST ARTICLE: Variations in stroke incidence and mortality in four US communities: The Cardiovascular Health Study (CHS)

2.1. ABSTRACT

BACKGROUND: Stroke continues as a leading cause of death and disability in the United States. Although stroke rates are much higher in old age, recent data on geographic variation in stroke incidence in older populations were rare.

OBJECTIVES: To compare stroke incidence and mortality rates in four US communities

METHODS: Participants in the Cardiovascular Health Study (CHS) who had no history of stroke at baseline (n=5639) were followed for 10 years in a predominantly whites cohort (n=5002) and 7 years in black cohort (n=637). Incident stroke was ascertained by questionnaire at annual visits and interim telephone contacts, and review of Medicare hospitalization data. All reported stroke cases were reviewed and adjudicated by a cerebrovascular endpoint committee.

RESULTS: Total stroke incidence rate for all CHS participants, age and sex standardized to the year 2000 US population, was 17.7 per 1000 person-years (95% CI 15.9, 19.5). The rates per 1000 person-years were significantly lower in Allegheny County, Pennsylvania 9.6 (95% CI 7.7, 11.5) than Forsyth County, North Carolina 19.2 (95% CI 15.6, 22.8), Sacramento County, California 20.7 (95% CI 16.9, 24.5), and Washington County, Maryland 19.8 (95% CI 16.1, 23.5). The lower stroke incidence rate in Allegheny County was consistent by cohort, gender, race, and age groups. Though not statistically significant, the total stroke mortality rates were also lower in Allegheny County than other three sites. The one month case fatality percentages

were similar in the four sites for all strokes ($p=0.947$) and stroke types ($p=0.871$ for ischemic and $p=0.234$ for hemorrhagic).

CONCLUSION: Further investigation is needed to clarify the cause of lower stroke incidence in Allegheny County. This may provide insight into stroke etiology, prevention, and treatment differences among these four communities

2.2. INTRODUCTION

Stroke continues as the third leading cause of death among the US population, after heart diseases and cancer. In 2001, about 164,000 Americans died from stroke (6.8% of all deaths).¹ Stroke is a leading cause of serious, long-term disability in the United States. In 1999 more than 1,100,000 American adults reported some form of disability resulting from stroke.^{1, 2} The American Heart Association reported that each year about 700,000 people experience a new or recurrent stroke. About 500,000 of these were first events, and 200,000 were recurrent.³

Excess stroke mortality (RR=1.3-1.5) in the Southeastern region of the United States than the remainder of the nation “stroke belt” was first documented in 1965 and has existed at least since 1940. Despite the persistence of the stroke belt over the past half-century, the contributing cause or causes remain a mystery.⁴ Geographic or secular comparisons of stroke incidence or mortality are only meaningful if they are based on studies that use similar definitions, methods, and data presentation.⁵ In United States in the last three decades, a number of studies assessed stroke incidence in different regions, with a two-fold reported variation in stroke incidence.⁶⁻¹⁶ The incidence rates calculated from most of these studies, based on populations from localized geographical areas, have limited potential to assess geographic or secular comparisons of stroke incidence across the United States, due to different methodologies used for case ascertainment, and different population characteristics (race and upper age limit, or time periods of data collection). The ARIC study⁸ was the first study to use a standard multi-center prospective cohort design, which allowed stroke incidence comparisons in four geographically-separated US communities. More than 2.5 fold difference in stroke incidence between sites was reported. However, old people (65 years or more), who suffer approximately 75% of the stroke burden, were excluded from the study.

There is a need for a stroke incidence study including older men and women enrolled in geographically-separated US communities, and using a standardized prospective design for case ascertainment and validation. All these requirements have been fulfilled in the current study, the Cardiovascular Health Study (CHS), a multi-center population-based cohort study, with a main objective of identifying factors related to the onset and course of coronary heart disease and stroke in the elderly. We hypothesized that stroke incidence rates (crude and adjusted for age, gender, race, and follow up years) were lower in Allegheny County site compared to the other three CHS sites (Forsyth County, Sacramento County, and Washington County).

2.3. METHODS

2.3.1. Study population:

The Cardiovascular Health Study (CHS) design, including recruitment techniques, definitions of risk factors and outcomes, has been described in detail.^{17, 18} CHS is a population-based, longitudinal study of coronary heart disease and stroke in adults aged 65 years and older. Participants of the CHS were recruited from a random sample of Health Care Financing Administration (HCFA) Medicare eligibility lists in four US communities: Forsyth County, NC; Sacramento County, CA; Washington County, MD; and Allegheny County, PA. Potentially eligible participants were excluded if they were institutionalized, wheelchair-bound in the home, or were receiving cancer treatment. The Allegheny County field center population was entirely urban; and the other three centers recruited a mixture of urban and rural populations. 5888 men and women 65 years of age or older at study entry, were recruited in 2 waves. A total of 5,201 participants were recruited in 1989 to 1990 in the first wave (original cohort) and additional 687 black participants were recruited in 1992 to 1993 in the second wave (new cohort), to improve the racial representativeness of the study. No second wave participants were recruited in Washington County, MD.

2.3.2. Outcome assessment:

The main study outcomes were myocardial infarction, angina pectoris, congestive heart failure, peripheral vascular disease, stroke, transient ischemic attack, and all-cause mortality. Extensive historical, physical and laboratory evaluations were performed at baseline examination for each cohort to identify the presence and severity of cardiovascular risk factors.¹⁷

Ascertainment methods of stroke and other CHS endpoints, either incident or prevalent have been described.¹⁹⁻²¹ Prevalent stroke at baseline line was assessed by answering “yes” to a

question “has a doctor ever told that you had stroke?” These self reported events were then validated using other information from baseline examination, from medical records or a physician questionnaire.²⁰ Some undetected pre-baseline events were later detected during investigation of potential incident events and added to the prevalent cases.²⁰ Ascertainment of new stroke events was carried out by questionnaire at the annual visits and interim telephone contacts, from notification of events by participants, and reviewing Medicare hospitalization data. For suspected stroke events clinical records were sought, and copies including admission and discharge notes, results of pertinent tests, and copies of any brain images (CT and MRI) were obtained.^{19, 21}

Provisional diagnoses of stroke were assigned by the field center principal investigator, and then reviewed and adjudicated at periodic meetings of the cerebrovascular disease endpoint committee. The committee also classified the stroke types and determined if death was caused by stroke.¹⁹ Stroke was classified as hemorrhagic if there was bloody spinal fluid by lumbar puncture, or evidence of hemorrhage at surgery or autopsy. Stroke was classified as ischemic infarction if there was evidence of focal brain deficit without evidence of primary hemorrhage.¹⁹ Information for classification of death was obtained from death certificates, autopsy and coroners’ forms (if available), hospital records, and interviews with attending physicians, next-of-kin, and witnesses.¹⁷

2.3.3. Statistical analysis:

Participants with pre-baseline stroke were excluded from all analyses. Incident stroke cases were adjudicated from the baseline examination for each cohort through June 30, 2000. Years of follow up were classified as the time from the baseline visit to occurrence of stroke for those who had a stroke and as the time from the baseline visit to censoring or the end of follow up for

those who did not have a stroke. Participants who died and never had a stroke were censored at time of death. Participants who survived to June 30, 2000 were censored at that time if they were still under active follow-up in the study. If lost to follow-up prior to that time, they were censored at the maximum of the last contact plus 6 months and Dec 31, 1999.

Stroke incidence rates per 1000 person-years were calculated by dividing new stroke events by the person years at risk. The 95% confidence interval for stroke incidence rates per 1000 person-years were created by calculating the lower (C1) and upper limits (C2) of the 95% confidence interval for the expected number of the new stroke events (x) using this formula $\{x \pm z_{1-\alpha/2} \sqrt{x}\}$. C1 & C2 were then divided by the person years at risk and multiplied by 1000. Stroke mortality rate was calculated in the same way as the incidence rate except that, the numerator consisted of those with fatal stroke events rather than all new stroke events. Incidence rates were compared across the sites for all participants and also by cohort, race, gender, and age groups at baseline (65-74 years, 75-84 years, and 85 years and older).

Stroke rates were either age specific or age standardized. Rates were also sex standardized when applicable. Age standardization was done using the 2000 US census population distribution²² using the direct method (Appendix A). The weight for those 65-74 years at baseline was 52.6%, for those 75-84 years 35.3%, and for those 85 years and older was 12.1%. The 95% confidence intervals for standardized stroke incidence rates per 1000 person-years (R-adj) were created by calculating the standard error for the standardized rates (se R-adj) as described by Breslow and Day²³. The upper and lower 95% confidence interval, are then were calculated using this formula $\{R \times \pm z_{1-\alpha/2} *se R-adj\}$.

Stroke case fatality rates were calculated by dividing the number of fatal strokes by all new strokes. The cumulative stroke incidence and mortality over the total follow up period were

calculated using a Cox regression (Appendix B). The following covariates were entered simultaneously in the model for adjustment; age, race, gender. The model was then stratified by field center.

2.4. RESULTS

2.4.1. Demographics:

The total number of participants at risk for incident stroke at baseline in the four sites was 5639. There were 5002 (88.7%) recruited between 1989 and 1990 (original cohort) and 637 (11.3%) recruited between 1992 and 1993 (new cohort). The mean age at baseline was 72.8 years (median 72 years, range 65-100 years); 3759 (66.7%) participants were aged 65-74 years, 1668 (29.6%) were 75-84 years, and 212 (3.8%) were 85 or more years old. 58% of the participants were women. There were no significant age or gender differences between sites. Approximately 85% of the participants were white and 15% were black with a significantly low percentage of blacks at the Washington County site ([Table 1](#)).

2.4.2. Crude incidence rates:

There were 665 incident strokes in the four sites together, in 46,976 years of follow up, with an average 8.6 years (median = 10.2 years) of follow up in the original cohort and 6.3 years (median = 7.2 years) in the new cohort. The number of stroke events and the crude incidence rates were lower in Allegheny County (110 events and 9.1 per 1000 person-years, 95% CI 7.4, 10.8) than Forsyth County (185 events and 15.1 per 1000 person-years, 95% CI 13.0, 17.3), Sacramento County (200 events and 16.2 per 1000 person-years, 95% CI 14.0, 18.5) and Washington County (170 events and 16.4 per 1000 person-years, 95% CI 13.9, 18.8). The lower number of total stroke events in Allegheny County compared to the other three sites was consistently observed in each of the three age groups, both sexes, both cohorts, and in whites and blacks ([Table 2](#)).

2.4.3. Age standardized incidence rates:

Total stroke incidence rate for all CHS participants, age and sex standardized to the year 2000 US population, was 17.7 per 1000 person-years (95% CI 15.9, 19.5). The rates per 1000 person-

years were significantly lower in Allegheny County, Pennsylvania 9.6 (95% CI 7.7, 11.5) than Forsyth County, North Carolina 19.2 (95% CI 15.6, 22.8), Sacramento County, California 20.7 (95% CI 16.9, 24.5), and Washington County, Maryland 19.8 (95% CI 16.1, 23.5) (Table 3). The rates were significantly lower in Allegheny County for the original cohort, females, and whites. The rates were insignificant but still lower in Allegheny County for the new cohort, males, and blacks. Blacks in all sites together had a slightly higher incidence rate per 1000 person-years than whites (18.2 versus 17.3 per 1000, $p=0.651$). Similarly, the new cohort had a slightly higher incidence rate than original cohort (19.7 versus 17.0 per 1000, $p=0.846$). Women had a slightly higher incidence rate than men (18.1 versus 16.4 per 1000, $p=0.887$) (Table 3).

2.4.4. Age specific incidence rates:

Allegheny County had a lower total stroke incidence rate than the other three sites for all age groups. For those aged 65-74 years, the difference was statistically significant. For those aged 75-84 years, Allegheny County had a significantly lower rate than Forsyth County and Sacramento County. For those aged 85 and older, the differences were not statistically significant (Figure 1). The incidence rate steadily increased with increasing age groups at all four sites. For all CHS participants, the incidence rates were 10.6 per 1000 person-years for those aged 65-74 (95% CI 9.5, 11.7), 22.0 for those aged 75-84 (95% CI 19.5, 24.7), and 32.7 (95% CI 23.8, 44.9) for those aged 85 and older (Figure 1).

2.4.5. Stroke type-specific incidence:

The distribution of incident stroke types was similar among the four sites ($p=0.681$). For all CHS participants, this was 85% ischemic, 10% hemorrhagic and 5% undefined stroke type (Figure 2). Most of the difference in sites for stroke incidence was due to a difference in

ischemic stroke. For ischemic but not hemorrhagic stroke there were statistically significant differences among the four sites (Figure 3).

2.4.6. Mortality and case fatality:

Though not significant, age and sex standardized total stroke mortality rates per 1000 person-years were lower in Allegheny County (1.55; 95% CI 0.77, 2.43) than Forsyth County (2.79; 95% CI 1.34, 4.26), Sacramento County (2.67; 95% CI 1.16, 4.24), and Washington County (3.07; 95% CI 1.37, 4.83) (Figure 4). The one month case fatality percentages were similar in the four sites for all strokes ($p=0.947$) and stroke types ($p=0.871$ for ischemic and $p=0.234$ for hemorrhagic). For all CHS participants, case fatality was 12.6% for all strokes, 8.1% for ischemic strokes, and 44.6% for hemorrhagic strokes (Figure 5).

2.4.7. Cumulative incidence and mortality:

The cumulative total stroke incidence rates per 1000, through June 30 2000, adjusted for age, gender, race, and cohort were significantly different among the four sites ($p < 0.001$). The cumulative total stroke incidence was lower in Allegheny County; 156 per 1000 (95% CI 144.2, 167.8) compared to Forsyth County; 172 (95% CI 148.5, 195.5), Sacramento County; 175 (95% CI 153.4, 196.6), and Washington County; 176 (95% CI 150.5, 201.5) (Figure 6). The cumulative total stroke mortality rates per 1000, through June 30 2000, were lower, but not statistically significantly, in Allegheny County after adjusting for age, gender, race, and cohort ($p=0.467$) (Figure 6). For all CHS participants, the cumulative total stroke mortality was 19 deaths per 1000 (95% CI 15.1, 22.9)

Table 1: CHS participants at baseline by cohort and demographic characteristics by site

	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Total
	N %	N %	N %	N %	N %
Total number of those at stroke risk at baseline	1488 100.0%	1471 100.0%	1251 100.0%	1429 100.0%	5639 100.0%
Cohort:					
Original cohort	1266 85.1%	1267 86.1%	1251 100.0%	1218 85.2%	5002 88.7%
New cohort	222 14.9%	204 13.9%	NA NA	211 14.8%	637 11.3%
Age groups at baseline:					
65-74 years	997 67.0%	989 67.2%	801 64.0%	972 68.0%	3759 66.7%
75-84 years	443 29.8%	420 28.6%	394 31.5%	411 28.8%	1668 29.6%
85+ years	48 3.2%	62 4.2%	56 4.5%	46 3.2%	212 3.8%
Gender:					
Males	900 60.5%	850 57.8%	726 58.0%	811 56.8%	3287 58.3%
Females	588 39.5%	621 42.2%	525 42.0%	618 43.2%	2352 41.7%
Race:					
Whites	1154 78.0%	1228 84.6%	1238 99.1%	1123 79.0%	4743 84.7%
Blacks	326 22.0%	224 15.4%	11 0.9%	299 21.0%	860 15.3%

Table 2: Incident total stroke events, stroke follow up period (person-years), and crude rates of CHS participants at baseline by cohort and demographic characteristics by site

	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Total
	Events P-Y Crude rate	Events P-Y Crude rate	Events P-Y Crude rate	Events P-Y Crude rate	Events P-Y Crude rate
Total number of those at stroke risk at baseline	185 12221.9 15.1	200 12324.5 16.2	170 10389.7 16.4	110 12039.4 9.1	665 46975.7 14.2
Cohort:					
Original cohort	159 10843.1 14.7	175 11016.9 15.9	170 10389.7 16.4	101 10697.4 9.4	605 42947.3 14.1
New cohort	26 1378.8 18.9	25 1307.5 19.1	NA NA NA	9 1342.0 6.7	60 4028.3 14.9
Age groups at baseline:					
65-74 years	94 8695.8 10.8	109 8811.9 12.4	90 7164.6 12.6	60 8650.8 6.9	353 33323.2 10.6
75-84 years	81 3264.4 24.8	79 3162.2 25.0	68 2925.2 23.2	46 3138.0 14.7	274 12489.7 21.9
85+ years	10 261.8 38.2	12 350.4 34.2	12 300.0 40.0	4 250.8 15.9	38 1162.9 32.7
Gender:					
Males	71 4583.5 15.5	79 4998.9 15.8	74 4015.4 18.4	50 4925.7 10.2	274 18523.6 14.8
Females	114 7638.4 14.9	121 7325.5 16.5	96 6374.2 15.1	60 7113.7 8.4	391 28452.0 13.7
Race:					
Whites	143 9930.8 14.4	172 10667.5 16.1	168 10292.1 16.3	91 9905.9 9.2	574 40796.4 14.1
Blacks	41 2233.3 18.4	27 1491.4 18.1	2 84.7 23.6	19 2084.3 9.1	89 5893.8 15.1

Table 3: Age standardized total stroke incidence rates and 95% confidence intervals per 1000 person-years of CHS participants by cohort, gender, and race by site

	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Total
	Rate 95% CI	Rate 95% CI	Rate 95% CI	Rate 95% CI	Rate 95% CI
All CHS participants*	19.2 15.6, 22.8	20.7 16.9, 24.5	19.8 16.1, 23.5	9.6 7.7, 11.5	17.7 15.9, 19.5
Cohort:					
Original cohort	17.9 14.2, 21.6	19.1 15.7, 22.5	19.7 16.1, 23.3	10.7 8.1, 13.5	17.0 15.3, 18.7
New cohort	23.6 13.3, 34.1	23.1 12.3, 34.1	NA NA	10.4 1.4, 19.6	19.7 13.6, 25.8
Gender:					
Males	17.8 11.6, 24.0	16.0 12.1, 19.9	21.1 15.4, 26.8	12.2 8.3, 16.1	16.4 14.1, 18.8
Females	19.7 15.2, 24.2	22.8 17.5, 28.0	18.8 14.1, 23.5	8.4 6.1, 10.6	18.1 15.7, 20.5
Race:					
Whites	18.4 14.3, 22.5	19.8 16.1, 23.4	19.4 15.8, 23.0	10.7 7.7, 13.6	17.3 15.4, 19.1
Blacks	21.4 13.7, 29.1	20.2 11.1, 29.4	24.4 0, 59.4	12.0 5.6, 18.4	18.2 13.7, 22.8

* Age and sex standardized




Figure 1: Age specific total stroke incidence rates per 1000 person-years of CHS participants by site




Figure 2: Proportionate frequency of incident stroke types of stroke type of CHS participants by site




Figure 3: Age and sex standardized stroke type-specific incidence rates per 1000 person-years of CHS participants by site




Figure 4 Age and sex standardized stroke mortality rates and 95% confidence intervals per 1000 person-years of CHS participants by site





Figure 5: Stroke type-specific one-month case fatality of CHS participants by site



Cummulative total stroke mortality




Figure 6: Adjusted* cumulative total stroke incidence (above) and mortality (below) per 1000 CHS participants over follow up years by site

* Adjusted for age, gender, race.

2.5. DISCUSSION

2.5.1. Overall total stroke Incidence:

Comparing rates of disease on national or international levels, and attempting to determine factors that explain any geographic differences have often led to important knowledge about etiology and prevention. Comparing stroke incidence rates reported in different studies is not without risk because of definition criteria, methodology of case ascertainment, population, age range, and time period covered. The overall total (all stroke types) stroke incidence reported in this report was substantial at 17.7 per 1000 person years and many-fold higher than that reported in other population based studies estimating stroke incidence in the United States⁶⁻¹⁵ and worldwide^{5, 24, 25} because of the older age of CHS population. The overall annual stroke incidence rates in United States studies⁶⁻¹⁵ per 100,000 populations, approximately ranged between 93 and 293. In all these studies, the populations used were either all age groups, adults 35 years and over, or the older population excluded. This may resulted in dilution of the rates by including (into the denominator) the younger population who had a very low stroke risk. In ARIC study⁸ which used a similar design to CHS study in people aged 45 to 64 years in 4 US communities, the age-adjusted total stroke incidence rates per 1000 person-years were 4.45 for blacks and 1.72 for whites. The current CHS rates per 1000 person-years were 18.2 for blacks and 17.3 for whites.

When age-specific rates for older people were compared between this study and other stroke incidence population studies in United States, CHS rates were generally higher.^{6, 7, 9, 12, 14} The more through case ascertainment and validation of the CHS population using different overlapping techniques probably yielded more stroke cases than might be discovered using the registry-based methodology applied in these studies. In the Lehigh Valley, a region in

Pennsylvania and New Jersey, in 1982-1983,¹⁴ the age specific stroke incidence per 100,000 populations were estimated to be 652 for those 65-74 years, 1408 for those 75-84 years and 2243 for those 85 years and more. These rates compare with CHS rates of 1060, 2200, and 3270 in these age groups respectively. In Northern Manhattan, New York City, between 1993 and 1996,⁷ the average annual stroke incidence rates per 100,000 for those 65-74 years were 650 for males and 468 for females, those 75-84 years were 688 for males and 629 for females, and those 85 years and more were 857 for males and 931 for females.

The rates in CHS were comparable to those reported in many westernized countries. For example, comparing the current stroke incidence rates in those aged 85 years or older (32.7 per 1000 person-years) to other studies showed that the annual stroke incidence per 1000 population were either higher than in France (18.2)²⁶, The United Kingdom (18.9)²⁷, and Germany (21.2)²⁸, similar to Greece (26.6)²⁹, Italy(28.8)³⁰ and Norway(30.4)³¹, and lower than in Japan (38.5 in females and 49.2 in males).³²

Our age standardized results showed a non-significant slightly higher incidence rate per 1000 person-years for blacks than whites (18.2 and 17.3 respectively). Although racial differences in stroke incidence and mortality with more blacks affected than whites was well documented in United States,^{7, 8, 12, 13, 33-35} it was also reported that older age groups have a smaller racial difference in stroke incidence as compared to younger population.^{7, 8, 12, 34, 36} Broderick and colleagues¹² reported that blacks under age 65 in Greater Cincinnati had a two to four times greater stroke incidence rate compared to whites of similar age in the Rochester, Minnesota. Above 65 years, however, the differences disappeared and the age-specific stroke incidence rates were similar for elderly blacks and whites. Absence of racial difference in stroke risk in people 65 years or older was also documented in a nationally representative data.³⁶

The crude incidence rates we observed were slightly higher in males than females (14.8 and 13.7). After age standardization, females had slightly higher rates than males (18.1 and 16.4). None of these differences in incidence were statistically significant. Older populations may have less gender differences in stroke incidence. The data reported for age specific stroke incidence rates in males and females in the Northern Manhattan Stroke Study ⁷ showed that male/female risk decrease steadily from 2.5 times in those aged 45-54 years until it reversed in those aged 85 years or older, when females had slightly higher stroke incidence than males. Similar observations were noted in Rochester, Minnesota ⁹ and the French West Indies. ²⁶

2.5.2. Site specific total stroke incidence:

Our results showed significantly lower stroke incidence rates in Allegheny County field center than the other three study sites in Forsyth County, Sacramento County, and Washington County. The lower stroke incidence rate in Allegheny County was consistent over time and began as early as the fourth year of follow up. The lower stroke incidence rate in Allegheny County was consistent by cohort, gender, race, and age groups. Differences between Allegheny County and the other three sites were statistically significant for the original cohort, females, whites, and those aged 65-74 and 75-84. Lack of statistical significance for differences in rates for the Allegheny County new cohort, blacks and those aged 85 years or older, can be explained by the small total number of events in these three groups (60, 89, and 38 respectively).

In ARIC study ⁸ which used a similar design to CHS in people aged 45 to 64 years in 4 US communities, there were noticeably higher rates for stroke incidence per 1000 person-years in the Jackson, Mississippi site (4.47) than the other 3 sites (Forsyth County, NC; (1.72) Washington County, MD; (1.92) and Minneapolis, MN (1.80)). This may be explained by the fact that all participants at the Jackson site were blacks and blacks in this study had higher rates

than whites (4.45 and 1.72 respectively). In the current study, however, the racial differences between sites did not account for site-differences in stroke rates for two reasons; blacks did not have a significantly higher stroke incidence than whites, and also Washington County, the site with a significantly lower percentage of blacks percentage, had significantly higher rates than Allegheny County and similar rates to Forsyth County and Sacramento County.

The lower stroke incidence in Allegheny County, both incidence rates and cumulative incidence, may be due to lower prevalence of stroke risk factors in Allegheny County at baseline, better control of these factors at baseline and over the years, or both together. These two hypothesis will be discussed in the next articles. The degree of urbanization has been linked with stroke risk, with higher rates in non-metropolitan areas.³⁷⁻³⁹ Allegheny County was entirely urban while the other sites were mixed urban/rural communities.

2.5.3. Type-specific stroke incidence:

The significantly lower incidence rates in Allegheny County for total strokes were replicated for ischemic strokes but not hemorrhagic strokes. This was not surprising giving the fact that 85% of incident strokes were ischemic (566 events) and only 10% were hemorrhagic (65 events). The frequency of ischemic strokes in the CHS population (85%) was either similar to other US studies (84%)^{8, 12} or slightly higher (77%).⁷ The hemorrhagic strokes were less frequent in the CHS population (10%) than other American populations of younger age (14.5% and 23%).^{7, 8, 12} MRI use was noticeably higher in this study (62%) than the other recent studies like the Greater Cincinnati (22%) or ARIC (27%) studies. One advantage of this study was the use of validated events rather than reliance on the less accurate discharge diagnosis coding or death certificate.⁴⁰

⁴¹ For example, in Framingham study, analysis of death certificate validity disclosed marked over-reporting of cerebral hemorrhage and under-reporting of cerebral embolus.⁴¹

2.5.4. Stroke mortality and case fatality:

The overall one month case fatality rates reported for all CHS participants were comparable to other US studies (10% -15%)^{6,7} but lower than that reported in Europe, Russia, and Japan (17% to 33%)^{25-32, 42-44} probably due to better health care. The stroke mortality rate per 1000 person-years was also lower in Allegheny County (1.55) than the other three sites (2.79, 2.67, 3.07). However, the differences were not significant probably due to the small number of fatal strokes (84 events). The same observation was obtained after plotting the cumulative total stroke mortality rates over time, adjusted for age, gender, race, and cohort. The lower mortality rate in Allegheny County than the other three sites might be explained by the lower incidence and similar case fatality and proportional frequencies of incident stroke types in Allegheny County compared to the other three sites. Though much higher due to older population, the current study findings were consistent with national data (1999) that showed lower age-adjusted stroke mortality rates per 100,000 American of all ages in Pennsylvania (58.0) compared to North Carolina (78.1), California (63.3), and Maryland (63.1).⁴⁵ The similar one month case fatality across sites might be due to similar stroke management or stroke severity across sites, for example, there were no significant differences between sites for total mortality or incident CHD (Appendix C) also those who had incident CHD before stroke were similar across sites. In addition, longer time period (for example one year case fatality) might be needed to delineate between sites differences in case fatality.

2.5.5. Conclusions:

This report was unique in examining geographic differences in stroke incidence in older populations in United States. Stroke incidence rates steadily increased with increasing age at all four CHS sites. There were little or no race and sex differences in incidence. Total stroke

incidence rates were significantly lower in Allegheny County than other three sites. Though not statistically significant, the total stroke mortality rates were also lower in Allegheny County than other three sites. The differences could not be explained by age or race differences between sites. Case fatality rates and proportional frequencies of incident stroke types were not significantly different between the four sites. Further studies are needed to investigate the cause of lower stroke incidence in Allegheny County. This may provide insight into stroke etiology, prevention, and treatment differences among these four communities.

2.6. REFERENCES

1. National Center for Health Statistics. Health, United States, 2003 with chartbook on trends in the health of Americans. 2003
2. CDC. Prevalence of disabilities and associated health conditions among adults, United States, 1999. MMWR. 2001;50:120-125
3. American Heart Association. Heart disease and stroke statistics — 2004 update. 2004
4. Howard G. Why do we have a stroke belt in the southeastern United States? A review of unlikely and uninvestigated potential causes. American Journal of the Medical Sciences. 1999;317:160-167
5. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration. International Stroke Incidence Collaboration. Stroke. 1997;28:491-499
6. Lackland DT, Bachman DL, Carter TD, Barker DL, Timms S, Kohli H. The geographic variation in stroke incidence in two areas of the southeastern stroke belt : The Anderson and Pee Dee stroke study. Stroke. 1998;29:2061-2068
7. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA. Stroke incidence among White, Black, and Hispanic residents of an urban community: The Northern Manhattan Stroke Study. Am J Epidemiol. 1998;147:259-268
8. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743
9. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373-380
10. Brown RD, Whisnant JP, Sicks JD, Christianson TJ, O'Fallon WM, Wiebers DO. A population-based study of the first-ever and total stroke incidence rates in rochester, minnesota: 1990-1994. Stroke. 2000;31:279
11. Woo D, Gebel J, Miller R, Kothari R, Brott T, Khoury J, Salisbury S, Shukla R, Pancioli A, Jauch E, Broderick J. Incidence rates of first-ever ischemic stroke subtypes among blacks: A population-based study. Stroke. 1999;30:2517-2522
12. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minneci L, Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415-421

13. Broderick J, Miller R, Khoury J, Alwell K, Kissela B, Woo D, Shukla R, Moomaw C, Gebel J, Pancioli A, Brott T, Kothari R. Incidence rates of stroke for blacks and whites: Preliminary results from the Greater Cincinnati/Northern Kentucky Stroke Study. *Stroke*. 2001;32:320
14. Alter M, Sobel E, McCoy RL, Francis ME, Shofer F, Levitt LP, Meehan EF. Stroke in the Lehigh Valley: Incidence based on a community-wide hospital register. *Neuroepidemiology*. 1985;4:1-15
15. Gross CR, Kase CS, Mohr JP, Cunningham SC, Baker WE. Stroke in South Alabama: Incidence and diagnostic features--a population based study. *Stroke*. 1984;15:249-255
16. Stolley PD, Kuller LH, Nefzger MD, Tonascia S, Lilienfeld AM, Miller GD, Diamond EL. Three-area epidemiological study of geographic differences in stroke mortality. II. Results. *Stroke*. 1977;8:551-557
17. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al. The Cardiovascular Health Study: Design and rationale. *Ann Epidemiol*. 1991;1:263-276
18. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in The Cardiovascular Health Study. *Ann Epidemiol*. 1993;3:358-366
19. Price TR, Psaty B, O'Leary D, Burke G, Gardin J. Assessment of cerebrovascular disease in The Cardiovascular Health Study. *Ann Epidemiol*. 1993;3:504-507
20. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in The Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:270-277
21. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:278-285
22. Hetzel L, Smith A. The 65 years and over population: 2000. *Census 2000 Brief*. U.S. Census Bureau. 2001
23. Breslow NE, Day NE. *Statistical methods in cancer research volume II-the design and analysis of cohort studies*. 1987.
24. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: A review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. *Lancet Neurol*. 2003;2:43-53
25. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas A-M, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. *Stroke*. 1995;26:361-367

26. Smadja D, Cabre P, May F, Fanon JL, Rene-Corail P, Riocreux C, Charpentier JC, Fournier P, Saint-Vil M, Ketterle et al. ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies: Part I: Methodology, incidence, and 30-day case fatality rate. *Stroke*. 2001;32:2741-2747
27. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CDA. Ethnic differences in incidence of stroke: Prospective study with stroke register. *British Medical Journal*. 1999;318:967-971
28. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann K-G, von Stockert TR. A prospective community-based study of stroke in Germany-the Erlanger Stroke Project (ESPRO): Incidence and case fatality at 1, 3, and 12 months. *Stroke*. 1998;29:2501-2506
29. Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamateopoulos S. Stroke incidence and case fatality in southern Greece: The Arcadia Stroke Registry. *Stroke*. 1999;30:363-370
30. Carolei A, Marini C, Di Napoli M, Di Gianfilippo G, Santalucia P, Baldassarre M, De Matteis G, di Orio F. High stroke incidence in the prospective community-based L'Aquila Registry (1994-1998). First year's results. *Stroke*. 1997;28:2500-2506
31. Ellekjaer H, Holmen J, Indredavik B, Terent A. Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate. *Stroke*. 1997;28:2180-2184
32. Morikawa Y, Nakagawa H, Naruse Y, Nishijo M, Miura K, Tabata M, Hirokawa W, Kagamimori S, Honda M, Yoshita K, Hayashi K. Trends in stroke incidence and acute case fatality in a Japanese rural area : The Oyabe Study. *Stroke*. 2000;31:1583-1587
33. Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic differences in stroke mortality between Non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. *Stroke*. 1994;25:2120-2125
34. Gaines K, Burke G. Ethnic differences in stroke: Black-white differences in the United States population. SECORDS investigators. Southeastern Consortium on Racial Differences in Stroke. *Neuroepidemiology*. 1995;14:209-239
35. Howard G, Howard VJ. Ethnic disparities in stroke: The scope of the problem. *Ethn Dis*. 2001;11:761-768
36. Giles WH, Kittner SJ, Hebel JR, Losonczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction. The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. *Arch Intern Med*. 1995;155:1319-1324

37. Gillum RF, Ingram DD. Relation between residence in the southeast region of the United States and stroke incidence. The NHANES I epidemiologic followup study. *Am J Epidemiol.* 1996;144:665-673
38. Gillum RF. Secular trends in stroke mortality in African Americans: The role of urbanization, diabetes and obesity. *Neuroepidemiology.* 1997;16:180-184
39. Obisesan TO, Vargas CM, Gillum RF. Geographic variation in stroke risk in the United States: Region, urbanization, and hypertension in the Third National Health and Nutrition Examination Survey. *Stroke.* 2000;31:19
40. Rinaldi R, Vignatelli L, Galeotti M, Azzimondi G, de Carolis P. Accuracy of ICD-9 codes in identifying ischemic stroke in the general hospital of Lugo di Romagna (Italy). *Neurol Sci.* 2003;24:65-69
41. Corwin LE, Wolf PA, Kannel WB, McNamara PM. Accuracy of death certification of stroke: The Framingham study. *Stroke.* 1982;13:818-821
42. Feigin VL, Wiebers DO, Nikitin YP, O'Fallon WM, Whisnant JP. Stroke epidemiology in Novosibirsk, Russia: A population-based study. *Mayo Clinic Proceedings.* 1995;70:847-852
43. Feigin VL, Wiebers DO, Whisnant JP, O'Fallon WM. Stroke incidence and 30-day case-fatality rates in Novosibirsk, Russia, 1982 through 1992. *Stroke.* 1995;26:924-929
44. Mihalka L, Smolanka V, Bulecza B, Mulesa S, Bereczki D. A population study of stroke in west Ukraine: Incidence, stroke services, and 30-day case fatality. *Stroke.* 2001;32:2227-2231
45. CDC. The burden of chronic diseases and their risk factors: National and state perspectives. 2002

3. SECOND ARTICLE: Variations in stroke risk factors at baseline relative to variations in stroke incidence among four US communities: The Cardiovascular Health Study (CHS)

3.1. ABSTRACT

BACKGROUND: Geographic variation in stroke incidence and mortality remain unexplained in United States. In older adults (≥ 65 years) recruited from Medicare eligibility lists in four US communities, stroke but not CHD incidence rates were significantly lower in Allegheny County, PA than the other three Counties.

OBJECTIVES: To compare the prevalence of baseline potential stroke risk factors relative to incident stroke events in four US communities.

METHODS: Participants in the Cardiovascular Health Study (CHS) who had no history of stroke at baseline ($n=5639$) were followed for about 10 years for the development of stroke. Extensive historical, physical and laboratory evaluations were performed at baseline to identify possible stroke risk factors. The prevalence of baseline potential risk factors was compared among the four CHS sites. Hazard ratios for stroke incidence were calculated with Cox regression models.

RESULTS: Total stroke incidence unadjusted hazards in Forsyth County, North Carolina; Sacramento County, California; and Washington County, Maryland combined compared to Allegheny County, Pennsylvania was 1.74 (95% CI= 1.42, 2.14; $p < 0.001$). Although Allegheny County had the lowest stroke hazard among the four sites, risk factor distributions were relatively similar. After adjustment for age, hypertension, diabetes, education, BMI, LDL

cholesterol and previous coronary heart disease, transient ischemic attack, and atrial fibrillation, there was modest reduction of the excess hazard in the other three sites compared to Allegheny County (HR=1.52, CI 1.17, 1.98 compared to 1.74 CI 1.42, 2.14). White matter grade (WMG) \geq 3 on the baseline brain MRI was less common in Allegheny County than the other 3 sites (25.8% and 36.3% respectively, $p < 0.001$) and accounted for 25% of the excess hazard in the other three sites compared to Allegheny County (HR=1.65, CI 1.20-2.26 compared to 1.87 CI 1.36-2.55)

CONCLUSION: Site-differences in stroke risk factors at baseline only partially explain site-differences in stroke incidence. White matter grade might be more helpful in explaining these differences. Further study is needed to delineate the causes of geographic differences in stroke incidence.

3.2. BACKGROUND

The Southeast regions of United States have consistently excess stroke mortality and incidence (the “stroke belt”). This pattern has, at times, been attributed to less favorable stroke risk factors profiles. For example, hypertension prevalence,¹ less desirable response to antihypertensive medications,² and hypertension related mortality and morbidity³⁻⁵ were all reported to be high among southeastern states. In another report,⁶ however, high hypertension prevalence among southeastern states was confirmed only in black females. Although low socioeconomic status (SES) and education levels are common in the Southeast US,^{1, 7} these factors did not make a significant contribution to the stroke belt.

Few studies in United States examined the association between geographic variations of multiple stroke risk factors and stroke incidence and/or mortality. Relatively inconsistent patterns of association have been shown in these studies. Recent data are lacking. In addition, prior studies frequently included only one or a few traditional cardiovascular risk factors, typically did not incorporate the effect of many potentially important factors as medication use, education level, or markers of sub-clinical cardiovascular disease such as carotid artery stenosis or MRI findings. For example, NHANES I¹ data show that the prevalence of current smoking and abstinence from alcohol were higher in the southeast than other regions of the United States, but that the highest diabetes prevalence rates were in the northeast in women and midwest in men. In the three-area epidemiological study,⁸ only blood pressure in white men and black women and glucose intolerance in both races mirrored a gradient observed for stroke mortality in three US regions: Savannah, Georgia (high stroke rates), Hagerstown, Maryland (intermediate stroke rates) and Pueblo, Colorado (low stroke rates). No consistent pattern was found correlating

stroke mortality with other cerebrovascular risk factors, including the prevalence of transient ischemic attacks, angina, cigarette smoking, cholesterol levels, or height and weight.

Among international studies, hypertension emerges as the only factor with a prevalence pattern consistently linked with stroke risk. In the MONICA study,^{9, 10} set in a predominantly European population, there were large variations of baseline risk-factor patterns: prevalence of smoking and elevated blood pressure were associated with higher stroke rates, however, high total cholesterol was not. One recent report comparing stroke incidence in Hungary and Japan showed that¹¹ Hungary had a higher stroke incidence. While hypertension was higher in Hungary; atrial fibrillation, smoking and regular alcohol consumption were more frequent in Japan, there were no differences in diabetes or ischemic heart disease. In China,¹² ecological data showed a north-south gradient, with higher prevalence of hypertension and stroke incidence and mortality in the north compared with the south of the country. In Spain,¹³ stroke mortality and cigarette smoking, as well as illiteracy rates, and sedentary lifestyle were substantially higher and wine consumption were substantially lower along the Mediterranean coast than in the rest of the country. Among 22 Scottish health districts, hospital admission rates for stroke were associated with prevalence of hypertension, absence of fruit consumption and alcohol consumption in men and smoking in women.¹⁴

The current report utilized data from a big prospective study comparing large number of possible stroke risk factors in older people in four geographically separated US communities using standardized methodology. The aim of this report was to determine whether the differences in stroke incidence among the four CHS sites observed in a previous report (First Article) can be explained by site-differences in the prevalence of potential stroke risk factors at baseline relative to incident stroke events.

3.3. METHODS

3.3.1. Study population:

The Cardiovascular Health Study (CHS) design, including recruitment techniques, definitions of risk factors and outcomes, has been described in detail.^{15, 16} CHS is a population-based, longitudinal study of coronary heart disease and stroke in older adults. Participants of the CHS were recruited from a random sample of Health Care Financing Administration (HCFA) Medicare eligibility lists in four US communities: Forsyth County, NC; Sacramento County, CA; Washington County, MD; and Allegheny County, PA. Potentially eligible participants were excluded if they were institutionalized, wheelchair-bound in the home, or were receiving cancer treatment. The Allegheny County field center population was entirely urban; and the other three sites recruited a mixture of urban, suburban, and rural populations. 5888 men and women, 65 years of age or older at study entry, were recruited in 2 waves. A total of 5,201 participants were recruited in 1989 to 1990 in the first wave (original cohort). An additional 687 black participants were recruited in 1992 to 1993 in the second wave (new cohort), to improve the racial representativeness of the study. No second wave participants were recruited in Washington County, MD.

3.3.2. Risk factors and outcome assessments:

Extensive historical, physical and laboratory evaluations were performed at baseline examination for each cohort to identify the presence and severity of the conventional cardiovascular risk factors such as hypertension, smoking, hypercholesterolemia and glucose intolerance. Sub-clinical cardiovascular disease, such as carotid artery atherosclerosis and left ventricular enlargement, was also assessed.

Hypertension was defined as SBP \geq 140, DBP \geq 90, or a history of hypertension plus use of antihypertensive medication.¹⁷ Diabetes was defined according ADA guidelines¹⁸ (fasting

glucose ≥ 126 or taking insulin or oral hypoglycemics). Baseline brain MRI examination was done in years 4, 5 and 6. White matter grade was scored with a value of 0 to 9 with 0 = no changes and 9 = most pronounced changes. Any MRI lesion with a maximum diameter of at least 3 mm was considered a large infarct. Up to five large infarcts were described for each participant. Smokers were categorized as current or non-smoker including former smokers. Body Mass Index was calculated by dividing weight (kg) by height (m) squared. History of coronary heart disease at baseline was confirmed by a report of angioplasty or bypass surgery prior to study entry. Aspirin use was confirmed by reported using aspirin 3 or more days in past 2 weeks. Any sub-clinical cardiovascular disease variable was a composite measure including any of the following: ankle arm index (AAI) ≤ 0.9 , internal or carotid wall thickness $> 80^{\text{th}}$ percentile, carotid stenosis $> 25\%$, major ECG abnormalities, claudication from Rose questionnaire, and angina from Rose questionnaire.¹⁹

Ascertainment methods of stroke and other CHS endpoints, either incident or prevalent have been described.²⁰⁻²² Ascertainment of new stroke events was carried out by questionnaire at the annual visits and interim telephone contacts, from notification of events by participants, and reviewing Medicare hospitalization data.^{20, 22} Provisional diagnoses of stroke were assigned by the field center principal investigator, and then reviewed and adjudicated at periodic meetings of the cerebrovascular disease endpoint committee. The committee also classified the stroke types as hemorrhagic or ischemic infarction.²⁰ Participants with pre-baseline stroke were excluded from the analysis.

3.3.3. Statistical analysis:

Potential stroke risk factors at baseline were compared between the four sites for significant differences. Data were checked for normality. ANOVA test was used for continuous variables

that were normally distributed. Kruskal-Wallis test was used for continuous variables that were not normally distributed. Pearson Chi square was used for categorical variables. Potential stroke risk factors at baseline were also compared between Allegheny County and the other three sites combined for significant differences using the t-test or Mann-Whitney for continuous variables and Chi square for categorical variables. A five percent level of significance was used for all tests.

Hazard ratios for stroke incidence were calculated using Cox regression models. Hazards in Forsyth County, Sacramento County, Washington County and then these three sites combined were compared to that in Allegheny County. Years of follow up were defined as the time from the baseline visit to occurrence of stroke, or as the time from the baseline visit to censoring or the end of follow up for those who did not have a stroke. All models were adjusted for age, race, gender, and education. The effects conventional cardiovascular risk factors on stroke incidence hazard ratios among sites (including hypertension, diabetes, smoking, BMI, LDL and HDL cholesterol, alcohol drinking, previous coronary heart disease (CHD), atrial fibrillation (AF), or transient ischemic attacks (TIA)) were then evaluated.

Sub-clinical cardiovascular diseases (including Intima-Media Thickness “IMT”, carotid stenosis, abnormal Ankle-Arm blood pressure Index (AAI) measured by ultrasound and major ECG abnormalities), specific MRI findings (including presence of one or more large infarcts and white matter grade), the use of medications (including aspirin, oral anticoagulants, and medications for hypertension, diabetes, or hyperlipidemia) and the availability of supplemental insurance (to Medicare) were all evaluated in age adjusted models. Covariates were entered into the model if their significance level was less than 0.05, and were removed from the model if their significance level was greater than 0.10.

The percentage of excess-hazard reduction in a specific model was calculated by comparing the excess hazard reduction for that model to a reference model.

3.4. RESULTS

3.4.1. Socio-demographics:

The total number of participants at risk for incident stroke at baseline in the four sites was 5639. Of these, 5002 (88.7%) were recruited between 1989 and 1990 (original cohort) and 637 (11.3%) were recruited between 1992 and 1993 (new cohort). The mean age at baseline was 72.8 years (median 72 years, range 65-100 years); 3759 (66.7%) participants were aged 65-74 years, 1668 (29.6%) were 75-84 years, and 212 (3.8%) were 85 or more years old. More than half (58%) of the participants were women. There were no significant age or gender differences between sites. Approximately 85% of the participants were white and 15% were black; the Washington County site had a significantly lower percentage of black participants (Table 4). Allegheny County had more higher education (more than 12 years) than the other three sites (49.4% and 41.7% respectively, $p < 0.001$). Allegheny County had lower percentage of additional insurance to Medicare compared to the other three sites (88.4% and 92.1% respectively, $p < 0.001$).

3.4.2. Hypertension:

The prevalence of hypertension was slightly lower in Allegheny County than in the other three sites (56.0% and 58.8% respectively, $p=0.070$). This difference was significant among white participants ($p=0.016$) but not black participants ($p=0.168$). The systolic blood pressure was similar and the diastolic pressure was slightly higher in Allegheny County compared to the other three sites ($p=0.903$ and $p < 0.001$ respectively). Diastolic blood pressure was significantly lower in Washington County than the other three sites ($p < 0.001$) (Table 5). The percentage of hypertensive CHS participants treated by any antihypertensive medication was significantly lower in Allegheny County than the other three sites (65.0% versus 68.7%; $p < 0.048$). This was true for both diuretics and vasodilators ($p < 0.001$ and $p=0.006$ respectively).

3.4.3. Diabetes:

There was no significant difference in diabetes prevalence at baseline between Allegheny County and the other three sites (16.6% and 15.6% respectively, $p < 0.074$). However, diabetes prevalence was significantly lower in Sacramento County than Allegheny County (13.0% and 16.6% respectively, $p < 0.001$). (Table 5) Among participants with diabetes, there were no significant differences between Allegheny County and the other three sites regarding the use of any diabetic medication, any hypertensive medication, or any lipid lowering medication (p value=0.390, 0.141, and 0.102 respectively)

3.4.4. Blood cholesterol:

Both Allegheny County and the other three sites had similar percentage of those having high LDL cholesterol (100 mg/dl or more) (85.5% and 83% respectively, $p=0.085$), Low HDL cholesterol (35 mg/dl or less) (6.3% and 6.5% respectively, $p=0.759$) and high triglycerides (200 mg/dl or more) (13.6% and 14.6% respectively, $p=0.372$) (Table 5). Among participants with hypertension or diabetes, in both Allegheny County and the other three sites, there were no significant differences in either LDL or HDL levels (In those with hypertension: $p=0.831$ for high LDL and $p=0.652$ for low HDL. In those with diabetes: $p=0.375$ for high LDL and $p=0.123$ for low HDL). High triglycerides (200 mg/dl or more) among those with diabetes was observed less frequently in Allegheny County than the other three sites (20.8% and 28.5% respectively, $p=0.020$).

3.4.5. Smoking and alcohol drinking:

Current smoking was more common in Allegheny County than the other three sites, the difference however was not significant (13.2% and 11.5% respectively, p value=0.074). The number of cigarettes pack-years smoked in Allegheny County (mean \pm SD 20.8 \pm 29.3) was

higher than the other three sites (mean \pm SD 16.5 \pm 25.2, p value=0.015) (Table 5). Those who drank 8 alcohol drinks per week (more than 90th percentile) were more common in Allegheny County than the other three sites, the difference however was not significant (11.2% and 9.7% respectively, p value=0.103) (Table 5).

3.4.6. Medical and family History:

There were no significant differences between Allegheny County and the other three sites as regards previous history of coronary heart disease, atrial fibrillation, or transient ischemic attacks (p value=0.720, 0.191, and 0.879 respectively). Family history of stroke was lower in Allegheny County than the other three sites (28.7% and 32.0% respectively, p< 0.026) (Table 5).

3.4.7. Sub-clinical cardiovascular disease and MRI findings:

Using the composite variable for any sub-clinical disease, there was no significant difference between Allegheny County and the other three sites. However, carotid stenosis (\geq 25%) in Allegheny County was significantly less frequent than the other three sites (43.2% and 48.2% respectively, p< 0.001) and abnormal Ankle-Arm blood pressure Index (AAI) was more common in Allegheny County than the other three sites (14.6% and 12.0% respectively, p< 0.010). White matter grade \geq 3 was less common in Allegheny County than the other three sites (25.8% and 36.3% respectively, p< 0.001) (Table 7). After adjustment for age and white matter grade and comparing that to age adjusted model, there was 25% reduction of the excess hazard in the other three sites compared to Allegheny County (Table 7). Those who had two or more large infarct were not significantly different between sites.

3.4.8. Stroke Hazards:

Total stroke incidence unadjusted hazards compared to Allegheny County were 1.66 in Forsyth County (95% CI= 1.31, 2.10; p< 0.001), 1.78 in Sacramento County (95% CI= 1.41, 2.24; p<

0.001), 1.79 in Washington County (95% CI= 1.41, 2.27; $p < 0.001$), and 1.74 in all the three sites combined (95% CI= 1.42, 2.14; $p < 0.001$). In models adjusted for all traditional cardiovascular risk factors, reduced stroke incidence hazard was consistently observed in Allegheny County. There was slight reduction of the excess hazard in the other three sites compared to Allegheny County after adjustment for age, gender, race, and education (1.71, 95% CI= 1.39, 2.11; $p < 0.001$). There was almost 30% reduction of the excess hazard in the other three sites compared to Allegheny County after adjustment for traditional stroke risk factors including age, hypertension, diabetes, education, BMI, LDL cholesterol and previous CHD, TIA and atrial fibrillation (1.52, 95% CI= 1.17-1.98; $p=0.002$) (Table 8).

Table 4: CHS participants by cohort and demographic characteristics by site

	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Total
	N %	N %	N %	N %	N %
Total number of those at stroke risk at baseline	1488 100.0%	1471 100.0%	1251 100.0%	1429 100.0%	5639 100.0%
Cohort:					
Original cohort	1266 85.1%	1267 86.1%	1251 100.0%	1218 85.2%	5002 88.7%
New cohort	222 14.9%	204 13.9%	NA NA	211 14.8%	637 11.3%
Age groups at baseline:					
65-74 years	997 67.0%	989 67.2%	801 64.0%	972 68.0%	3759 66.7%
75-84 years	443 29.8%	420 28.6%	394 31.5%	411 28.8%	1668 29.6%
85+ years	48 3.2%	62 4.2%	56 4.5%	46 3.2%	212 3.8%
Gender:					
Males	900 60.5%	850 57.8%	726 58.0%	811 56.8%	3287 58.3%
Females	588 39.5%	621 42.2%	525 42.0%	618 43.2%	2352 41.7%
Race:					
Whites	1154 78.0%	1228 84.6%	1238 99.1%	1123 79.0%	4743 84.7%
Blacks	326 22.0%	224 15.4%	11 0.9%	299 21.0%	860 15.3%

Table 5: Prevalence of potential stroke risk factors at baseline among CHS participants by sites

	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Other three sites	Total	P-value ¹	P-value ²
Blood pressure								
Systolic BP mm Hg (Mean±SD)	136.7 ±21.8	139.7 ±22.0	132.1 ±20.6	136.3 ±21.8	136.4 ±21.7	136.4 ±21.7	< 0.001	0.903
Diastolic BP mm Hg (Mean±SD)	72.6 ±10.9	72.3 ±11.8	65.6 ±10.8	71.6 ±10.5	70.4 ±11.6	70.7 ±11.4	< 0.001	< 0.001
Hypertension								
Hypertension	869 58.5%	882 60.2%	719 57.5%	799 56.0%	2470 58.8%	3269 58.1%	0.147	0.070
History of hypertension & its medication	566 38.0%	515 35.1%	518 41.4%	485 34.0%	1599 38.0%	2084 37.0%	< 0.001	0.006
BP ≥140/90 mm Hg	598 40.3%	691 47.2%	405 32.4%	592 41.5%	1694 40.3%	2286 40.6%	< 0.001	0.455
Blood glucose:								
Fasting glucose mg/dl (Mean±SD)	110.3 ±41.2	107.5 ±31.2	113.1 ±35.1	112.7 ±37.6	110.2 ±36.1	110.8 ±36.5	< 0.001 KWT	0.002 MWT
2-hour glucose mg/dl (Mean±SD)	145.5 ±59.4	149.9 ±54.2	149.2 ±58.3	142.9 ±60.5	148.1 ±57.3	147.3 ±57.8	< 0.001 KWT	< 0.001 MWT
Diabetes :								
Diabetes	234 16.0%	188 13.0%	228 18.3%	237 16.6%	650 15.6%	887 15.9%	< 0.001	0.074
Fasting glucose ≥126 mg/dl	197 13.6%	168 11.6%	210 16.8%	213 15.0%	575 13.9%	788 14.2%	< 0.001	.107
History of diabetes & its medication	129 8.7%	94 6.4%	112 9.0%	119 8.3%	335 8.0%	454 8.1%	0.051	0.657
Cholesterol:								
High LDL (≥ 100 mg/dl)	1172 80.9%	1198 83.4%	1050 85.0%	656 85.5%	3420 83.0%	4076 83.4%	0.011	0.085
Low HDL (≤35 mg/dl)	103 7.0%	72 5.0%	97 7.8%	90 6.3%	272 6.5%	362 6.5%	0.021	0.759
High triglycerides (≥200 mg/dl)	185 12.6%	202 13.9%	219 17.5%	194 13.6%	606 14.6%	800 14.3%	0.002	0.372
Smoking:								
Current smoking	215 14.5%	144 9.8%	123 9.8%	189 13.2%	482 11.5%	671 11.9%	< 0.001	0.074
Pack-years smoked (Mean±SD)	17.5 ±26.4	16.3 ±24.9	15.5 ±24.0	20.8 ±29.3	16.5 ±25.2	17.6 ±26.4	< 0.001 KWT	< 0.001 MWT

1= Differences across sites 2= Differences between Allegheny County and the other three sites combined

Table 5 (continued)

	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Other three sites	Total	P-value ¹	P-value ²
Alcohol:								
drinks/ week (Mean±SD)	1.7 ±5.2	3.7 ±7.9	1.6 ±4.8	2.8 ±6.7	2.4 ±6.3	2.5 ±6.4	< 0.001 KWT	< 0.001 MWT
≥8 drinks/ week (> 90th)	103 6.9%	228 15.6%	74 5.9%	159 11.2%	405 9.7%	564 10.0%	< 0.001	0.103
Medical history:								
Coronary heart disease (CHD)	256 17.2%	258 17.5%	281 22.5%	276 19.3%	795 18.9%	1071 19.0%	0.002	0.720
Atrial fibrillation (AF)	29 2.3%	40 3.2%	38 3.0%	26 2.1%	107 2.8%	133 2.7%	0.275	0.191
TIA (Transient ischemic attack)	21 1.4%	20 1.4%	33 2.6%	26 1.8%	74 1.8%	100 1.8%	0.047	0.879
Family history of stroke	451 32.4%	355 27.4%	425 36.8%	377 28.7%	1231 32.0%	1608 31.2%	< 0.001	0.026
Education:								
More than 12 years	553 37.4%	774 52.8%	422 33.7%	705 49.4%	1749 41.7%	2454 43.6%	< 0.001	< 0.001
College or higher	421 28.6%	604 41.2%	300 24.0%	603 42.3%	1325 31.6%	1928 34.3%	< 0.001	< 0.001
Body mass index (Mean±SD)								
	26.2 ±4.8	26.9 ±4.5	26.9 ±4.7	26.8 ±4.8	26.7 ±4.7	26.7 ±4.7	< 0.001	0.470
Creatinine level mg/dl (Mean±SD)								
	1.05 ±0.30	1.03 ±0.44	1.08 ±0.41	1.08 ±0.38	1.05 ±0.39	1.06 ±0.39	0.002	0.026

1= Differences across sites 2= Differences between Allegheny County and the other three sites combined

Table 6: Control of potential stroke risk factors at baseline among CHS participants by sites

	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Other three sites	Total	P-value ¹	P-value ²
Hypertension:								
Any hypertension medication	605 69.7%	547 62.1%	544 75.7%	519 65.0%	1696 68.7%	2215 67.8%	< 0.001	0.048
Diuretics	390 44.9%	323 36.7%	399 55.5%	289 36.2%	1112 45.1%	1401 42.9%	< 0.001	< 0.001
Beta blockers	150 17.3%	138 15.7%	146 20.3%	147 18.4%	434 17.6%	581 17.8%	0.103	0.601
Vasodilators	105 12.1%	101 11.5%	130 18.1%	79 9.9%	336 13.6%	415 12.7%	< 0.001	0.006
ACE inhibitors ⁵	104 12.0%	123 14.0%	71 9.9%	109 13.6%	298 12.1%	407 12.5%	0.059	0.244
Diabetes:								
Any diabetic medication	137 58.5%	96 51.3%	114 50.0%	119 50.2%	347 53.5%	466 52.6%	0.204	0.390
Insulin intake In diabetics	44 18.8%	19 10.2%	34 14.9%	28 11.8%	97 14.9%	125 14.1%	0.050	0.236
Any oral Hypoglycemic	95 40.6%	81 43.3%	83 36.4%	92 38.8%	259 39.9%	351 39.6%	0.530	0.769
Lipid lowering medication in:								
LDL ≥ 100 mg/dl	65 5.6%	67 5.6%	69 6.6%	32 4.9%	201 5.9%	233 5.7%	0.500	0.310
Hypertension	40 4.6%	57 6.5%	49 6.8%	44 5.5%	146 5.9%	190 5.8%	0.218	0.673
Diabetes	20 8.5%	12 6.4%	22 9.6%	12 5.1%	54 8.3%	66 7.4%	0.235	0.102
Aspirin	524 35.2%	442 30.1%	419 33.5%	478 33.4%	1385 32.9%	1863 33.1%	0.028	0.772
Oral anticoagulants	13 .9%	16 1.1%	20 1.6%	18 1.3%	49 1.2%	67 1.2%	0.359	0.775
Surgery:								
Carotid endarterectomy	16 1.1%	12 .8%	28 2.2%	10 0.7%	56 1.3%	66 1.2%	0.001	0.055
Coronary bypass or angioplasty	63 4.3%	87 6.0%	62 5.0%	79 5.6%	212 5.1%	291 5.2%	0.182	0.476
Additional insurance	1103 91.2%	1168 94.0%	918 91.0%	1095 88.4%	3189 92.1%	4284 91.1%	< 0.001	< 0.001

1= Differences across sites 2= Differences between Allegheny County and the other three sites combined

Table 7: Sub-clinical cardiovascular disease and multiple risk factors at baseline among CHS participants by sites

	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Other three sites	Total	P-value ¹	P-value ²
Ultrasound								
Common carotid IMT (Mean±SD mm)	1.06 ±0.22	1.06 ±0.21	1.06 ±0.21	1.06 ±0.21	1.06 ±0.22	1.06 ±0.21	0.673 KWT	0.729 MWT
Internal carotid IMT (Mean±SD mm)	1.39 ±0.54	1.47 ±0.59	1.45 ±0.57	1.42 ±0.55	1.44 ±0.57	1.43 ±0.56	< 0.001 KWT	0.239 MWT
Carotid stenosis (≥25%)	634 43.2%	720 49.1%	659 53.0%	617 43.2%	2013 48.2%	2630 46.9%	< 0.001	0.001
Carotid stenosis (≥50%)	64 4.4%	41 2.8%	74 5.9%	63 4.4%	179 4.3%	242 4.3%	0.001	0.837
Low Ankle-Arm Index (≤0.9)	173 11.9%	183 12.7%	135 11.1%	205 14.6%	491 12.0%	696 12.6%	0.039	0.010
ECG:								
Left ventricular hypertrophy	70 4.8%	53 3.7%	65 5.3%	71 5.4%	188 4.6%	259 4.8%	0.132	0.247
Atrial fibrillation	31 2.1%	42 2.9%	38 3.0%	27 1.9%	111 2.6%	138 2.5%	0.137	0.115
MRI:								
White matter grade 3 or more	294 33.0%	336 37.0%	295 39.6%	226 25.8%	925 36.3%	1151 33.6%	<0.001	<0.001
One or more large infarct	239 26.7%	266 29.0%	192 25.4%	284 32.2%	697 27.1%	981 28.4%	0.012	0.004
Two or more large infarct	92 10.3%	105 11.4%	66 8.7%	104 11.8%	263 10.2%	367 10.6%	0.184	0.196
Multiple risk								
Any sub-clinical disease (group 1)	1005 67.5%	989 67.2%	847 67.7%	978 68.4%	2841 67.5%	3819 67.7%	0.914	0.504
History of CHD, TIA, AF, or family history of stroke (group 2)	625 50.7%	568 46.1%	621 52.7%	582 48.1%	1814 49.8%	2396 49.4%	0.006	0.299
Groups 1&2	419 31.9%	381 29.0%	424 35.4%	397 31.3%	1224 32.0%	1621 31.8%	0.007	0.655
Hypertension & diabetes (group 3)	163 11.1%	145 10.0%	167 13.4%	160 11.2%	475 11.4%	635 11.4%	0.050	0.839
Groups 1,2 &3	48 3.3%	45 3.1%	70 5.6%	46 3.3%	163 3.9%	209 3.8%	0.002	0.253

1= Differences across sites 2= Differences between Allegheny County and the other three sites combined

Table 8: Total stroke incidence hazard reduction for the other three CHS sites compared to Allegheny County

Models	N	HR	95% CI	P value	Hazard reduction ¹
Traditional risk factors:					
Model-0: Unadjusted	665	1.740	(1.418-2.135)	<0.001	Reference
Model-1: adjusted for age at baseline	665	1.716	(1.399-2.106)	<0.001	3.2%
Model-2: adding gender, race, education to Model-1	660	1.712	(1.392-2.105)	<0.001	3.8%
Model-3: adding hypertension, diabetes to Model-2	651	1.693	(1.376-2.084)	<0.001	6.4%
Model-4: adding smoking, alcohol drinks, LDL, HDL and BMI to Model-3	584	1.572	(1.211-2.041)	0.001	22.7%
Model-5: adding previous CHD, TIA and atrial fibrillation to Model-4	544	1.529	(1.175-1.989)	0.002	28.5%
Adjusted for age, education, hypertension, diabetes, BMI, LDL and previous CHD, TIA and atrial fibrillation	544	1.525	(1.173-1.982)	0.002	29.1%
Sub-clinical disease and medication use:					
Adjusted for age at baseline	665	1.716	(1.399-2.106)	<0.001	Reference
Adjusted for age and any sub-clinical disease	665	1.717	(1.399-2.107)	<0.001	-0.1%
Adjusted for age and treatments	665	1.712	(1.395-2.101)	<0.001	0.6%
White matter grade:					
Adjusted for age at MRI	304	1.865	(1.362-2.552)	<0.001	Reference
Adjusted for age and white matter grade	301	1.647	(1.201-2.257)	0.002	25.2%

¹ Taken as the percentage of excess hazard reduction for the model compared to a reference model

3.5. DISCUSSION

The current report was unique in examining multiple possible stroke risk factors, collected using standardized methodology, in four geographically separated US communities, with the aim to explain geographic variations in stroke incidence.

3.5.1. Prevalence of potential risk factors at baseline:

Allegheny County, which had the lowest stroke hazard among the four sites, had relatively similar risk factors distributions to the other three sites. Hypertension prevalence, the most frequently reported single risk factor associated with high stroke incidence/mortality geographic areas both in United States ^{1, 8} and worldwide ^{10-12, 14, 23}, was generally lower in Allegheny County than the other three sites, though the trend was significant only among white participants. However, better response to hypertension medications in Allegheny County could not be shown in this report as was expected from the stroke belt experience.² Despite a strong link with cardiovascular disease, diabetes prevalence did not vary directly with stroke risk – similar to most previous reports. ^{1, 11, 13} Better education (12 years or more or collage education) were more prevalent in Allegheny County. Similarly, an inverse relationship between education and stroke incidence or mortality was shown in most of the reports from the industrialized countries.^{13, 24, 25}

3.5.2. Multiple risk factors at baseline and site-differences in stroke risk:

The current findings indicated that traditional stroke risk factors can explain to certain extent the site differences in stroke risk. A 30% reduction in stroke risk was obtained after adjustment for age, hypertension, diabetes, education, BMI, LDL level and previous CHD, TIA and atrial fibrillation. Similarly, most previous reports show that geographic differences in stroke incidence and/or mortality, at most, can be partially explained by the differences in stroke risk factors. National data ¹ showed that baseline risk factors, that including age, sex, race, smoking status,

history of diabetes, history of heart disease, education, systolic blood pressure, alcohol use, and physical activity, played a very minor role in the estimated excess stroke risk in the Southeast. In England,²⁶ the hazard ratio for stroke in the rest of Britain compared with southern England was 1.44 (95% confidence interval =1.16 to 1.78). After adjustment for baseline systolic blood pressure, smoking status, physical activity, social class, and height, the hazard ratio decreased moderately, but was still significant (1.24, 95% CI, 1.00 to 1.54). In different MONICA populations,¹⁰ smoking and elevated blood pressure explained 21% of the variation in stroke incidence among men and 42% in women. In Sweden,²³ cardiovascular score (hypertension, diabetes, smoking, and being overweight) and socioeconomic status together accounted for 44% of the geographic variation of stroke incidence among men and 63% among women..

3.5.3. White matter grade at baseline and site-differences in stroke risk:

Recently, white matter lesion which is most likely associated with small-vessel pathology²⁷ was identified as a strong stroke predictor with three or more folds increase in stroke risk.²⁸⁻³⁰ One of the most interesting finding in this report was that white matter grade was responsible for 25% of the excess stroke hazard observed in the other three sites compared to Allegheny County. So white matter grade was the most important single risk factor to explain the observed site differences in stroke risk. White matter grade may be a marker of integrated exposure and control of stroke risk factors and may help in explaining geographic variations in stroke incidence. As Allegheny County had a similar stroke history and lower white matter grade at baseline, the current results suggested the importance of white matter lesion to point any future increase or reduction of stroke risk in a given community, probably many years before it happen. The current findings suggested white matter grade progression could be used a marker of the efficacy of the various pharmacologic and non-pharmacologic therapies of stroke on the

individual level and as a marker of the efficacy of different stroke prevention strategies on a community level.

3.5.4. Medication use and sub-clinical cardiovascular disease:

Inclusion of medication usage and sub-clinical cardiovascular disease was an important innovation in the current study. Medication usage and sub-clinical cardiovascular disease in this report had very little to do with site differences in stroke risk. The rate for any sub-clinical disease at baseline was similar across sites. With few exceptions, the rates for medication use at baseline were generally similar across sites. However, risk factors investigated in this report and their treatment were limited to baseline data and did not take in consideration the changes over time in controlling conditions like hypertension, diabetes, and high blood lipids.

3.5.5. Alternative explanation of site-differences in stroke risk:

As the site-differences in stroke risk were only partially explained in this report, factors other than traditional stroke risk factors and sub-clinical cardiovascular disease should be investigated further. These factors might be more helpful in explaining regional differences in stroke risk. Limited data have identified several potential factors, including genetic influences on stroke³¹⁻³³ – especially compelling as family history of stroke was lower in Allegheny County than in other sites. The degree of urbanization has likewise been linked with stroke risk, with higher rates in non-metropolitan areas.^{1, 34, 35} Allegheny County was entirely urban while the other sites were mixed urban/rural communities. Dietary life style including the consumption of fish, fruits and vegetables and dietary calcium and potassium may help in explaining geographic stroke incidence variations.^{36, 37} Finally, environmental factors such as the quality of drinking water and environmental exposure to lead and perhaps cadmium may have some role in explaining these stroke variations.^{38, 39}

3.5.6. Conclusions:

Site-differences in stroke risk factors only partially explain site-differences in stroke incidence.

White matter grade may be a marker of integrated exposure and control of stroke risk factors and may help in explaining geographic variations in stroke incidence. Further study is needed to delineate the causes of geographic differences in stroke incidence.

3.6. REFERENCES

1. Gillum RF, Ingram DD. Relation between residence in the southeast region of the United States and stroke incidence. The NHANES I epidemiologic follow-up study. *Am J Epidemiol.* 1996;144:665-673
2. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs cooperative study group on antihypertensive agents. *Arch Intern Med.* 2000;160:825-831
3. Perry HM, Jr., Gillespie KN, Romeis JC, Smith MM, Virgo KS, Carmody SE, Sambhi MP. Effects of 'stroke-belt' residence, screening blood pressure and personal history risk factors on all-cause mortality among hypertensive veterans. *J Hypertens.* 1994;12:315-321
4. Lackland DT, Moore MA. Hypertension-related mortality and morbidity in the southeast. *South Med J.* 1997;90:191-198
5. Hall WD, Ferrario CM, Moore MA, Hall JE, Flack JM, Cooper W, Simmons JD, Egan BM, Lackland DT, Perry M, Jr., Roccella EJ. Hypertension-related morbidity and mortality in the southeastern United States. *Am J Med Sci.* 1997;313:195-209
6. Roccella EJ, Lenfant C. Regional and racial differences among stroke victims in the United States. *Clin Cardiol.* 1989;12:IV18-22
7. Howard G, Anderson R, Johnson NJ, Sorlie P, Russell G, Howard VJ. Evaluation of social status as a contributing factor to the stroke belt region of the United States. *Stroke.* 1997;28:936-940
8. Stolley PD, Kuller LH, Nefzger MD, Tonascia S, Lilienfeld AM, Miller GD, Diamond EL. Three-area epidemiological study of geographic differences in stroke mortality. II. Results. *Stroke.* 1977;8:551-557
9. World Health Stat Q. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. The WHO MONICA project. *World Health Stat Q.* 1988;41:115-140
10. Stegmayr B, Asplund K, Kuulasmaa K, Rajakangas AM, Thorvaldsen P, Tuomilehto J. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA project. An ecological study of 18 populations. *Stroke.* 1997;28:1367-1374
11. Ovary C, Suzuki K, Nagy Z. Regional differences in incidence rates, outcome predictors and survival of stroke. *Neuroepidemiology.* 2004;23:240-246

12. He J, Klag MJ, Wu Z, Whelton PK. Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors. *Stroke*. 1995;26:2222-2227
13. Rodriguez Artalejo F, Guallar-Castillon P, Gutierrez-Fisac JL, Ramon Banegas J, del Rey Calero J. Socioeconomic level, sedentary lifestyle, and wine consumption as possible explanations for geographic distribution of cerebrovascular disease mortality in Spain. *Stroke*. 1997;28:922-928
14. Starr JM, Thomas B, Whalley LJ. Population risk factors for hospitalization for stroke in Scotland. *Int J Epidemiol*. 1996;25:276-281
15. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al. The Cardiovascular Health Study: Design and rationale. *Ann Epidemiol*. 1991;1:263-276
16. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. *Ann Epidemiol*. 1993;3:358-366
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension*. 2003;42:1206-1252
18. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 1997;20:1183-1197
19. Lethbridge-ÇejkuM, SchillerJS, BernadelL. Summary health statisticsfor u.S. Adults: National health interview survey, 2002. National Center for Health Statistics. *Vital health stat* 10(222). 2004.
20. Price TR, Psaty B, O'Leary D, Burke G, Gardin J. Assessment of cerebrovascular disease in the Cardiovascular Health Study. *Ann Epidemiol*. 1993;3:504-507
21. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:270-277
22. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:278-285
23. Engstrom G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund G, Janzon L. Geographic distribution of stroke incidence within an urban population: Relations to socioeconomic circumstances and prevalence of cardiovascular risk factors. *Stroke*. 2001;32:1098-1103

24. Gillum RF, Mussolino ME. Education, poverty, and stroke incidence in whites and blacks: The NHANES I epidemiologic follow-up study. *J Clin Epidemiol.* 2003;56:188-195
25. Lindstrom E, Boysen G, Nyboe J. Risk factors for stroke in Copenhagen, Denmark. I. Basic demographic and social factors. *Neuroepidemiology.* 1993;12:37-42
26. Morris RW, Whincup PH, Emberson JR, Lampe FC, Walker M, Shaper AG. North-south gradients in Britain for stroke and CHD: Are they explained by the same factors? *Stroke.* 2003;34:2604-2609
27. Inzitari D. Leukoaraiosis: An independent risk factor for stroke? *Stroke.* 2003;34:2067-2071
28. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: The Rotterdam Scan Study. *Stroke.* 2003;34:1126-1129
29. Kuller LH, Longstreth WT, Jr., Arnold AM, Bernick C, Bryan RN, Beauchamp NJ, Jr. White matter hyperintensity on cranial magnetic resonance imaging: A predictor of stroke. *Stroke.* 2004;35:1821-1825
30. Yamauchi H, Fukuda H, Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis. *J Neurol Neurosurg Psychiatry.* 2002;72:576-582
31. Strachan DP, Leon DA, Dodgeon B. Mortality from cardiovascular disease among interregional migrants in England and Wales. *BMJ.* 1995;310:423-427
32. Rastenyte D, Tuomilehto J, Sarti C. Genetics of stroke, a review. *J Neurol Sci.* 1998;153:132-145
33. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke. The Framingham study. *Stroke.* 1993;24:1366-1371
34. Gillum RF. Secular trends in stroke mortality in African Americans: The role of urbanization, diabetes and obesity. *Neuroepidemiology.* 1997;16:180-184
35. Obisesan TO, Vargas CM, Gillum RF. Geographic variation in stroke risk in the United States: Region, urbanization, and hypertension in the Third National Health and Nutrition Examination Survey. *Stroke.* 2000;31:19
36. Fung TT, Stampfer MJ, Manson JE, Rexrode KM, Willett WC, Hu FB. Prospective study of major dietary patterns and stroke risk in women. *Stroke.* 2004;35:2014-2019
37. He K, Song Y, Davignus ML, Liu K, Van Horn L, Dyer AR, Goldbourt U, Greenland P. Fish consumption and incidence of stroke: A meta-analysis of cohort studies. *Stroke.* 2004;35:1538-1542

38. Neuberger JS, Mulhall M, Pomatto MC, Sheverbush J, Hassanein RS. Health problems in Galena, Kansas: A heavy metal mining superfund site. *Sci Total Environ.* 1990;94:261-272
39. Shaper AG, Packham RF, Pocock SJ. The British Regional Heart Study: Cardiovascular mortality and water quality. *J Environ Pathol Toxicol.* 1980;4:89-111

4. THIRD ARTICLE: Control of stroke risk factors across visits relative to variations in stroke incidence among four US communities: The Cardiovascular Health Study (CHS)

4.1. ABSTRACT

BACKGROUND: Control of modifiable stroke risk factors specially hypertension, diabetes, blood lipids, smoking, atrial fibrillation, and carotid stenosis have been associated with subsequent reduced risk of stroke. In older adults (≥ 65 years) recruited from Medicare eligibility lists in four US communities, stroke but not CHD incidence rates were significantly lower in Allegheny County, Pennsylvania than the other three Counties.

OBJECTIVES: To compare the control of stroke risk factors across visits relative to incident stroke events in four US communities.

METHODS: Participants in the Cardiovascular Health Study (CHS) who had no history of stroke at baseline ($n=5639$) were followed for about 10 years for the development of stroke. Stroke risk factors and their control were compared at baseline, year-5 and year-9 between Allegheny County, Pennsylvania and the other three CHS sites combined (Forsyth County, North Carolina; Sacramento County, California; and Washington County, Maryland).

RESULTS: The total number of participants at risk for incident stroke in the four sites was 5639 at baseline, 4513 at year 5 and 4306 at year 9. After adjustment for age, gender and race, the hazards of stroke incidence in all the three sites combined compared to Allegheny County were 1.75 (95% CI= 1.42, 2.14) at baseline, 2.01 (95% CI= 1.49, 2.71) at year 5, and 2.39 (95% CI= 1.54, 3.73) at year 9. Between baseline and year 9, control of hypertension, diabetes, blood

lipids, smoking, atrial fibrillation and transient ischemic attack were generally similar across sites. White matter grade ≥ 3 on brain MRI was lower in Allegheny County than the other three sites in both the first (25.8%, 36.3%, $p < 0.001$) and second MRI (37.8%, 44.2%, $p = 0.009$). White matter grade was a strong stroke predictor irrespective of site and was responsible for one fifth to one fourth of the reduced risk in Allegheny County.

CONCLUSION: Control of stroke traditional risk factors probably played a minor role in explaining the difference in stroke hazard between CHS sites. White matter grade may be a marker of integrated exposure and control of stroke risk factors and may help in explaining geographic variations in stroke incidence.

4.2. BACKGROUND

There is strong evidence from epidemiological studies and clinical trials that control of modifiable traditional stroke risk factors specially hypertension, diabetes, blood lipids, smoking, atrial fibrillation, and carotid stenosis were associated with subsequent reduced risk of stroke.¹ Data from randomized controlled trials in older population indicated that a 10 mm Hg reduction in systolic BP was associated with a reduction in risk of stroke of approximately one third.² Tight control of hypertension in diabetics significantly reduces stroke incidence.³ Angiotensin-converting-enzyme (ACE) was reported to reduce the risk of stroke in high-risk diabetic patients by one third.⁴

The double stroke risk (RR=1.8) associated with current smoking in Framingham study was shown to disappear about 5 years after cessation.⁵ Several meta-analysis of large randomized trials suggests that statins reduce the incidence of stroke by about 20-25% in patients with and without coronary heart disease.⁶⁻⁸ Carotid endarterectomy was repeatedly reported as a highly effective stroke preventive measure among patients with severe carotid stenosis and recent transient ischemic attack.^{9, 10} Warfarin and to a less extent aspirin were reported in clinical trials to be highly effective in reducing stroke in atrial fibrillation patients.¹¹

In a recent report from Oxfordshire (United Kingdom),¹² a 29% reduction in stroke incidence over the last 2 decades was associated with substantial reductions in the pre-morbid proportion of smokers, mean total cholesterol, and mean systolic and diastolic blood pressures and well as major increases in pre-morbid treatment with antiplatelet, lipid-lowering, and blood pressure lowering drugs. In a previous report from the Cardiovascular Health Study (First article), it was shown that Forsyth, Sacramento, and Washington Counties had similar stroke risk that was significantly higher than the risk in Allegheny County. In another report from the same

study (Second article) , the distribution of stroke risk factors between sites at baseline explained less than one third of the difference in stroke risk between Allegheny County and the other three sites. In this report, we tested the hypothesis that control of potentially modifiable stroke risk factors (traditional and sub-clinical) across visits (baseline, year 5, and year9) was better in Allegheny County compared to the other three CHS site.

4.3. METHODS

4.3.1. Study population:

The Cardiovascular Health Study (CHS) design, including recruitment techniques, definitions of risk factors and outcomes, has been described in detail.^{13, 14} CHS is a population-based, longitudinal study of coronary heart disease and stroke in adults aged 65 years and older. Participants of the CHS were recruited from a random sample of Health Care Financing Administration (HCFA) Medicare eligibility lists in four US communities: Forsyth County, NC; Sacramento County, CA; Washington County, MD; and Allegheny County, PA. Potentially eligible participants were excluded if they were institutionalized, wheelchair-bound in the home, or were receiving cancer treatment. 5888 men and women 65 years of age or older at study entry, were recruited in 2 waves. A total of 5,201 participants were recruited in 1989 to 1990 in the first wave (original cohort) and additional 687 black participants were recruited in 1992 to 1993 in the second wave (new cohort).

4.3.2. Risk factors and outcome assessments:

Baseline and thereafter annual extensive historical, physical and laboratory evaluations were performed to identify the presence and severity of the conventional cardiovascular risk factors such as hypertension, hypercholesterolemia and glucose intolerance; as well as sub-clinical disease such as carotid artery atherosclerosis and left ventricular enlargement. Ascertainment methods of stroke and other CHS endpoints, either incident or prevalent have been described.¹⁵⁻¹⁷ Ascertainment of new stroke events was carried out by questionnaire at the annual visits and interim telephone contacts, from notification of events by participants, and reviewing Medicare hospitalization data.^{15, 17}

Hypertension was defined as SBP ≥ 140 , DBP ≥ 90 , or history of hypertension plus taking antihypertensive medication.¹⁸ Diabetes was defined according ADA guidelines¹⁹ (fasting glucose ≥ 126 or taking insulin or oral hypoglycemics). Carotid ultrasounds were done 3 times at baseline, year 5 and year 11. Brain MRIs were done twice, once in years 4, 5 and 6 and again in years 10 and 11. White matter grade was scored with a value of 0 to 9 with 0 indicating no changes and 9 indicating most pronounced changes. Any MRI lesion with a maximum diameter of at least 3 mm was considered a large infarct. Up to five large infarcts were described for each participant. History of coronary heart disease at baseline was confirmed by a report of angioplasty or bypass surgery prior to study entry. Aspirin use was confirmed by reported using aspirin 3 or more days in past 2 weeks. Smokers were categorized as current or non-smoker including former smokers.

4.3.3. Statistical analysis:

Participants were included in the analyses at baseline (1989-90), year 5 (1992-93), year 9 (1996-97), and at the time of their brain MRI or carotid ultrasound only if they were stroke-free at the time of visit and stroke follow up data were available after that specified visit time. Incident stroke cases were adjudicated from the baseline examination for each cohort through June 30, 2000. Years of follow up were calculated as the time from the baseline visit to occurrence of stroke for those who had a stroke and as the time from the baseline visit to censoring or the end of follow up for those who did not have a stroke.

Control of potential stroke risk factors were compared between Allegheny County and the other three sites combined for significant differences. Data was checked for normality. The t-test was used for continuous variables that were normally distributed. Mann-Whitney test was used for continuous variables that were not normally distributed. Pearson Chi square was used for

categorical variables. A five percent level of significance was used for all tests. Stroke incidence hazard ratios at different visits were calculated using a Cox regression model. Hazards in all the three sites combined were compared to that in Allegheny County after adjustment for age, race, and gender. In both MRIs, the effect of white matter grade was evaluated after controlling for age, site, or both. The percentage of excess-hazard reduction in a specific model was calculated by comparing the excess hazard reduction for that model to an age adjusted model.

4.4. RESULTS

4.4.1. Demographics and stroke hazard:

The total number of participants at risk for incident stroke in the four sites was 5639 at baseline, 4513 at year 5 and 4306 at year 9. Baseline and year 9 data included both cohorts while year 5 was entirely original cohort. The mean age was 72.8 years at baseline (SD 5.6 years), 75.4 years at year 5 (SD 5.6 years), and 78.5 at year 9 (SD 5.1 years). Approximately 85% of the participants were white at baseline and year 9 and almost 60% of the participants were females at all the three visits. Allegheny County had a higher percentage of African Americans at all visits compared to the other three sites because Washington County did not recruit African American cohort (Table 9). The number of adjudicated incident stroke events within almost 10 years of follow-up after baseline was 665 events. A total of 359 incident stroke events developed after year 5 and 164 developed after year 9. After adjustment for age, gender and race, the hazards of stroke incidence in all the three sites combined (Forsyth, Sacramento, and Washington Counties) compared to Allegheny County were 1.75 (95% CI= 1.42, 2.14; $p < 0.001$) at baseline, 2.01 (95% CI= 1.49, 2.71; $p < 0.001$) at year 5, and 2.39 (95% CI= 1.54, 3.73; $p < 0.001$) at year 9 (Figure 7).

4.4.2. Blood pressure and hypertension:

In both Allegheny County and the other three sites, both systolic and diastolic blood pressure was relatively constant across visits with slight differences (Table 10). The proportion of participants who had systolic blood pressure 140 mmHg or more and/or diastolic blood pressure 90 mmHg or more were 48.2% at baseline and 46.2% at year 9 in Allegheny County, and 46.7% at baseline and 46.3% at year 9 in the other three sites. In both study populations, there was more than a 10% increase in the use of blood pressure medication across visits. Allegheny County had

a significantly lower percentage of use of any blood pressure medication at baseline compared to the other three sites (65.0% and 68.7% respectively). The percents of any blood pressure medication use were similar in both Allegheny County and the other three sites in both year 5 (69.4% and 69.2% respectively) and year 9 (78.8% and 78.5% respectively).

4.4.3. Blood glucose and diabetes:

Fasting blood glucose was slightly higher in Allegheny County compared to the other three sites at baseline (112.7 and 110.2 mg/dl respectively, $p=0.002$) and year 9 (104.7 and 101.7 mg/dl respectively, $p=0.020$) (Table 11) Both study populations had 8 to 9 mg/dl decrease in fasting blood glucose level between baseline and year 9. The use of insulin and/or oral hypoglycemic was similar and increased across visits in both Allegheny County (50.2% at baseline, 58.2% at year 5 and 72.7% at year9) and the other three sites (53.5% at baseline, 62.9% at year 5 and 76.2% at year9).

4.4.4. Blood cholesterol:

There were no significant differences at baseline and year 5 between Allegheny County and the other three sites in the use of lipid lowering medication for all participants or for those who had $LDL \geq 100$ (Table 11). No significant differences were observed between Allegheny County and the other three sites at baseline or year 5 for those who had high $LDL \geq 100$ ($p=0.085$ for baseline and $p=0.405$ for year 5), low HDL ≤ 35 mg/dl ($p=0.759$ for baseline and $p=0.291$ for year 5) and high triglycerides ≥ 200 mg/dl ($p= 0.372$ for baseline and $p= 0.821$ for year 5). Those who used any lipid lowering medication and had their LDL cholesterol level below 100 mg/dl were increased from 8.6% at baseline to 23.9% at year 5 in Allegheny County and from 12.2% at baseline to 21.9% at year 5 in the other three sites.

4.4.5. Smoking and alcohol drinking:

In both Allegheny County and the other three sites, current smoking rates were relatively similar and decreasing across visits (13.2% and 11.5% respectively at baseline and 8.0% and 7.9% respectively at year 9). The number of alcoholic drinks per week were consistently higher in Allegheny County compared to the other three sites at baseline (Mean± SD 2.8±6.7 and 2.4±6.3 respectively, $p<0.001$), year 5 (Mean± SD 2.3±5.3 and 1.9±4.9 respectively, $p<0.001$), and year 9 (Mean± SD 2.2±5.3 and 1.7±5.2 respectively, $p<0.001$) (Table 12).

4.4.6. Medical history:

History of coronary heart disease and atrial fibrillation were relatively similar in Allegheny County and the other three sites at baseline ($p=0.720$ and $p=0.191$ respectively), year 5 ($p=0.439$ and $p=0.469$ respectively), and year 9 ($p=0.062$ and $p=0.804$ respectively). History of transient ischemic attacks was lower in Allegheny County than the other three sites at year 5 (1.1% and 2.4%, $p=0.008$) and year 9 (2.7% and 3.8%, $p=0.093$) (Table 12).

4.4.7. Carotid stenosis:

In all the three visits, common and internal carotid wall thickness were generally similar in both study populations. Those who had carotid stenosis $\geq 25\%$ were lower in Allegheny County than the other three sites at baseline (43.2%, 48.2%, $p=0.001$) and year 5 (42.0%, 47.7%, $p=0.003$) but similar at year 9 (29.2%, 28.2%, $p=0.638$). Those who had carotid stenosis $\geq 50\%$ were not significantly different between Allegheny County and the other three sites at any visit (Table 12).

4.4.8. Brain MRI findings:

White matter grade ≥ 3 was lower in Allegheny County than the other three sites in both the first (25.8%, 36.3%, $p<0.001$) and second MRI (37.8%, 44.2%, $p=0.009$) (Table 12). After controlling for center and age, white matter grade was a strong stroke predictor in both the first

(2.61, 95%CI 2.06, 3.31; $p<0.001$) and second MRI (2.97, 95%CI 1.65, 5.35; $p<0.001$). After controlling for white matter grade and age, the excess stroke hazard in the other three sites compared to Allegheny County was reduced in both the first (25.2%; $p<0.001$) (Figure 8) and second MRI (20.1%, $p=0.243$). Those who had one or more large infarct by MRI was more in Allegheny County compared to the other three sites at the first (32.2%, 27.1% respectively, $p=0.004$) but not the second MRI (27.2%, 30.8% respectively, $p=0.113$) (Table 12).





Figure 7: Total stroke adjusted* hazard ratio at different CHS visits in the three CHS sites separately (above) and combined (below) compared to Allegheny County

* Adjusted for age, gender and race

Table 9: Demographic characteristics of CHS participants at baseline, year 5, and year 9 by site

	Baseline (1989-90 for original cohort) (1992-93 for new cohort)			Year 5 (1992-93)			Year 9 (1996-97)		
	Other three sites	Allegheny County, PA	Total	Other three sites	Allegheny County, PA	Total	Other three sites	Allegheny County, PA	Total
At stroke risk total	4210 100.0%	1429 100.0%	5639 100.0%	3486 100.0%	1027 100.0%	4513 100.0%	3167 100.0%	1139 100.0%	4306 100.0%
Age in years (Mean±SD)	72.8 ±5.7	72.8 ±5.3	72.8 ±5.6	75.4 ±5.4	75.5 ±5.4	75.4 ±5.4	78.6 ±5.0	78.2 ±5.1	78.5 ±5.1
Males	1734 41.2%	618 43.2%	2352 41.7%	1378 39.5%	440 42.8%	1818 40.3%	1289 40.7%	490 43.0%	1779 41.3%
Females	2476 58.8%	811 56.8%	3287 58.3%	2108 60.5%	587 57.2%	2695 59.7%	1878 59.3%	649 57.0%	2527 58.7%
Whites	3620 86.6%	1123 79.0%	4743 84.7%	3333 96.4%	942 92.3%	4275 95.4%	2709 86.1%	897 79.2%	3606 84.3%
Blacks	561 13.4%	299 21.0%	860 15.3%	126 3.6%	79 7.7%	205 4.6%	437 13.9%	236 20.8%	673 15.7%

Table 10: Hypertension control in CHS participants at baseline, year 5, and year 9 by site

	Baseline (1989-90 for original cohort) (1992-93 for new cohort)			Year 5 (1992-93)			Year 9 (1996-97)		
	Other three sites	Allegheny County, PA	P- value	Other three sites	Allegheny County, PA	P- value	Other three sites	Allegheny County, PA	P- value
Systolic BP (M±SD mm Hg)	136.4 ±21.7	136.3 ±21.8	0.903	136.1 ±21.2	134.1 ±21.6	0.018	136.9 ±20.7	136.9 ±20.5	0.997
Diastolic BP (M±SD mm Hg)	70.4 ±11.6	71.6 ±10.5	<.001	70.9 ±11.3	69.7 ±11.3	0.008	69.6 ±11.3	70.2 ±11.2	0.164
Hypertension	2470 58.8%	799 56.0%	0.070	1626 55.4%	483 54.6%	0.651	1602 64.0%	580 65.0%	0.576
History of hypertension & its medication	1599 38.0%	485 34.0%	0.006	997 33.1%	298 32.5%	0.723	1166 42.7%	427 44.8%	0.257
BP ≥140/90	1694 40.3%	592 41.5%	0.455	1144 39.5%	325 37.4%	0.271	971 40.8%	357 41.6%	0.666
BP < 140/90 with medication	1048 53.3%	335 51.8%	0.514	774 54.6%	244 58.0%	0.227	727 53.7%	273 53.8%	0.965
BP ≥140/90 with medication	920 46.7%	312 48.2%		643 45.4%	177 42.0%		626 46.3%	234 46.2%	
hypertension & any hypertension medication	1696 68.7%	519 65.0%	0.048	1125 69.2%	335 69.4%	0.943	1257 78.5%	457 78.8%	0.888
hypertension & diuretics	1112 45.1%	289 36.2%	<.001	616 37.9%	166 34.4%	0.160	680 42.5%	233 40.2%	0.336
hypertension & beta blockers	434 17.6%	147 18.4%	0.601	272 16.7%	72 14.9%	0.341	351 21.9%	97 16.7%	0.008
hypertension & vasodilators	336 13.6%	79 9.9%	0.006	161 9.9%	65 13.5%	0.027	191 11.9%	53 9.1%	0.068
hypertension & ACE inhibitors	298 12.1%	109 13.6%	0.244	262 16.1%	99 20.5%	0.025	357 22.3%	156 26.9%	0.025

Table 11: Diabetes and blood lipids control in CHS participants at baseline, year 5, and year 9 by site

	Baseline (1989-90 for original cohort) (1992-93 for new cohort)			Year 5 (1992-93)			Year 9 (1996-97)		
	Other three sites	Allegheny County, PA	P- value	Other three sites	Allegheny County, PA	P- value	Other three sites	Allegheny County, PA	P- value
Fasting glucose (Mean ±SD mg/dl)	110.2 ±36.1	112.7 ±37.6	0.002 MWT	106.7 ±31.8	107.7 ±32.8	0.643 MWT	101.7 ±29.4	104.7 ±37.1	0.020 MWT
2-hour glucose (Mean ±SD mg/dl)	148.1 ±57.3	142.9 ±60.5	<.001 MWT	N/A	N/A	N/A	139.7 ±52.0	139.7 ±51.8	0.823 MWT
Diabetes	650 15.6%	237 16.6%	0.074	411 14.9%	134 16.0%	0.247	378 16.5%	132 16.0%	0.928
Fasting glucose ≥126 mg/dl	575 13.9%	213 15.0%	0.107	328 12.0%	114 13.7%	0.187	262 11.7%	95 11.8%	0.961
History of diabetes & its medication	335 8.0%	119 8.3%	0.657	238 7.8%	74 8.0%	0.890	273 9.8%	91 9.3%	0.608
Any diabetic medication In diabetics	347 53.5%	119 50.2%	0.390	258 62.9%	78 58.2%	0.329	288 76.2%	96 72.7%	0.427
Insulin intake In diabetics	97 14.9%	28 11.8%	0.236	65 15.9%	22 16.4%	0.877	87 23.0%	28 21.2%	0.669
Any oral Hypoglycemic In diabetics	259 39.9%	92 38.8%	0.769	200 48.8%	59 44.0%	0.339	217 57.4%	72 54.5%	0.568
BP≥130/80 in diabetes	451 69.4%	158 66.7%	0.440	259 64.8%	84 64.1%	0.896	223 64.3%	78 63.9%	0.948
Fasting glucose <126 mg/dl with med	61 18.3%	23 19.5%	0.778	55 23.9%	13 18.3%	0.324	64 27.1%	20 25.3%	0.754
Fasting glucose ≥126 mg/dl with med	272 81.7%	95 80.5%		175 76.1%	58 81.7%		172 72.9%	59 74.7%	
High LDL (≥ 100 mg/dl)	3420 83.0%	656 85.5%	0.085 0.759	2000 72.0%	589 70.5%	0.405	N/A	N/A	N/A
Low HDL (≤35 mg/dl)	272 6.5%	90 6.3%	0.372	218 7.9%	75 9.0%	0.291	N/A	N/A	N/A
High triglycerides (≥200 mg/dl)	606 14.6%	194 13.6%		535 19.3%	158 18.9%	0.821	N/A	N/A	N/A
Any lipid lowering medication	235 5.6%	68 4.8%	0.231	214 7.1%	72 7.8%	0.465	N/A	N/A	N/A
Any lipid lowering medication in LDL ≥ 100	201 5.9%	32 4.9%	0.310	157 7.9%	51 8.7%	0.526	N/A	N/A	N/A
LDL <100 mg/dl with medication	28 12.2%	3 8.6%	0.532	44 21.9%	16 23.9%	0.735	N/A	N/A	N/A
LDL ≥ 100 mg/dl with medication	201 87.8%	32 91.4%		157 78.1%	51 76.1%				

Table 12: Control of other potential stroke risk factors in CHS participants at baseline, year 5, and year 9 by site

	Baseline (1989-90 for original cohort) (1992-93 for new cohort)			Year 5 (1992-93)			Year 9 (1996-97)		
	Other three sites	Allegheny County, PA	P-value	Other three sites	Allegheny County, PA	P-value	Other three sites	Allegheny County, PA	P-value
Current smoking	482 11.5%	189 13.2%	0.074	277 9.4%	79 8.9%	0.650	212 7.9%	72 8.0%	0.900
Alcoholic drinks per week (Mean±SD)	2.4 ±6.3	2.8 ±6.7	<.001 MWT	1.9 ±4.9	2.3 ±5.3	<.001 MWT	1.7 ±5.2	2.2 ±5.3	<.001 MWT
7-8 alcohol drinks per week (> 90 th percentile)	405 9.7%	159 11.2%	0.103	277 9.2%	102 11.1%	0.087	239 8.8%	109 11.9%	0.005
History of coronary heart disease	795 18.9%	276 19.3%	0.720	768 22.0%	238 23.2%	0.439	803 25.4%	321 28.2%	0.062
History of Atrial fibrillation	107 2.8%	26 2.1%	0.191	85 2.8%	22 2.4%	0.469	93 3.9%	31 3.7%	0.804
History of transient ischemic attacks	74 1.8%	26 1.8%	0.879	85 2.4%	11 1.1%	0.008	120 3.8%	31 2.7%	0.093
Use of aspirin	1385 32.9%	478 33.4%	0.772	1122 37.3%	345 37.4%	0.195	1056 88.1%	339 84.8%	0.077
Use of oral anticoagulants	49 1.2%	18 1.3%	0.775	84 2.8%	27 2.9%	0.818	114 4.2%	46 4.7%	0.510
Coronary angioplasty or angiography	59 1.4%	33 2.3%	0.019	77 2.5%	22 2.4%	0.766	40 1.5%	15 1.6%	0.727
common carotid wall thickness (M±SD mm)	1.06 ±0.22	1.06 ±0.21	0.729 MWT	1.07 ±0.22	1.07 ±0.24	0.721 MWT	1.08 ±0.26	1.10 ±0.27	0.142 MWT
Internal carotid wall thickness (M±SD mm)	1.44 ±0.57	1.42 ±0.55	0.239 MWT	1.42 ±0.54	1.42 ±0.59	0.181 MWT	1.71 ±0.78	1.67 ±0.83	0.092 MWT
Carotid stenosis (≥25%)	2013 48.2%	617 43.2%	0.001	1408 47.7%	385 42.0%	0.003	506 28.2%	186 29.2%	0.638
Low Ankle-Arm Index (≤0.9)	491 12.0%	205 14.6%	0.010	329 12.0%	106 12.5%	0.664	325 18.3%	145 21.7%	0.057
LV hypertrophy by ECG	188 4.6%	71 5.4%	0.247	123 4.4%	37 4.4%	0.979	136 5.8%	49 5.9%	0.960
White matter grade 3 or more	N/A	N/A	N/A	925 36.3%	226 25.8%	<.001	718 44.2%	204 37.8%	0.009
One or more large infarct	N/A	N/A	N/A	697 27.1%	284 32.2%	0.004	500 30.8%	147 27.2%	0.113
Two or more large infarct	N/A	N/A	N/A	263 10.2%	104 11.8%	0.196	191 11.8%	54 10.0%	0.260




Figure 8: Total stroke hazard ratio at first MRI in the three CHS sites combined compared to Allegheny County

4.5. DISCUSSION

4.5.1. Blood pressure and hypertension:

Several clinical trials suggested a dose-response relationship between blood pressure lowering and reduction of stroke risk. In these trials, regardless the agent used, 30% to 40% reduction in stroke risk was reported.² The current data showed that both Allegheny County and the other three sites had a relatively constant blood pressure between baseline and year 9 which could be considered as having experienced a relative improvement given the increasing age of the cohort. In meta-analyses of randomized trials, the efficacy of blood pressure medications in reducing stroke risk was dependent on the type and dosage of medication.^{20, 21} The data showed reduction in stroke risk by 51% with high dose diuretics,²¹ 30% with ACE inhibitors²⁰ and 29% with beta blockers.²¹ By year 9, Allegheny County had a higher use of ACE inhibitors, lower use of beta blockers, and a similar use of diuretics compared to the other three sites.

4.5.2. Blood glucose and diabetes:

In both Allegheny County and the other three sites, a 20% increase in the rate of diabetes medication accompanied by improved glycemic control was shown between baseline and year 9. Although tight glycemic control is recommended to prevent microvascular disease, previous studies failed to demonstrate the benefit of tight glycemic control in stroke risk reduction.¹ In addition, previous studies showed the tight control of hypertension (less than 130/80) in diabetics significantly reduces stroke incidence.^{3, 22} Blood pressure less than 130/80 was slightly improved in both study populations between baseline and year 9 without significant differences between study populations.

4.5.3. LDL cholesterol:

Although many clinical trials showed reduced stroke risk after lowering LDL levels,²³ the current data did show any better LDL control in Allegheny County compared to other three sites. The improved LDL control (LDL <100 mg/dl with medication) in both Allegheny County and the other three sites between baseline (8.6% and 12.2% respectively, p=0.532) and year 5 (23.9% and 21.9% respectively, p=0.735) could be explained by the higher percentage of people who use any lipid lowering medication at year 5 compared to baseline.

4.5.4. Alcohol drinking and cigarette smoking:

Results from observational studies indicated that heavy alcohol consumption increases the relative risk for both ischemic and hemorrhagic stroke while light or moderate alcohol consumption may be protective for ischemic stroke.^{24, 25} Allegheny County had significantly higher number of alcohol drinks per week, however, the stroke risk due to alcohol drinking should not be considered higher in Allegheny County because in both study populations the amount of alcohol consumed was relatively small (1.7-2.8 drinks per week). Current cigarette smoking has been long recognized as a major risk factor for stroke with almost doubling of relative risk and disappearance of the risk about 5 years after cessation.^{5, 26} In the current data, by year 9, Allegheny County had similar smoking rates compared to the other three sites indicating comparable smoking cessation rates.

4.5.5. Carotid stenosis:

Severe symptomatic carotid artery stenosis is responsible for approximately 20 to 30% of ischemic strokes and almost 3 times more than asymptomatic one.^{9, 27} Carotid stenosis $\geq 25\%$ was lower while carotid stenosis $\geq 50\%$ was similar in Allegheny County compared to the other three sites at baseline and year 5. Little differences in stroke risk between sites based on carotid

stenosis could be expected because symptomatic (with TIA) carotid stenosis ($\geq 25\%$ or $\geq 50\%$), a more important stroke risk factor than the asymptomatic stenosis, was not significantly different between study populations at any visits. Large randomized controlled trials have documented that carotid endarterectomy is a highly effective stroke preventive measure among patients with severe carotid stenosis and recent transient ischemic attack.^{9, 10} Because carotid endarterectomy was not different between study populations at baseline and data were not available at other visits, we could not verify the differences between study populations in surgical control of carotid stenosis.

4.5.6. History of transient ischemic attack and atrial fibrillation:

In clinical trials, warfarin was highly effective in reducing stroke risk in atrial fibrillation patients while Aspirin, to a less extent, reduced the stroke risk in both transient ischemic attack and atrial fibrillation.¹¹ The current data did not show any better control of either transient ischemic attack or atrial fibrillation (oral anti-coagulant or aspirin use) in Allegheny County compared to the other three sites. Moreover, atrial fibrillation prevalence was similar in both study populations at all visits. The lower prevalence of transient ischemic attack in Allegheny County at year 5 ($p=0.008$) and year 9 ($p=0.093$) may be explained by the lower prevalence of carotid stenosis ($>25\%$) at baseline and year 5.

4.5.7. Brain MRI white matter grade (WMG):

Several recent reports from prospective studies indicated that higher grade of white matter lesion is a strong predictor of stroke specially lacunar infarction and the risk is independent of traditional risk factors.²⁸⁻³⁰ In this report, likewise white matter grade was a strong stroke predictor irrespective of sites. Moreover, the excess hazard in the other three sites compared to Allegheny County was reduced in both the first and second brain MRI explaining almost one

fifth to one fourth of the lower risk of stroke in Allegheny County which had significantly lower prevalence of white matter grade ≥ 3 in both MRIs. White matter grade was shown to be strongly related to age³¹ which might explain the higher prevalence of those who had white matter grade ≥ 3 in the second MRI irrespective of sites. White matter grade may be a marker of integrated exposure and control of stroke risk factors and may help in explaining geographic variations in stroke incidence. As Allegheny County had a similar stroke history and lower white matter grade at baseline, the current results suggested the importance of white matter lesion to point any future increase or reduction of stroke risk in a given community, probably many years before it happen. The current findings suggested white matter grade progression could be used a marker of the efficacy of the various pharmacologic and non-pharmacologic therapies of stroke on the individual level and as a marker of the efficacy of different stroke prevention strategies on a community level.

4.5.8. Conclusion:

The current report showed some degree of improvement of control of traditional stroke risk factors specially LDL cholesterol, diabetes, smoking, and hypertension between baseline and year 9. However, the improvements were not significantly different between Allegheny County and the other three sites suggesting that these factors did not play a major role in explaining the observed difference in stroke hazard between study populations. The prevalence of coronary heart disease, atrial fibrillation and transient ischemic attack were increased in both study populations across visits with out significant differences with the exception of transient ischemic attack that was significantly lower in Allegheny County at year 5. The use of aspirin and oral anti-coagulants were markedly increased in both study populations across visits with out significant differences. White matter grade which was a strong predictor of stroke irrespective of

sites and was lower in Allegheny County in both MRIs may be a marker of integrated exposure and control of stroke risk factors and may help in explaining geographic variations in stroke incidence.

4.6. REFERENCES

1. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: A statement for healthcare professionals from the stroke council of the American Heart Association. *Stroke*. 2001;32:280-299
2. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: An overview of published reviews. *Stroke*. 2004;35:776-785
3. Tuomilehto J, Rastenyte D. Diabetes and glucose intolerance as risk factors for stroke. *J Cardiovasc Risk*. 1999;6:241-249
4. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. *Diabetes Metab Res Rev*. 2002;18 Suppl 3:S82-85
5. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham study. *JAMA*. 1988;259:1025-1029
6. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials. *Am J Med*. 2004;117:596-606
7. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. *Br J Clin Pharmacol*. 2004;57:640-651
8. Vreecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. *Int J Clin Pharmacol Ther*. 2003;41:567-577
9. Dodick DW, Meissner I, Meyer FB, Cloft HJ. Evaluation and management of asymptomatic carotid artery stenosis. *Mayo Clin Proc*. 2004;79:937-944
10. Brott TG, Brown RD, Jr., Meyer FB, Miller DA, Cloft HJ, Sullivan TM, Dodick DW, Meissner I. Carotid revascularization for prevention of stroke: Carotid endarterectomy and carotid artery stenting. Evaluation and management of asymptomatic carotid artery stenosis. *Mayo Clin Proc*. 2004;79:1197-1208
11. Matchar DB, McCrory DC, Barnett HJM, Feussner JR. Medical treatment for stroke prevention. *Ann Intern Med*. 1994;121:41-53

12. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). *Lancet*. 2004;363:1925-1933
13. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al. The Cardiovascular Health Study: Design and rationale. *Ann Epidemiol*. 1991;1:263-276
14. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. *Ann Epidemiol*. 1993;3:358-366
15. Price TR, Psaty B, O'Leary D, Burke G, Gardin J. Assessment of cerebrovascular disease in the Cardiovascular Health Study. *Ann Epidemiol*. 1993;3:504-507
16. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:270-277
17. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:278-285
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension*. 2003;42:1206-1252
19. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 1997;20:1183-1197
20. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration. *Lancet*. 2000;356:1955-1964
21. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. *JAMA*. 1997;277:739-745
22. Kernan WN, Inzucchi SE. Type 2 diabetes mellitus and insulin resistance: Stroke prevention and management. *Curr Treat Options Neurol*. 2004;6:443-450

23. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. *BMJ*. 2003;326:1423
24. Daniel S, Bereczki D. Alcohol as a risk factor for hemorrhagic stroke. *Ideggyogy Sz*. 2004;57:247-256
25. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J, Lewis BL. Alcohol consumption and risk of stroke: A meta-analysis. *JAMA*. 2003;289:579-588
26. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ*. 1989;298:789-794
27. Barth A. Carotid stenosis: Diagnosis, patient selection, therapy. *Ther Umsch*. 2003;60:563-568
28. Kuller LH, Longstreth WT, Jr., Arnold AM, Bernick C, Bryan RN, Beauchamp NJ, Jr. White matter hyperintensity on cranial magnetic resonance imaging: A predictor of stroke. *Stroke*. 2004;35:1821-1825
29. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: The Rotterdam Scan Study. *Stroke*. 2003;34:1126-1129
30. Yamauchi H, Fukuda H, Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis. *J Neurol Neurosurg Psychiatry*. 2002;72:576-582
31. Longstreth WT, Jr., Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O'Leary D, Fried L. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. *Stroke*. 1996;27:1274-1282

5. GENERAL DISCUSSION

5.1. Studying stroke incidence in CHS population:

CHS was an ideal study to examine geographic variations in stroke incidence and/or mortality for a number of reasons; CHS was the first study to allow comparisons of stroke incidence and/or mortality in older people (65 years and more) in four United States communities on the same time using a standardized methodology, the stroke incidence reported before in ARIC study's four centers was for younger people (less than 65 years).¹ As stroke is very dependent on age with doubling of stroke incidence for each decade after the age of 55, the older age of the CHS population allowed more events to happen on the study period as well as shedding the light on that stroke high risk group. Another reason to catch more stroke events in the CHS population (665 incident stroke events) was the long follow-up period (10 years in the original cohort and 7 years in the new cohort). The recruitment of additional African American (new) cohort after the beginning of the study allowed racial comparisons of stroke incidence. Unlike most previous stroke incidence studies in United States, CHS had a prospective cohort design that allowed detecting incident stroke events as they happened "what is called hot pursuit". One of the disadvantages of comparing stroke incidence rates obtained from different studies was the different case ascertainment methodology. Also comparing rates from different studies that were obtained at different points of time should be done with caution. CHS sites used the same case ascertainment methodology on the same time. One advantage of this study was the use of validated events rather than reliance on the less accurate discharge diagnosis coding or death

certificate.^{2, 3} Provisional diagnoses of stroke were assigned by the field center principal investigator, and then reviewed and adjudicated at periodic meetings of the cerebrovascular disease endpoint committee. In addition, collecting and validating information on previous history of stroke allowed calculating rates in only stroke-free participants; this was very difficult or even impossible to achieve in previous registry-based studies. MRI use was noticeably higher in this study (62%) than the other recent studies like the Greater Cincinnati (22%) or ARIC (27%) studies allowing more accurate classification of stroke types and sub-types. Collecting information about a large number of cardiovascular risk factors (at baseline and annually) like hypertension, diabetes, smoking, sub-clinical disease, medication use....etc allowed studying the role these factors played in site-differences in stroke risk. CHS data had some limitations in studying stroke incidence, the old age of participants at baseline resulted in a large number of participants died (28.7%) during the follow-up period. Although the percentage of African Americans (15%) was a little bit higher than the national average (13%), it was difficult to bi-racially compare the rates by age group and gender due to small number of events, one of the sites (Washington County) could not recruit African Americans cohort, also absence of information about the Hispanic origin did not allow more racial comparisons. The complexity of CHS data with thousands of variables and many data files grouped by year, cohort, event type (incident versus prevalent), and diagnostic procedures (like MRI and ultra-sound files) required a lot of extra caution by any researcher to handle these data.

5.2. Overall total stroke Incidence:

Comparing stroke incidence rates reported in different studies is not without risk because of definition criteria, methodology of case ascertainment, population, age range, and time period covered. The overall total (all stroke types) stroke incidence reported in this report was

substantial at 17.7 per 1000 person years and many-fold higher than that reported in other population based studies estimating stroke incidence in the United States^{1, 4-12} and worldwide¹³⁻¹⁵ because of the older age of CHS population. The overall annual stroke incidence rates in United States studies^{1, 4-12} per 100,000 populations, approximately ranged between 93 and 293. In all these studies, the populations used were either all age groups, adults 35 years and over, or the older population excluded. This may resulted in dilution of the rates by including (into the denominator) the younger population who had a very low stroke risk. In ARIC study¹ which used a similar design to CHS study in people aged 45 to 64 years in 4 US communities, the age-adjusted total stroke incidence rates per 1000 person-years were 4.45 for blacks and 1.72 for whites. The current CHS rates per 1000 person-years were 18.2 for blacks and 17.3 for whites.

When age-specific rates for older people were compared between this study and other stroke incidence population studies in United States, CHS rates were generally higher.^{4-6, 9, 11} The more through case ascertainment and validation of the CHS population using different overlapping techniques probably yielded more stroke cases than might be discovered using the registry-based methodology applied in these studies. In the Lehigh Valley, a region in Pennsylvania and New Jersey, in 1982-1983,¹¹ the age specific stroke incidence per 100,000 populations were estimated to be 652 for those 65-74 years, 1408 for those 75-84 years and 2243 for those 85 years and more. These rates compare with CHS rates of 1060, 2200, and 3270 in these age groups respectively. In Northern Manhattan, New York City, between 1993 and 1996,⁵ the average annual stroke incidence rates per 100,000 for those 65-74 years were 650 for males and 468 for females, those 75-84 years were 688 for males and 629 for females, and those 85 years and more were 857 for males and 931 for females.

The rates in CHS were comparable to those reported in many westernized countries. For example, comparing the current stroke incidence rates in those aged 85 years or older (32.7 per 1000 person-years) to other studies showed that the annual stroke incidence per 1000 population were either higher than in France (18.2)¹⁶, The United Kingdom (18.9)¹⁷, and Germany (21.2)¹⁸, similar to Greece (26.6)¹⁹, Italy(28.8)²⁰ and Norway(30.4)²¹, and lower than in Japan (38.5 in females and 49.2 in males).²²

Our age standardized results showed a non-significant slightly higher incidence rate per 1000 person-years for blacks than whites (18.2 and 17.3 respectively). Although racial differences in stroke incidence and mortality with more blacks affected than whites was well documented in United States,^{1, 5, 9, 10, 23-25} it was also reported that older age groups have a smaller racial difference in stroke incidence as compared to younger population.^{1, 5, 9, 24, 26} Broderick and colleagues⁹ reported that blacks under age 65 in Greater Cincinnati had a two to four times greater stroke incidence rate compared to whites of similar age in the Rochester, Minnesota. Above 65 years, however, the differences disappeared and the age-specific stroke incidence rates were similar for elderly blacks and whites. Absence of racial difference in stroke risk in people 65 years or older was also documented in a nationally representative data.²⁶

The crude incidence rates we observed were slightly higher in males than females (14.8 and 13.7). After age standardization, females had slightly higher rates than males (18.1 and 16.4). None of these differences in incidence were statistically significant. Older populations may have less gender differences in stroke incidence. The data reported for age specific stroke incidence rates in males and females in the Northern Manhattan Stroke Study⁵ showed that male/female risk decrease steadily from 2.5 times in those aged 45-54 years until it reversed in those aged 85

years or older, when females had slightly higher stroke incidence than males. Similar observations were noted in Rochester, Minnesota⁶ and the French West Indies.¹⁶

5.3. Site specific total stroke incidence:

Our results showed significantly lower stroke incidence rates in Allegheny County field center than the other three study sites in Forsyth County, Sacramento County, and Washington County. The lower stroke incidence rate in Allegheny County was consistent over time and began as early as the fourth year of follow up. The lower stroke incidence rate in Allegheny County was consistent by cohort, gender, race, and age groups. Differences between Allegheny County and the other three sites were statistically significant for the original cohort, females, whites, and those aged 65-74 and 75-84. Lack of statistical significance for differences in rates for the Allegheny County new cohort, blacks and those aged 85 years or older, can be explained by the small total number of events in these three groups (60, 89, and 38 respectively).

In ARIC study¹ which used a similar design to CHS in people aged 45 to 64 years in 4 US communities, there were noticeably higher rates for stroke incidence per 1000 person-years in the Jackson, Mississippi site (4.47) than the other 3 sites (Forsyth County, NC; (1.72) Washington County, MD; (1.92) and Minneapolis, MN (1.80)). This may be explained by the fact that all participants at the Jackson site were blacks and blacks in this study had higher rates than whites (4.45 and 1.72 respectively). In the current study, however, the racial differences between sites did not account for site-differences in stroke rates for two reasons; blacks did not have a significantly higher stroke incidence than whites, and also Washington County, the site with a significantly lower percentage of blacks percentage, had significantly higher rates than Allegheny County and similar rates to Forsyth County and Sacramento County.

The lower stroke incidence in Allegheny County, both incidence rates and cumulative incidence, may be due to lower prevalence of stroke risk factors in Allegheny County at baseline, better control of these factors at baseline and over the years, or both together. These two hypothesis will be discussed in the next articles. The degree of urbanization has been linked with stroke risk, with higher rates in non-metropolitan areas.²⁷⁻²⁹ Allegheny County was entirely urban while the other sites were mixed urban/rural communities.

5.4. Type-specific stroke incidence:

The significantly lower incidence rates in Allegheny County for total strokes were replicated for ischemic strokes but not hemorrhagic strokes. This was not surprising giving the fact that 85% of incident strokes were ischemic (566 events) and only 10% were hemorrhagic (65 events). The frequency of ischemic strokes in the CHS population (85%) was either similar to other US studies (84%)^{1, 9} or slightly higher (77%).⁵ The hemorrhagic strokes were less frequent in the CHS population (10%) than other American populations of younger age (14.5% and 23%).^{1, 5, 9} MRI use was noticeably higher in this study (62%) than the other recent studies like the Greater Cincinnati (22%) or ARIC (27%) studies. One advantage of this study was the use of validated events rather than reliance mainly on the less accurate discharge diagnosis coding or death certificate.^{2, 3} For example, in Framingham study, analysis of death certificate validity disclosed marked over-reporting of cerebral hemorrhage and under-reporting of cerebral embolus.³

5.5. Stroke mortality and case fatality:

The overall one month case fatality rates reported for all CHS participants were comparable to other US studies (10% -15%)^{4, 5} but lower than that reported in Europe, Russia, and Japan (17% to 33%)^{15-22, 30-32} probably due to better health care. The stroke mortality rate per 1000 person-years was also lower in Allegheny County (1.55) than the other three sites (2.79, 2.67, 3.07).

However, the differences were not significant probably due to the small number of fatal strokes (84 events). The same observation was obtained after plotting the cumulative total stroke mortality rates over time, adjusted for age, gender, race, and cohort. The lower mortality rate in Allegheny County than the other three sites might be explained by the lower incidence and similar case fatality and proportional frequencies of incident stroke types in Allegheny County compared to the other three sites. Though much higher due to older population, the current study findings were consistent with national data (1999) that showed lower age-adjusted stroke mortality rates per 100,000 American of all ages in Pennsylvania (58.0) compared to North Carolina (78.1), California (63.3), and Maryland (63.1).³³ The similar one month case fatality across sites might be due to similar stroke management or stroke severity across sites, for example, there were no significant differences between sites for total mortality or incident CHD also those who had incident CHD before stroke were similar across sites. In addition, longer time period (for example one year case fatality) might be needed to delineate between sites differences in case fatality.

5.6. Prevalence of potential risk factors at baseline:

The current report was unique in examining multiple possible stroke risk factors, collected using standardized methodology, in four geographically separated US communities, with the aim to explain geographic variations in stroke incidence. Allegheny County, which had the lowest stroke hazard among the four sites, had relatively similar risk factors distributions to the other three sites.

Allegheny County showed lower prevalence of a number of traditional cardiovascular risk factors and markers of sub-clinical cardiovascular disease than the other sites, partially explaining the geographic discrepancy in stroke incidence. For example, in Allegheny County,

higher prevalence of better education and alcohol consumption, and lower prevalence of family history of stroke, hypertension among white participants, carotid stenosis ($\geq 25\%$), higher white matter grades (≥ 3), and elevated triglycerides (≥ 200 mg/dl) among diabetic participants; were among the differences of possible stroke risk factors that support the low stroke hazard in Allegheny County compared to the other three sites.

On the other hand, higher proportion of abnormal Ankle-Arm blood pressure Index (≤ 0.9), lower use of any hypertension medications among hypertensives and lower percentage of people having supplemental insurance were among the possible risk factors profile in Allegheny County that did not support the low stroke hazard compared to the other three sites.

Hypertension prevalence, the most frequently reported single risk factor associated with high stroke incidence/mortality geographic areas both in United States^{27, 34} and worldwide³⁵⁻³⁹, was generally lower in Allegheny County than the other three sites, though the trend was significant only among white participants. However, better response to hypertension medications in Allegheny County could not be shown in this report as was expected from the stroke belt experience.⁴⁰ Despite a strong link with cardiovascular disease, diabetes prevalence did not vary directly with stroke risk – similar to most previous reports.^{27, 37, 41} Better education (12 years or more or college education) were more prevalent in Allegheny County. Similarly, an inverse relationship between education and stroke incidence or mortality was shown in most of the reports from the industrialized countries.⁴¹⁻⁴³

5.7. Multiple risk factors at baseline and site-differences in stroke risk:

The current findings indicated that traditional stroke risk factors can explain to certain extent the site differences in stroke risk. A 30% reduction in stroke risk was obtained after adjustment for age, hypertension, diabetes, education, BMI, LDL cholesterol and previous CHD, TIA and atrial

fibrillation. Similarly, most previous reports show that geographic differences in stroke incidence and/or mortality, at most, can be partially explained by the differences in stroke risk factors. Data from the First National Health and Nutrition Examination Survey (NHANES I) Epidemiologic Follow-up Study (1971-1987) ²⁷ showed that baseline risk factors, that including age, sex, race, smoking status, history of diabetes, history of heart disease, education, systolic blood pressure, alcohol use, and physical activity, played a very minor role in the estimated excess stroke risk in the Southeast. In England,⁴⁴ the hazard ratio for stroke in the rest of Britain compared with southern England was 1.44 (95% confidence interval =1.16 to 1.78), After adjustment for baseline systolic blood pressure, smoking status, physical activity, social class, and height, the hazard ratio decreased moderately, but was still significant (1.24, 95% CI, 1.00 to 1.54). In different MONICA populations,³⁶ smoking and elevated blood pressure explained 21% of the variation in stroke incidence among men and 42% in women. In Sweden,³⁹ cardiovascular score (hypertension, diabetes, smoking, and being overweight) and socioeconomic status together accounted for 44% of the geographic variation of stroke incidence among men and 63% among women..

5.8. Medication use and sub-clinical disease at baseline:

Inclusion of medication usage and sub-clinical cardiovascular disease was an important innovation in the current study. Medication usage and sub-clinical cardiovascular disease at baseline in this report had very little to do with site differences in stroke risk. The rate for any sub-clinical disease at baseline was similar across sites. With few exceptions, the rates for medication use at baseline were generally similar across sites. However, risk factors investigated in this report and their treatment were limited to baseline data and did not take in consideration the changes over time in controlling conditions like hypertension, diabetes, and high blood lipids.

5.9. Blood pressure and hypertension control across visits:

Several clinical trials suggested a dose-response relationship between blood pressure lowering and reduction of stroke risk. In these trials, regardless the agent used, 30% to 40% reduction in stroke risk was reported⁴⁵ The current data showed that both Allegheny County and the other three sites had a relatively constant blood pressure between baseline and year 9 which could be considered as having experienced a relative improvement given the increasing age of the cohort. In meta-analyses of randomized trials, the efficacy of blood pressure medications in reducing stroke risk was dependent on the type and dosage of medication.^{46, 47} They showed reduction in stroke risk by 51% with high dose diuretics,⁴⁷ 30% with ACE inhibitors⁴⁶ and 29% with beta blockers.⁴⁷ By year 9, Allegheny County had a higher use of ACE inhibitors, lower use of beta blockers, and a similar use of diuretics compared to the other three sites.

5.10. Blood glucose and diabetes control across visits:

In both Allegheny County and the three sites, a 20% increase in the rate of diabetes medication accompanied by improved glycemic control was shown between baseline and year 9. Although tight glycemic control is recommended to prevent microvascular disease, previous studies failed to demonstrate the benefit of tight glycemic control in stroke risk reduction.⁴⁸ In addition, previous studies showed the tight control of hypertension (less than 130/80) in diabetics significantly reduces stroke incidence.^{49, 50} Blood pressure less than 130/80 was slightly improved in both study populations between baseline and year 9 without significant differences between study populations.

5.11. LDL cholesterol control across visits:

Although many clinical trials showed reduced stroke risk after lowering LDL levels,⁵¹ the current data did show any better LDL control in Allegheny County compared to other three sites. The improved LDL control (LDL <100 mg/dl with medication) in both Allegheny County and the other three sites between baseline (8.6% and 12.2% respectively, p=0.532) and year 5 (23.9% and 21.9% respectively, p=0.735) could be explained by the higher percentage of people who use any lipid lowering medication at year 5 compared to baseline.

5.12. Alcohol drinking and cigarette smoking control across visits:

Results from observational studies indicated that heavy alcohol consumption increases the relative risk for both ischemic and hemorrhagic stroke while light or moderate alcohol consumption may be protective for ischemic stroke.^{52, 53} Allegheny County had significantly higher number of alcohol drinks per week, however, the stroke risk due to alcohol drinking should not be considered higher in Allegheny County because in both study populations the amount of alcohol consumed was relatively small (1.7-2.8 drinks per week). Current cigarette smoking has been long recognized as a major risk factor for stroke with almost doubling of relative risk and disappearance of the risk about 5 years after cessation.^{54, 55} In the current data by year 9, Allegheny County had similar smoking rates compared to the other three sites indicating comparable smoking cessation rates.

5.13. Carotid stenosis across visits:

Severe symptomatic carotid artery stenosis is responsible for approximately 20 to 30% of ischemic strokes and almost 3 times more than asymptomatic one.^{56, 57} Carotid stenosis \geq 25%

was lower while carotid stenosis $\geq 50\%$ was similar in Allegheny County compared to the other three sites at baseline and year 5. Little differences in stroke risk between sites based on carotid stenosis could be expected because symptomatic (with TIA) carotid stenosis ($\geq 25\%$ or $\geq 50\%$), a more important stroke risk factor than the asymptomatic stenosis, were not significantly different between study populations at all visits. Large randomized controlled trials have documented that carotid endarterectomy is a highly effective stroke preventive measure among patients with severe carotid stenosis and recent transient ischemic attack.^{57, 58} Because carotid endarterectomy was not different between study populations at baseline and data were not available at other visits, we could not verify the differences between study populations in surgical control of carotid stenosis.

5.14. History of transient ischemic attack and atrial fibrillation across visits:

In clinical trials, warfarin was highly effective in reducing stroke risk in atrial fibrillation patients while Aspirin, to a less extent, reduced the stroke risk in both transient ischemic attack and atrial fibrillation.⁵⁹ The current data did not show any better control of either transient ischemic attack or atrial fibrillation (oral anti-coagulant or aspirin use) in Allegheny County compared to the other three sites. Moreover, atrial fibrillation prevalence was similar in both study populations at all visits. The lower prevalence of transient ischemic attack in Allegheny County at year 5 ($p=0.008$) and year 9 ($p=0.093$) may be explained by the lower prevalence of carotid stenosis ($>25\%$) at baseline and year 5.

5.15. Brain MRI white matter grade and stroke risk:

Several recent reports from prospective studies indicated that higher grade of white matter lesion is a strong predictor of stroke specially lacunar infarction and the risk is independent of

traditional risk factors.⁶⁰⁻⁶² In this report, likewise white matter grade was a strong stroke predictor irrespective of sites. One of the most interesting finding in this report was that white matter grade at baseline was responsible for 25% of the excess stroke hazard observed in the other three sites compared to Allegheny County which had significantly lower prevalence of high white matter grade. So white matter grade was the most important single risk factor to explain the observed site differences in stroke risk. White matter grade was shown to be strongly related to age⁶³ which might explain the higher prevalence of those who had white matter grade ≥ 3 in the second MRI irrespective of sites. As Allegheny County had a similar stroke history and lower white matter grade at baseline, the current results suggested the importance of white matter lesion to point any future increase or reduction of stroke risk in a given community, probably many years before it happen. White matter grade may be a marker of integrated exposure and control of stroke risk factors and may help in explaining geographic variations in stroke incidence. White matter grade progression could be used a marker of the efficacy of the various pharmacologic and non-pharmacologic therapies of stroke on the individual level and as a marker of the efficacy of different stroke prevention strategies on a community level.

5.16. Alternative explanation of site-differences in stroke

As the site-differences in stroke risk in this report were only partially explained by risk factors distributions at baseline, also the control of major stroke risk factors did not play a major role in explaining the observed difference, factors other than traditional stroke risk factors and sub-clinical cardiovascular disease should be investigated further. These factors might be more helpful in explaining regional differences in stroke risk. Limited data have identified several potential factors, including genetic influences on stroke⁶⁴⁻⁶⁶ – especially compelling as family history of stroke was lower in Allegheny County than in other sites. The degree of urbanization

has likewise been linked with stroke risk, with higher rates in non-metropolitan areas.²⁷⁻²⁹ Allegheny County was entirely urban while the other sites were mixed urban/rural communities. Dietary life style including the consumption of fish, fruits and vegetables and dietary calcium and potassium may help in explaining geographic stroke incidence variations.^{67, 68} Finally, environmental factors such as the quality of drinking water and environmental exposure to lead and perhaps cadmium may have some role in explaining these stroke variations.^{69, 70}

5.17. REFERENCES

1. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. *Stroke*. 1999;30:736-743
2. Rinaldi R, Vignatelli L, Galeotti M, Azzimondi G, de Carolis P. Accuracy of ICD-9 codes in identifying ischemic stroke in the general hospital of Lugo di Romagna (Italy). *Neurol Sci*. 2003;24:65-69
3. Corwin LE, Wolf PA, Kannel WB, McNamara PM. Accuracy of death certification of stroke: The Framingham study. *Stroke*. 1982;13:818-821
4. Lackland DT, Bachman DL, Carter TD, Barker DL, Timms S, Kohli H. The geographic variation in stroke incidence in two areas of the southeastern stroke belt : The Anderson and Pee Dee stroke study. *Stroke*. 1998;29:2061-2068
5. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA. Stroke incidence among white, black, and Hispanic residents of an urban community: The Northern Manhattan Stroke Study. *Am J Epidemiol*. 1998;147:259-268
6. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989. *Stroke*. 1996;27:373-380
7. Brown RD, Whisnant JP, Sicks JD, Christianson TJ, O'Fallon WM, Wiebers DO. A population-based study of the first-ever and total stroke incidence rates in Rochester, Minnesota: 1990-1994. *Stroke*. 2000;31:279
8. Woo D, Gebel J, Miller R, Kothari R, Brott T, Khoury J, Salisbury S, Shukla R, Pancioli A, Jauch E, Broderick J. Incidence rates of first-ever ischemic stroke subtypes among blacks: A population-based study. *Stroke*. 1999;30:2517-2522
9. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minneci L, Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks. *Stroke*. 1998;29:415-421
10. Broderick J, Miller R, Khoury J, Alwell K, Kissela B, Woo D, Shukla R, Moomaw C, Gebel J, Pancioli A, Brott T, Kothari R. Incidence rates of stroke for blacks and whites: Preliminary results from The Greater Cincinnati/Northern Kentucky Stroke Study. *Stroke*. 2001;32:320
11. Alter M, Sobel E, McCoy RL, Francis ME, Shofer F, Levitt LP, Meehan EF. Stroke in the Lehigh Valley: Incidence based on a community-wide hospital register. *Neuroepidemiology*. 1985;4:1-15

12. Gross CR, Kase CS, Mohr JP, Cunningham SC, Baker WE. Stroke in south Alabama: Incidence and diagnostic features--a population based study. *Stroke*. 1984;15:249-255
13. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration. International stroke incidence collaboration. *Stroke*. 1997;28:491-499
14. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: A review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. *Lancet Neurol*. 2003;2:43-53
15. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas A-M, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. *Stroke*. 1995;26:361-367
16. Smadja D, Cabre P, May F, Fanon JL, Rene-Corail P, Riocreux C, Charpentier JC, Fournier P, Saint-Vil M, Ketterle et al. ERMANCIA: Epidemiology of stroke in Martinique, French west Indies: Part I: Methodology, incidence, and 30-day case fatality rate. *Stroke*. 2001;32:2741-2747
17. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CDA. Ethnic differences in incidence of stroke: Prospective study with stroke register. *British Medical Journal*. 1999;318:967-971
18. Kolominsky-Rabas PL, Sarti C, Heuschmann P, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann K-G, von Stockert T. A prospective community-based study of stroke in Germany-the Erlangen Stroke Project (ESPRO): Incidence and case fatality at 1, 3, and 12 months. *Stroke*. 1998;29:2501-2506
19. Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamateopoulos S. Stroke incidence and case fatality in southern greece: The arcadia stroke registry. *Stroke*. 1999;30:363-370
20. Carolei A, Marini C, Di Napoli M, Di Gianfilippo G, Santalucia P, Baldassarre M, De Matteis G, di Orio F. High stroke incidence in the prospective community-based L'Aquila registry (1994-1998). First year's results. *Stroke*. 1997;28:2500-2506
21. Ellekjaer H, Holmen J, Indredavik B, Terent A. Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate. *Stroke*. 1997;28:2180-2184
22. Morikawa Y, Nakagawa H, Naruse Y, Nishijo M, Miura K, Tabata M, Hirokawa W, Kagamimori S, Honda M, Yoshita K, Hayashi K. Trends in stroke incidence and acute case fatality in a Japanese rural area : The Oyabe Study. *Stroke*. 2000;31:1583-1587
23. Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic differences in stroke mortality between Non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. *Stroke*. 1994;25:2120-2125

24. Gaines K, Burke G. Ethnic differences in stroke: Black-white differences in the United States population. SECORDS investigators. Southeastern consortium on racial differences in stroke. *Neuroepidemiology*. 1995;14:209-239
25. Howard G, Howard VJ. Ethnic disparities in stroke: The scope of the problem. *Ethn Dis*. 2001;11:761-768
26. Giles WH, Kittner SJ, Hebel JR, Losonczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction. The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. *Arch Intern Med*. 1995;155:1319-1324
27. Gillum RF, Ingram DD. Relation between residence in the southeast region of the United States and stroke incidence. The NHANES I epidemiologic follow-up study. *Am J Epidemiol*. 1996;144:665-673
28. Gillum RF. Secular trends in stroke mortality in African Americans: The role of urbanization, diabetes and obesity. *Neuroepidemiology*. 1997;16:180-184
29. Obisesan TO, Vargas CM, Gillum RF. Geographic variation in stroke risk in the United States: Region, urbanization, and hypertension in the Third National Health and Nutrition Examination Survey. *Stroke*. 2000;31:19
30. Feigin VL, Wiebers DO, Nikitin YP, O'Fallon WM, Whisnant JP. Stroke epidemiology in Novosibirsk, Russia: A population-based study. *Mayo Clinic Proceedings*. 1995;70:847-852
31. Feigin VL, Wiebers DO, Whisnant JP, O'Fallon WM. Stroke incidence and 30-day case-fatality rates in Novosibirsk, Russia, 1982 through 1992. *Stroke*. 1995;26:924-929
32. Mihalka L, Smolanka V, Bulecza B, Mulesa S, Bereczki D. A population study of stroke in west Ukraine: Incidence, stroke services, and 30-day case fatality. *Stroke*. 2001;32:2227-2231
33. CDC. The burden of chronic diseases and their risk factors: National and state perspectives. 2002
34. Stolley PD, Kuller LH, Nefzger MD, Tonascia S, Lilienfeld AM, Miller GD, Diamond EL. Three-area epidemiological study of geographic differences in stroke mortality. II. Results. *Stroke*. 1977;8:551-557
35. Starr JM, Thomas B, Whalley LJ. Population risk factors for hospitalization for stroke in Scotland. *Int J Epidemiol*. 1996;25:276-281
36. Stegmayr B, Asplund K, Kuulasmaa K, Rajakangas AM, Thorvaldsen P, Tuomilehto J. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA project. An ecological study of 18 populations. *Stroke*. 1997;28:1367-1374

37. Ovary C, Suzuki K, Nagy Z. Regional differences in incidence rates, outcome predictors and survival of stroke. *Neuroepidemiology*. 2004;23:240-246
38. He J, Klag MJ, Wu Z, Whelton PK. Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors. *Stroke*. 1995;26:2222-2227
39. Engstrom G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund G, Janzon L. Geographic distribution of stroke incidence within an urban population: Relations to socioeconomic circumstances and prevalence of cardiovascular risk factors. *Stroke*. 2001;32:1098-1103
40. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs cooperative study group on antihypertensive agents. *Arch Intern Med*. 2000;160:825-831
41. Rodriguez Artalejo F, Guallar-Castillon P, Gutierrez-Fisac JL, Ramon Banegas J, del Rey Calero J. Socioeconomic level, sedentary lifestyle, and wine consumption as possible explanations for geographic distribution of cerebrovascular disease mortality in Spain. *Stroke*. 1997;28:922-928
42. Gillum RF, Mussolino ME. Education, poverty, and stroke incidence in whites and blacks: The NHANES I epidemiologic follow-up study. *J Clin Epidemiol*. 2003;56:188-195
43. Lindenstrom E, Boysen G, Nyboe J. Risk factors for stroke in Copenhagen, Denmark. I. Basic demographic and social factors. *Neuroepidemiology*. 1993;12:37-42
44. Morris RW, Whincup PH, Emberson JR, Lampe FC, Walker M, Shaper AG. North-south gradients in Britain for stroke and CHD: Are they explained by the same factors? *Stroke*. 2003;34:2604-2609
45. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: An overview of published reviews. *Stroke*. 2004;35:776-785
46. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration. *Lancet*. 2000;356:1955-1964
47. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. *JAMA*. 1997;277:739-745

48. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: A statement for healthcare professionals from the stroke council of the American Heart Association. *Stroke*. 2001;32:280-299
49. Kernan WN, Inzucchi SE. Type 2 diabetes mellitus and insulin resistance: Stroke prevention and management. *Curr Treat Options Neurol*. 2004;6:443-450
50. Tuomilehto J, Rastenyte D. Diabetes and glucose intolerance as risk factors for stroke. *J Cardiovasc Risk*. 1999;6:241-249
51. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. *BMJ*. 2003;326:1423
52. Daniel S, Bereczki D. Alcohol as a risk factor for hemorrhagic stroke. *Ideggyogy Sz*. 2004;57:247-256
53. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J, Lewis BL. Alcohol consumption and risk of stroke: A meta-analysis. *JAMA*. 2003;289:579-588
54. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ*. 1989;298:789-794
55. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham study. *JAMA*. 1988;259:1025-1029
56. Barth A. carotid stenosis: Diagnosis, patient selection, therapy. *Ther Umsch*. 2003;60:563-568
57. Dodick DW, Meissner I, Meyer FB, Cloft HJ. Evaluation and management of asymptomatic carotid artery stenosis. *Mayo Clin Proc*. 2004;79:937-944
58. Brott TG, Brown RD, Jr., Meyer FB, Miller DA, Cloft HJ, Sullivan TM, Dodick DW, Meissner I. Carotid revascularization for prevention of stroke: Carotid endarterectomy and carotid artery stenting. Evaluation and management of asymptomatic carotid artery stenosis. *Mayo Clin Proc*. 2004;79:1197-1208
59. Matchar DB, McCrory DC, Barnett HJM, Feussner JR. Medical treatment for stroke prevention. *Ann Intern Med*. 1994;121:41-53
60. Kuller LH, Longstreth WT, Jr., Arnold AM, Bernick C, Bryan RN, Beauchamp NJ, Jr. White matter hyperintensity on cranial magnetic resonance imaging: A predictor of stroke. *Stroke*. 2004;35:1821-1825

61. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: The Rotterdam Scan Study. *Stroke*. 2003;34:1126-1129
62. Yamauchi H, Fukuda H, Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis. *J Neurol Neurosurg Psychiatry*. 2002;72:576-582
63. Longstreth WT, Jr., Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O'Leary D, Fried L. Clinical correlates of white matter findings on cranial Magnetic Resonance Imaging of 3301 elderly people. The Cardiovascular Health Study. *Stroke*. 1996;27:1274-1282
64. Strachan DP, Leon DA, Dodgeon B. Mortality from cardiovascular disease among interregional migrants in England and Wales. *BMJ*. 1995;310:423-427
65. Rastenyte D, Tuomilehto J, Sarti C. Genetics of stroke: a review. *J Neurol Sci*. 1998;153:132-145
66. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke. The Framingham study. *Stroke*. 1993;24:1366-1371
67. Fung TT, Stampfer MJ, Manson JE, Rexrode KM, Willett WC, Hu FB. Prospective study of major dietary patterns and stroke risk in women. *Stroke*. 2004;35:2014-2019
68. He K, Song Y, Daviglius ML, Liu K, Van Horn L, Dyer AR, Goldbourt U, Greenland P. Fish consumption and incidence of stroke: A meta-analysis of cohort studies. *Stroke*. 2004;35:1538-1542
69. Neuberger JS, Mulhall M, Pomatto MC, Sheverbush J, Hassanein RS. Health problems in Galena, Kansas: A heavy metal mining superfund site. *Sci Total Environ*. 1990;94:261-272
70. Shaper AG, Packham RF, Pocock SJ. The british regional heart study: Cardiovascular mortality and water quality. *J Environ Pathol Toxicol*. 1980;4:89-111

6. APPLICATION TO PUBLIC HEALTH

Despite the advent in stroke treatment, stroke continues as the third leading cause of death among the US population in 2001, after heart diseases and cancer. 164,000 Americans died in 2001 from stroke (6.8% of all deaths).¹ It is now estimated that there are more than 700,000 incident strokes annually and 4.8 million stroke survivors.^{2, 3} Stroke imposes a substantial economic burden on individuals and society with more than \$140,000 estimated mean lifetime cost and 53 \$ billion estimated national direct and indirect cost.^{3,4}

6.1. Epidemiological studies and stroke prevention:

Comparing rates of disease on national or international levels, and attempting to determine factors that explain any geographic differences have often led to important knowledge about etiology and prevention. Major reductions in stroke mortality and morbidity may possibly be achieved through more effective prevention strategies.⁵ High-risk or stroke-prone individuals should be identified and targeted for specific interventions. Stroke risk is not homogeneous across the country, the so called stroke belt states have a stroke mortality that is 1.3-1.5 times the risk in the remainder of the nation.⁶ Epidemiological studies can detect geographical differences in stroke morbidity and mortality. Identifying areas of high and low stroke risk is very essential for stroke prevention for two reasons; in addition to targeting high stroke risk regions for specific interventions to achieve the best outcome, studying risk factors distribution associated with these regions will help in identifying the most important factor/factors that is/are responsible for these regional/geographical variability in stroke risk.

6.2. Stroke risk in older population:

Although United States had one of the lowest stroke incidence and mortality rates in the westernized countries, age-specific incidence rates in this study were higher than those reported for similar age groups in US but were comparable to those reported in many westernized countries suggesting that older Americans are at least less privileged compared to their younger counterparts as regards this lower stroke risk in United States and deserve more effective stroke prevention programs.

6.3. Reducing stroke risk:

After adjustment for age, hypertension, diabetes, education, BMI, LDL level and previous coronary heart disease, transient ischemic attack, and atrial fibrillation, there was almost 30% reduction of the excess hazard in the other three CHS sites compared to Allegheny County. These findings suggested that in a similar population, reducing the prevalence of these factors could lead to a considerable degree of stroke incidence reduction. However, as the site-differences in stroke risk were only partially explained in this report, factors other than traditional stroke risk factors and sub-clinical cardiovascular disease (like genetic, dietary, and environmental factors) should be investigated further.

6.4. White matter grade and stroke prediction:

As Allegheny County had a similar stroke history and lower white matter grade at baseline and significantly lower stroke risk thereafter, the current results suggested the importance of white matter lesion to point any future increase or reduction of stroke risk in a given community, probably many years before it happen. White matter grade progression could be used a marker of the efficacy of the various pharmacologic and non-pharmacologic therapies of stroke on the

individual level and as a marker of the efficacy of different stroke prevention strategies on a community level.

6.5. References

1. National Center for Health Statistics. Health, United States, 2003 with chartbook on trends in the health of Americans. 2003
2. Lethbridge-ÇejkuM, SchillerJS, BernadellL. Summary health statistics for U.S. Adults: National Health Interview Survey, 2002. National Center for Health Statistics. Vital health stat 10(222). 2004.
3. American Heart Association. Heart disease and stroke statistics — 2004 update. 2004
4. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466
5. Sacco RL. Identifying patient populations at high risk for stroke. Neurology. 1998;51:S27-30
6. Howard G. Why do we have a stroke belt in the southeastern United States? A review of unlikely and uninvestigated potential causes. American Journal of the Medical Sciences. 1999;317:160-167

7. SUMMARY

7.1. First article:

The first article examined the site-differences in stroke incidence, mortality and case fatality among CHS participants. Age and sex standardized total stroke incidence rates were significantly lower in Allegheny County than other three sites. The cumulative total stroke incidence rates were also significantly lower in Allegheny County than other three sites. Stroke incidence rates steadily increased with increasing age at all four CHS sites. In this old cohort, there were little or no race and sex differences in stroke incidence. Though not statistically significant, age and sex standardized total stroke mortality rates were also lower in Allegheny County than other three sites. The site-differences in stroke risk could not be explained by age or race differences between sites. Age and sex adjusted incidence and mortality rates for all CHS participant were many fold higher than reported by previous studies because of the older age of CHS participants compared to these studies. Stroke types were similar between sites with lower percentage of hemorrhagic stroke in CHS population compared to previous studies. One month case fatality rates were not significantly different between the four sites and were similar to those previously reported in previous studies.

7.2. Second article:

The second article compared the prevalence of potential stroke risk factors at baseline between CHS sites relative to incident stroke events with aim to explain site-differences in stroke

incidence. Stroke hazard ratios for the other three sites compared to Allegheny County were calculated with Cox regression models before and after adjusting to possible stroke risk factors at baseline. Total stroke incidence unadjusted hazards in Forsyth, Sacramento, and Washington Counties combined compared to Allegheny County was 1.74 (95% CI= 1.42, 2.14; $p < 0.001$). Although Allegheny County had the lowest stroke hazard among the four sites, risk factor distributions across sites were relatively similar. After adjustment for age, hypertension, diabetes, education, BMI, LDL cholesterol and previous coronary heart disease, transient ischemic attack, and atrial fibrillation, there was almost 30% reduction of the excess hazard in the other three sites compared to Allegheny County (1.52, 95% CI= 1.17-1.98; $p = 0.002$). The results indicated that site-differences in stroke risk can be only partially explained by site-differences in stroke risk factors at baseline. White matter grade ≥ 3 was less common in Allegheny County than the other three sites combined (25.8% and 36.3% respectively, $p < 0.001$). White matter grade was responsible for 25% of the excess hazard in the other three sites compared to Allegheny County. White matter grade may be a marker of integrated exposure and control of stroke risk factors and may help in explaining geographic variations in stroke incidence.

7.3. Third article:

The third article compared potential stroke risk factors and their control relative to incident stroke events across the CHS visits (baseline, year-5 and year-9) between Allegheny County and the other three CHS sites combined. After adjustment for age, gender and race, the hazards of stroke incidence in all the three sites combined compared to Allegheny County were 1.75 (95% CI= 1.42, 2.14) at baseline, 2.01 (95% CI= 1.49, 2.71) at year 5, and 2.39 (95% CI= 1.54, 3.73) at year 9. The current report showed some degree of improvement of control of traditional stroke

risk factors specially LDL cholesterol, diabetes, smoking, and hypertension between baseline and year 9. However, the improvements were not significantly different between Allegheny County and the other three sites suggesting that these factors did not play a major role in explaining the observed difference in stroke hazard between study populations. The prevalence of coronary heart disease, atrial fibrillation and transient ischemic attack were increased in both study populations across visits with out significant differences with the exception of transient ischemic attack that was significantly lower in Allegheny County at year 5. The use of aspirin and oral anti-coagulants were markedly increased in both study populations across visits with out significant differences. White matter grade which was a strong predictor of stroke irrespective of sites and was lower in Allegheny County in both MRIs may be a marker of integrated exposure and control of stroke risk factors and may help in explaining geographic variations in stroke incidence.

APPENDIX A: US census 2000 standard population

Population 65 years and over by Age:

	Number	% of 65 years or over population	% of total population
65-74 years	18,391	52.6	6.5
75-84 years	12,361	35.3	4.4
85+ years	4,240	12.1	1.5
Total	34,992	100.0	12.4

Total 2000 US population is: **281,422, 000**

Population 65 years and over by age and sex:

	Number	% of 65 years or over population	% of total population
Males 65-74 years	8,303	23.7	3.0
Females 65-74 years	10,088	28.8	3.6
Males 75-84 years	4,879	13.9	1.7
Females 75-84 years	7,482	21.4	2.7
Males 85+ years	1,227	3.5	0.4
Females 85+ years	3,013	8.6	1.1
Total	34,992	100.0	12.4

Total 2000 US population is: **281,422, 000**

APPENDIX B: Cumulative stroke incidence and mortality tables

Table 13: Cumulative total stroke incidence and SE per 1000 persons for all CHS participants*

Stroke follow up years	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Total
	Rate Standard error	Rate Standard error	Rate Standard error	Rate Standard error	Rate Standard error
1	13 3	9 2	13 3	8 2	11 1
2	22 4	20 4	26 4	17 3	21 2
3	31 4	37 5	38 5	29 4	34 2
4	47 5	49 5	49 6	36 5	45 3
5	63 6	63 6	62 7	42 5	57 3
6	80 7	80 7	86 8	49 6	73 4
7	100 8	100 8	102 9	57 6	89 4
8	116 9	124 9	122 9	67 7	107 4
9	131 9	143 10	137 10	76 7	121 5
10	146 10	164 10	157 11	89 8	138 5
11	172 12	175 11	176 13	102 10	156 6
95% lower CI	148.5	153.4	150.5	82.4	144.2
95% upper CI	195.5	196.6	201.5	121.6	167.8

*Adjusted for age, gender, and race

Table 14: Cumulative total stroke mortality and SE per 1000 persons for all CHS participants

Stroke follow up years	Forsyth County, NC	Sacramento County, CA	Washington County, MD	Allegheny County, PA	Total
	Rate Standard error	Rate Standard error	Rate Standard error	Rate Standard error	Rate Standard error
1	1 1	1 1	0 0	1 1	1 0
2	2 1	2 1	0 0	2 1	2 1
3	3 1	3 1	1 1	3 1	3 1
4	6 2	5 2	2 1	4 2	4 1
5	7 2	7 2	4 2	4 2	6 1
6	10 3	7 2	6 2	4 2	7 1
7	12 3	9 2	8 3	5 2	9 1
8	14 3	11 3	11 3	7 2	11 2
9	15 3	16 4	15 4	8 3	14 2
10	16 4	19 4	21 5	13 4	18 2
11	20 5	19 4	23 5	13 4	19 2
95% lower CI	10.2	11.2	13.2	5.2	15.1
95% upper CI	29.8	26.8	32.8	20.8	22.9

*Adjusted for age, gender, and race

APPENDIX C: Incident CHS end points

Table 15: Adjusted* hazard ratio of CHS cardiovascular end points in the three CHS sites combined compared to Allegheny County

Outcome	N	P value	HR	95% CI
Total mortality	1910	0.267	1.061	(0.956, 1.178)
CHD	1026	0.629	0.966	(0.838, 1.113)
MI	557	0.428	1.084	(0.889, 1.322)
CHF	980	0.703	0.972	(0.841, 1.124)
Angina	877	0.083	0.875	(0.753, 1.017)
Stroke	663	<0.001	1.747	(1.423, 2.145)
TIA	173	0.097	1.375	(0.944, 2.002)

*Adjusted for age, gender, and race

BIBLIOGRAPHY

- Alter, M., E. Sobel, et al. (1985). "Stroke in the Lehigh Valley: incidence based on a community-wide hospital register." *Neuroepidemiology* 4(1): 1-15.
- American Heart Association (2004). *Heart Disease and Stroke Statistics — 2004 Update*. Dallas, Tex, American Heart Association.
- Barth, A. (2003). "[Carotid stenosis: diagnosis, patient selection, therapy]." *Ther Umsch* 60(9): 563-8.
- Bonita, R., J. B. Broad, et al. (1995). "Approaches to the problems of measuring the incidence of stroke: the Auckland Stroke Study, 1991-1992." *International Journal Of Epidemiology* 24(3): 535-542.
- Bonita, R., J. B. Broad, et al. (1993). "Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981-91." *The Lancet* 342(8885): 1470-1473.
- Breslow, N. E. and N. E. Day (1987). *Statistical Methods in Cancer Research Volume II-The design and analysis of cohort studies*.
- Briel, M., M. Studer, et al. (2004). "Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials." *Am J Med* 117(8): 596-606.
- Broderick, J. M. D., T. M. D. Brott, et al. (1998). "The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary First-Ever and Total Incidence Rates of Stroke Among Blacks." *Stroke* 29(2): 415-421.
- Broderick, J. M. D., R. R. N. Miller, et al. (2001). "Incidence rates of stroke for blacks and whites: Preliminary results from the Greater Cincinnati/Northern Kentucky stroke study." *Stroke* 32(1): 320.
- Broderick, J. P. (1993). "Stroke trends in Rochester, Minnesota, during 1945 to 1984." *Ann Epidemiol* 3(5): 476-9.
- Broderick, J. P., S. J. Phillips, et al. (1989). "Incidence rates of stroke in the eighties: the end of the decline in stroke?" *Stroke* 20(5): 577-82.

- Brott, T. G., R. D. Brown, Jr., et al. (2004). "Carotid revascularization for prevention of stroke: carotid endarterectomy and carotid artery stenting. Evaluation and management of asymptomatic carotid artery stenosis." *Mayo Clin Proc* 79(9): 1197-208.
- Brown, R. D., J. P. Whisnant, et al. (2000). "A population-based study of the first-ever and total stroke incidence rates in Rochester, Minnesota: 1990-1994." *Stroke* 31(1): 279.
- Brown, R. D., J. P. Whisnant, et al. (1996). "Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989." *Stroke* 27(3): 373-80.
- Carolei, A., C. Marini, et al. (1997). "High stroke incidence in the prospective community-based L'Aquila registry (1994-1998). First year's results." *Stroke* 28(12): 2500-2506.
- Casper, M. L., S. Wing, et al. (1995). "The shifting stroke belt. Changes in the geographic pattern of stroke mortality in the United States, 1962 to 1988." *Stroke* 26(5): 755-60.
- CDC (2001). "Prevalence of Disabilities and Associated Health Conditions Among Adults, United States, 1999." *MMWR* 50(7): 120-5.
- CDC (2002). *The Burden of Chronic Diseases and Their Risk Factors: National and State Perspectives.*
- Cheung, B. M., I. J. Lauder, et al. (2004). "Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes." *Br J Clin Pharmacol* 57(5): 640-51.
- Chobanian, A. V., G. L. Bakris, et al. (2003). "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure." *Hypertension* 42(6): 1206-52.
- Cooper, R., C. Sempos, et al. (1990). "Slowdown in the decline of stroke mortality in the United States, 1978-1986." *Stroke* 21(9): 1274-9.
- Corwin, L. E., P. A. Wolf, et al. (1982). "Accuracy of death certification of stroke: the Framingham Study." *Stroke* 13(6): 818-21.
- Cushman, W. C., D. J. Reda, et al. (2000). "Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents." *Arch Intern Med* 160(6): 825-31.
- Daniel, S. and D. Bereczki (2004). "Alcohol as a risk factor for hemorrhagic stroke." *Ideggyogy Sz* 57(7-8): 247-56.

- Dodick, D. W., I. Meissner, et al. (2004). "Evaluation and management of asymptomatic carotid artery stenosis." *Mayo Clin Proc* 79(7): 937-44.
- Ellekjaer, H., J. Holmen, et al. (1997). "Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate." *Stroke* 28(11): 2180-2184.
- Engstrom, G., I. Jerntorp, et al. (2001). "Geographic distribution of stroke incidence within an urban population: relations to socioeconomic circumstances and prevalence of cardiovascular risk factors." *Stroke* 32(5): 1098-103.
- Feigin, V. L., C. M. Lawes, et al. (2003). "Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century." *Lancet Neurol* 2(1): 43-53.
- Feigin, V. L., D. O. Wiebers, et al. (1995). "Stroke epidemiology in Novosibirsk, Russia: a population-based study." *Mayo Clinic Proceedings* 70(9): 847-852.
- Feigin, V. L., D. O. Wiebers, et al. (1995). "Stroke incidence and 30-day case-fatality rates in Novosibirsk, Russia, 1982 through 1992." *Stroke* 26(6): 924-9.
- Fried, L. P., N. O. Borhani, et al. (1991). "The Cardiovascular Health Study: design and rationale." *Ann Epidemiol* 1(3): 263-76.
- Fung, T. T., M. J. Stampfer, et al. (2004). "Prospective study of major dietary patterns and stroke risk in women." *Stroke* 35(9): 2014-9.
- Gaines, K. and G. Burke (1995). "Ethnic differences in stroke: black-white differences in the United States population. SECORDS Investigators. Southeastern Consortium on Racial Differences in Stroke." *Neuroepidemiology* 14(5): 209-39.
- Gavin, J. R. (1997). Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 20: 1183-97.
- Gerstein, H. C. (2002). "Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE." *Diabetes Metab Res Rev* 18 Suppl 3: S82-5.
- Giles, W. H., S. J. Kittner, et al. (1995). "Determinants of black-white differences in the risk of cerebral infarction. The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study." *Arch Intern Med* 155(12): 1319-24.
- Gillum, R. F. (1997). "Secular trends in stroke mortality in African Americans: the role of urbanization, diabetes and obesity." *Neuroepidemiology* 16(4): 180-4.

- Gillum, R. F. and D. D. Ingram (1996). "Relation between residence in the southeast region of the United States and stroke incidence. The NHANES I Epidemiologic Followup Study." *Am J Epidemiol* 144(7): 665-73.
- Gillum, R. F. and M. E. Mussolino (2003). "Education, poverty, and stroke incidence in whites and blacks: the NHANES I Epidemiologic Follow-up Study." *J Clin Epidemiol* 56(2): 188-95.
- Goldstein, L. B., R. Adams, et al. (2001). "Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association." *Stroke* 32(1): 280-99.
- Gross, C. R., C. S. Kase, et al. (1984). "Stroke in south Alabama: incidence and diagnostic features--a population based study." *Stroke* 15(2): 249-55.
- Hall, W. D., C. M. Ferrario, et al. (1997). "Hypertension-related morbidity and mortality in the southeastern United States." *Am J Med Sci* 313(4): 195-209.
- Hasuo, Y., K. Ueda, et al. (1989). "Accuracy of diagnosis on death certificates for underlying causes of death in a long-term autopsy-based population study in Hisayama, Japan; with special reference to cardiovascular diseases." *J Clin Epidemiol* 42(6): 577-84.
- He, J., M. J. Klag, et al. (1995). "Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors." *Stroke* 26(12): 2222-7.
- He, K., Y. Song, et al. (2004). "Fish consumption and incidence of stroke: a meta-analysis of cohort studies." *Stroke* 35(7): 1538-42.
- Hetzel, L. and A. Smith (2001). *The 65 Years and Over Population: 2000. Census 2000 Brief.* U.S. Census Bureau. Washington, DC.
- Heyman, A., H. R. Karp, et al. (1971). "Cerebrovascular disease in the biracial population of Evans County, Georgia." *Arch Intern Med* 128(6): 949-55.
- Howard, G. (1993). "Decline in stroke mortality in North Carolina. Description, predictions, and a possible underlying cause." *Ann Epidemiol* 3(5): 488-92.
- Howard, G. (1999). "Why do we have a stroke belt in the southeastern United States? A review of unlikely and uninvestigated potential causes." *American Journal of the Medical Sciences* 317(3): 160-7.
- Howard, G., R. Anderson, et al. (1997). "Evaluation of social status as a contributing factor to the stroke belt region of the United States." *Stroke* 28(5): 936-40.

- Howard, G., R. Anderson, et al. (1994). "Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study." *Stroke* 25(11): 2120-5.
- Howard, G. and V. J. Howard (2001). "Ethnic disparities in stroke: the scope of the problem." *Ethn Dis* 11(4): 761-8.
- Inzitari, D. (2003). "Leukoaraiosis: an independent risk factor for stroke?" *Stroke* 34(8): 2067-71.
- Ives, D. G., A. L. Fitzpatrick, et al. (1995). "Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study." *Ann Epidemiol* 5(4): 278-85.
- Jorgensen, H. S., A.-M. Plesner, et al. (1992). "Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg, Denmark." *Stroke* 23(12): 1701-1704.
- Kernan, W. N. and S. E. Inzucchi (2004). "Type 2 Diabetes Mellitus and Insulin Resistance: Stroke Prevention and Management." *Curr Treat Options Neurol* 6(6): 443-450.
- Kiely, D. K., P. A. Wolf, et al. (1993). "Familial aggregation of stroke. The Framingham Study." *Stroke* 24(9): 1366-71.
- Kolominsky-Rabas, P. L., C. M. D. P. Sarti, et al. (1998). "A Prospective Community-Based Study of Stroke in Germany-The Erlangen Stroke Project (ESPro): Incidence and Case Fatality at 1, 3, and 12 Months." *Stroke* 29(12): 2501-2506.
- Kolominsky-Rabas, P. L., M. Weber, et al. (2001). "Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study." *Stroke* 32(12): 2735-40.
- Kuller, L. H., W. T. Longstreth, Jr., et al. (2004). "White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke." *Stroke* 35(8): 1821-5.
- Lackland, D. T., D. L. Bachman, et al. (1998). "The Geographic Variation in Stroke Incidence in Two Areas of the Southeastern Stroke Belt : The Anderson and Pee Dee Stroke Study." *Stroke* 29(10): 2061-2068.
- Lackland, D. T. and B. M. Egan (1999). "The dominant role of systolic hypertension as a vascular risk factor: evidence from the southeastern United States." *Am J Med Sci* 318(6): 365-8.
- Lackland, D. T., B. M. Egan, et al. (1999). "Impact of nativity and race on "Stroke Belt" mortality." *Hypertension* 34(1): 57-62.

- Lackland, D. T. and M. A. Moore (1997). "Hypertension-related mortality and morbidity in the southeast." *South Med J* 90(2): 191-8.
- Law, M. R., N. J. Wald, et al. (2003). "Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis." *BMJ* 326(7404): 1423.
- Lawes, C. M., D. A. Bennett, et al. (2004). "Blood pressure and stroke: an overview of published reviews." *Stroke* 35(3): 776-85.
- Lethbridge-ÇejkuM, SchillerJS, et al. (2004.). " Summary health statisticsfor U.S. Adults: National Health Interview Survey, 2002. National Center for Health Statistics.Vital Health Stat 10(222)."
- Lindenstrom, E., G. Boysen, et al. (1993). "Risk factors for stroke in Copenhagen, Denmark. I. Basic demographic and social factors." *Neuroepidemiology* 12(1): 37-42.
- Longstreth, W. T., Jr., T. A. Manolio, et al. (1996). "Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study." *Stroke* 27(8): 1274-82.
- Malmgren, R., C. Warlow, et al. (1987). "Geographical and secular trends in stroke incidence." *Lancet* 2(8569): 1196-200.
- Matchar, D. B., D. C. McCrory, et al. (1994). "Medical Treatment for Stroke Prevention." *Ann Intern Med* 121(1): 41-53.
- McGovern, P. G., G. L. Burke, et al. (1992). "Trends in mortality, morbidity, and risk factor levels for stroke from 1960 through 1990. The Minnesota Heart Survey." *JAMA* 268(6): 753-9.
- Mihalka, L., V. Smolanka, et al. (2001). "A population study of stroke in West Ukraine: incidence, stroke services, and 30-day case fatality." *Stroke* 32(10): 2227-2231.
- Morikawa, Y., H. Nakagawa, et al. (2000). "Trends in stroke incidence and acute case fatality in a Japanese rural area : the Oyabe study." *Stroke* 31(7): 1583-7.
- Morris, R. W., P. H. Whincup, et al. (2003). "North-south gradients in Britain for stroke and CHD: are they explained by the same factors?" *Stroke* 34(11): 2604-9.
- Muntner, P. P., E. P. Garrett, et al. (2002). "Trends in Stroke Prevalence Between 1973 and 1991 in the US Population 25 to 74 Years of Age." *Stroke* 33(5): 1209-1213.

- Murray, C. J. and A. D. Lopez (1997). "Mortality by cause for eight regions of the world: Global Burden of Disease Study." *Lancet* 349(9061): 1269-76.
- National Center for Health Statistics (2003). *Health, United States, 2003 With Chartbook on Trends in the Health of Americans*. Hyattsville, Maryland.
- Neal, B., S. MacMahon, et al. (2000). "Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration." *Lancet* 356(9246): 1955-64.
- Neuberger, J. S., M. Mulhall, et al. (1990). "Health problems in Galena, Kansas: a heavy metal mining Superfund site." *Sci Total Environ* 94(3): 261-72.
- Obisesan, T. O., C. M. Vargas, et al. (2000). "Geographic Variation in Stroke Risk in the United States: Region, Urbanization, and Hypertension in the Third National Health and Nutrition Examination Survey." *Stroke* 31(1): 19.
- Ovary, C., K. Suzuki, et al. (2004). "Regional differences in incidence rates, outcome predictors and survival of stroke." *Neuroepidemiology* 23(5): 240-6.
- Perry, H. M., Jr., K. N. Gillespie, et al. (1994). "Effects of 'stroke-belt' residence, screening blood pressure and personal history risk factors on all-cause mortality among hypertensive veterans." *J Hypertens* 12(3): 315-21.
- Perry, H. M. and E. J. Roccella (1998). "Conference report on stroke mortality in the southeastern United States." *Hypertension* 31(6): 1206-15.
- Price, T. R., B. Psaty, et al. (1993). "Assessment of cerebrovascular disease in the Cardiovascular Health Study." *Ann Epidemiol* 3(5): 504-7.
- Psaty, B. M., L. H. Kuller, et al. (1995). "Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study." *Ann Epidemiol* 5(4): 270-7.
- Psaty, B. M., N. L. Smith, et al. (1997). "Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis." *JAMA* 277(9): 739-45.
- Rastenyte, D., J. Tuomilehto, et al. (1998). "Genetics of stroke--a review." *J Neurol Sci* 153(2): 132-45.

- Reggio, A., G. Failla, et al. (1995). "Reliability of death certificates in the study of stroke mortality. A retrospective study in a Sicilian municipality." *Ital J Neurol Sci* 16(8): 567-70.
- Reynolds, K., B. Lewis, et al. (2003). "Alcohol consumption and risk of stroke: a meta-analysis." *JAMA* 289(5): 579-88.
- Rinaldi, R., L. Vignatelli, et al. (2003). "Accuracy of ICD-9 codes in identifying ischemic stroke in the General Hospital of Lugo di Romagna (Italy)." *Neurol Sci* 24(2): 65-9.
- Roccella, E. J. and C. Lenfant (1989). "Regional and racial differences among stroke victims in the United States." *Clin Cardiol* 12(12 Suppl 4): IV18-22.
- Rodriguez Artalejo, F., P. Guallar-Castillon, et al. (1997). "Socioeconomic level, sedentary lifestyle, and wine consumption as possible explanations for geographic distribution of cerebrovascular disease mortality in Spain." *Stroke* 28(5): 922-8.
- Rosamond, W. D., A. R. Folsom, et al. (1999). "Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort." *Stroke* 30(4): 736-43.
- Rothwell, P. M., A. J. Coull, et al. (2004). "Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study)." *Lancet* 363(9425): 1925-33.
- Sacco, R. L. (1998). "Identifying patient populations at high risk for stroke." *Neurology* 51(3 Suppl 3): S27-30.
- Sacco, R. L., B. Boden-Albala, et al. (1998). "Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study." *Am J Epidemiol* 147(3): 259-68.
- Shaper, A. G., R. F. Packham, et al. (1980). "The British Regional Heart Study: cardiovascular mortality and water quality." *J Environ Pathol Toxicol* 4(2-3): 89-111.
- Shinton, R. and G. Beevers (1989). "Meta-analysis of relation between cigarette smoking and stroke." *BMJ* 298(6676): 789-94.
- Smadja, D., P. Cabre, et al. (2001). "ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies: Part I: methodology, incidence, and 30-day case fatality rate." *Stroke* 32(12): 2741-2747.

- Soltero, I., K. Liu, et al. (1978). "Trends in mortality from cerebrovascular diseases in the United States, 1960 to 1975." *Stroke* 9(6): 549-58.
- Starr, J. M., B. Thomas, et al. (1996). "Population risk factors for hospitalization for stroke in Scotland." *Int J Epidemiol* 25(2): 276-81.
- Stegmayr, B., K. Asplund, et al. (1997). "Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project. An ecological study of 18 populations." *Stroke* 28(7): 1367-74.
- Stewart, J. A., R. Dundas, et al. (1999). "Ethnic differences in incidence of stroke: Prospective study with stroke register." *British Medical Journal* 318(7189): 967-971.
- Stolley, P. D., L. H. Kuller, et al. (1977). "Three-area epidemiological study of geographic differences in stroke mortality. II. Results." *Stroke* 8(5): 551-7.
- Strachan, D. P., D. A. Leon, et al. (1995). "Mortality from cardiovascular disease among interregional migrants in England and Wales." *BMJ* 310(6977): 423-7.
- Sudlow, C. L. and C. P. Warlow (1996). "Comparing stroke incidence worldwide: what makes studies comparable?" *Stroke* 27(3): 550-8.
- Sudlow, C. L. and C. P. Warlow (1997). "Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration." *Stroke* 28(3): 491-499.
- Taylor, T. N., P. H. Davis, et al. (1996). "Lifetime cost of stroke in the United States." *Stroke* 27(9): 1459-66.
- Tell, G. S., L. P. Fried, et al. (1993). "Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study." *Ann Epidemiol* 3(4): 358-66.
- Thorvaldsen, P., K. Asplund, et al. (1995). "Stroke Incidence, Case Fatality, and Mortality in the WHO MONICA Project." *Stroke* 26(3): 361-367.
- Tuomilehto, J. and D. Rastenyte (1999). "Diabetes and glucose intolerance as risk factors for stroke." *J Cardiovasc Risk* 6(4): 241-9.
- Vemmos, K. N., M. L. Bots, et al. (1999). "Stroke incidence and case fatality in southern Greece: the Arcadia stroke registry." *Stroke* 30(2): 363-70.

- Vermeer, S. E., M. Hollander, et al. (2003). "Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study." *Stroke* 34(5): 1126-9.
- Vreecer, M., S. Turk, et al. (2003). "Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials." *Int J Clin Pharmacol Ther* 41(12): 567-77.
- Warlow, C. P. (1998). "Epidemiology of stroke." *Lancet* 352 Suppl 3: SIII1-4.
- Whisnant, J. P. (1984). "The decline of stroke." *Stroke* 15(1): 160-8.
- Wolf, P. A., R. B. D'Agostino, et al. (1988). "Cigarette smoking as a risk factor for stroke. The Framingham Study." *JAMA* 259(7): 1025-9.
- Wolf, P. A., R. B. D'Agostino, et al. (1992). "Secular trends in stroke incidence and mortality. The Framingham Study." *Stroke* 23(11): 1551-5.
- Woo, D., J. Gebel, et al. (1999). "Incidence rates of first-ever ischemic stroke subtypes among blacks: a population-based study." *Stroke* 30(12): 2517-22.
- World Health Stat Q (1988). "Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. The WHO MONICA Project." *World Health Stat Q* 41(3-4): 115-40.
- Yamauchi, H., H. Fukuda, et al. (2002). "Significance of white matter high intensity lesions as a predictor of stroke from arteriosclerosis." *J Neurol Neurosurg Psychiatry* 72(5): 576-82.